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The use of medications in the elderly is a complex issue influenced by many health and 
non-health related factors. Drug therapy is one of the most important tools available 
for preserving and improving health. However, polypharmacy and the inappropriate 
use of medications can imply adverse effects and situations of vulnerability that 
condition negative health outcomes. The following work intends to study this 
phenomenon in different areas ―at population or community level, in institutionalized 
and hospitalized patients―, analyzing its relationship with different factors that may 
be of interest in the elderly patient, and especially with frailty. Finally, it focuses on the 
hospitalized elderly, one of the most vulnerable sectors to pharmacological 
iatrogenesis, investigating the impact of hospitalization on pharmacological therapy, 
reviewing the different strategies that have been proposed for pharmacological 
optimization in these patients and exploring the usefulness of an intervention 
specifically adapted to these patients in our environment.  
The most relevant methodology and results are summarized below:   
 
Chapter 1: Prevalence of polypharmacy and associated factors in older adults in 
Spain: Data from the National Health Survey 2017   
Background and objective: to estimate the prevalence of polypharmacy and 
hyperpolypharmacy in non-institutionalized older adults in Spain and assess the 
associated factors.  
Material and methods: a cross-sectional study based on data from the National Health 
Survey of Spain 2017, with participants over 65 years old. The prevalence of 
polypharmacy (≥5 medications) and hyperpolypharmacy (≥10) was estimated, as well 
as the association with several factors through multivariate logistic regression. A 
sensitivity analysis was also carried out considering the possible consumption of more 
than one drug for the same indication (polytherapy). 
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Results: 7023 participants were included, with a mean age of 76.0 (SD 7.6) years, 
59.4% women and an average consumption of 3.3 (SD 2.2) drugs per person. The 
prevalence of polypharmacy was 27.3% (95% CI 26.2-28.3), being 0.9% (95% CI 0.7-1.1) 
in the case of hyperpolypharmacy. The sensitivity analysis showed that the prevalence 
could be at least 37.5% and the average number of drugs 3.9 (SD 2.5) when 
considering polytherapy. The number of chronic diseases, the degree of dependence 
for the basic activities of daily living, the self-perceived health and contacts with the 
health system were the factors most associated with polypharmacy. Sensory deficits 
and incontinence were negatively associated. 
Conclusions: the prevalence of polypharmacy in the elderly in primary care continues 
to increase, and could be widely underestimated. In addition to the multimorbidity, 
factors such as functional capacity or geriatric syndromes, which are essential in 
elderly people, modulate the habits of consumption and prescription of drugs in this 
population. 
 
Chapter 2: The relationship between Frailty and Polypharmacy in older people: a 
Systematic Review   
Aims: Frailty is a complex geriatric syndrome resulting in decreased physiological 
reserves. Frailty and polypharmacy are common in older adults and the focus of 
extensive studies, although little is known about the impact they may have on each 
other. This is the first systematic review analysing the available evidence on the 
relationship between frailty and polypharmacy in older adults.  
Methods: Systematic review of quantitative studies. A comprehensive literature search 
for publications in English or Spanish was performed on MEDLINE, CINAHL, the 
Cohrane Database and PsycINFO in September 2017 without applying restrictions on 
the date of publication. Studies reporting any relationship between frailty and 
polypharmacy in older adults were considered.  
Results: A total of 25 publications were included, all of them observational studies. 
Evaluation of Fried’s frailty criteria was the most common approach, followed by the 
Edmonton Frail Scale and FRAIL scale. Sixteen of 18 cross-sectional analyses and five of 
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seven longitudinal analyses demonstrated a significant association between an 
increased number of medications and frailty. The causal relationship is unclear and 
appears to be bidirectional. Our analysis of published data suggests that polypharmacy 
could be a major contributor to the development of frailty.  
Conclusions: A reduction of polypharmacy could be a cautious strategy to prevent and 
manage frailty. Further research is needed to confirm the possible benefits of reducing 
polypharmacy in the development, reversion or delay of frailty.   
 
Chapter 3: The Relationship between frailty, polypharmacy, and underprescription in 
older adults living in nursing homes   
Purpose: Frailty, polypharmacy, and underprescription are considered a major matter 
of concern in nursing homes, but the possible relationships between them are not well 
known. The aim is to examine the possible association between medication 
underprescription, polypharmacy, and frailty in older people living in nursing homes. 
Methods: A cross-sectional analysis from a concurrent cohort study, including 110 
subjects ≥ 65 years living in two nursing homes. Four frailty scales were applied; 
polypharmacy was defined as ≥ 5 medications and underprescription was measured 
with Screening Tool to Alert to Right Treatment (START) criteria. Logistic regression 
models were performed to assess the associations.  
Results: The mean age was 86.3 years (SD 7.3) and 71.8% were female. 73.6% of 
subjects took ≥ 5 chronic medications and 60.9% met one or more START criteria. The 
non-frail participants took more medications than the frail subjects according to the 
imputated frailty Fried criteria (8.1 vs 6.7, p = 0.042) and the FRAIL-NH scale (7.8 vs 6.8, 
p=0.026). Multivariate analyses did not find an association between frailty and 
polypharmacy. Frail participants according to the Fried criteria met a higher number of 
START criteria (1.9 vs 1.0, p = 0.017), and had a higher prevalence of underprescription 
(87.5 vs 50.0%), reaching the limit of statistical significance in multivariate analysis. 
Conclusion: The positive association found in previous studies between frailty and 
polypharmacy cannot be extrapolated to institutionalized populations. There is a trend 
towards higher rates of underprescription in frail subjects. Underprescription in frail 
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older adults should be redefined and new strategies to measure it should be 
developed.   
 
Chapter 4: Impact of hospitalization in an acute geriatric unit on polypharmacy and 
potentially inappropriate prescriptions: A retrospective study   
Aim: Polypharmacy is a highly prevalent geriatric syndrome, and hospitalizations can 
worsen it. The aim of the present study was to analyze the influence of hospitalization 
on polypharmacy and indicators of quality of prescribing, and their possible association 
with health outcomes.   
Methods: A retrospective study of 200 patients discharged from an acute geriatric unit 
was carried out. Indicators of quality of prescription were registered at admission and 
discharge: polypharmacy defined as ≥5 medications, hyperpolypharmacy (≥10), 
potentially inappropriate prescribing by Beers and Screening Tool of Older Persons’ 
potentially inappropriate Prescriptions (STOPP) criteria, potentially prescribing 
omissions by Screening Tool to Alert doctors to the Right Treatment (START) criteria, 
drug interactions and anticholinergic burden measured with the Anticholinergic Risk 
Scale. Mortality, emergency room visits and hospital admissions occurring during 6 
months after discharge were also registered.   
Results: The total number of drugs increased at discharge (9.1 vs 10.1, P < 0.001), 
without increasing chronic medications (8.5 vs 8.3, P = 0.699). No significant variations 
were observed in the prevalence of polypharmacy (86.5% vs 82.2%), potentially 
inappropriate prescribing (68.5%vs 71.5%), potential prescribing omissions (58%vs 
58%) or drug interactions (82.5%vs 83.5%). Patients with anticholinergic drugs tended 
to increase, not reaching statistical significance (39.5% vs 44.5%; P = 0.064). 
Polypharmacy was associated with emergency room visits (OR 2.62, 95% CI 1.07–6.40; 
P = 0.034), and hyperpolypharmacy with hospitalizations (OR 2.49, 95% CI 1.25–4.93; P 
= 0.009).   
Conclusions: After hospitalization in an acute geriatric unit, the prevalence of 
polypharmacy, potentially inappropriate prescribing, potential prescribing omissions, 
interactions or anticholinergic drugs is still very high. Polypharmacy is a risk factor for 
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hospitalization and emergency room visits. Measuring indicators of quality of 
prescription might be useful to design interventions to optimize pharmacotherapy and 
improve health outcomes in elderly acute patients.     
 
Chapter 5:  Interventions to optimize pharmacologic treatment in hospitalized older 
adults: a systematic review 
Objective: To summarise the evidence on interventions aimed at optimising the drug 
treatment of hospitalised elderly patients. 
Material and methods: We conducted a search in the main medical literature 
databases, selecting prospective studies of hospitalised patients older than 65 years 
who underwent interventions aimed at optimising drug treatment, decreasing 
polypharmacy and improving the medication appropriateness, health outcomes and 
exploitation of the healthcare system. 
Results: We selected 18 studies whose interventions consisted of medication reviews, 
detection of predefined drugs as potentially inappropriate for the elderly, counselling 
from a specialised geriatric team, the use of a computer support system for 
prescriptions and specific training for the nursing team. Up to 14 studies assessed the 
medication appropriateness, 13 of which showed an improvement in one or more of 
the parameters. Seven studies measured the impact of the intervention on 
polypharmacy, but only one improved the outcomes compared with the control. Seven 
other studies analysed mortality, but none of them showed a reduction in that rate. 
Only 1 of 6 studies showed a reduction in the number of hospital readmissions, and 1 
of 4 studies showed a reduction in the number of emergency department visits.  
Conclusions: Despite the heterogeneity of the analysed interventions and variables, we 
obtained better results in the process variables (especially in medication 
appropriateness) than in those that measured health outcomes, which had greater 
variability. 
 
Chapter 6: A medicine optimization strategy in an acute geriatric unit: the pharmacist 
in the geriatric team 
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Aim: Older patients admitted to acute geriatric units (AGU) use frequently many 
medications and are particularly vulnerable to adverse drug events, so specific 
interventions in this setting are needed. In this study, we describe a new medicine 
optimization strategy in an AGU and explore its potential in reducing polypharmacy 
and improving medication appropriateness. 
Methods: Prospective study with patients aged ≥ 75 years who were admitted to an 
AGU in a tertiary hospital. An intervention based on a pharmacist clinical interview, 
medication history, and a structured medication review within a comprehensive 
geriatric assessment (CGA) was proposed. The differences regarding polypharmacy as 
the primary outcome (≥5 chronic drugs), hyperpolypharmacy (≥10), number of drugs, 
drug-related problems (DRP) and Screening Tool of Older Person’s Prescription 
(STOPP)/ Screening Tool to Alert doctors to Right Treatment (START) criteria between 
admission and discharge were evaluated.  
Results: From October 2016 to April 2017, 234 patients were enrolled, aged 87.6 years 
(SD = 4.6); 143 (61.1%) were female. The intervention resulted in a statistically 
significant improvement in polypharmacy (-10.2%, 95%CI,-15.3,-5.2), 
hyperpolypharmacy (-16.6%, 95%CI,-22.3,-11.0), number of medications (-1.4, 95%CI,-
1.8,-1.0), STOPP criteria (-19.2%, 95%CI,-24.9,-13.6), START criteria (-6.8%, 95%CI,-
10.1,-3.5) and DRP (-2.7, 95%CI,-2.9,-2.4) (p<0.001 for all).  
Conclusions: A systematic pharmacist-led intervention at hospital admission to an AGU 
within a CGA was associated to a decrease in polypharmacy, drug related problems 






El uso de medicamentos en ancianos es un asunto complejo influido por muchos 
factores tanto relacionados como ajenos al ámbito de la salud. La terapia 
farmacológica es una de las herramientas más importantes de las que disponemos 
para conservar o mejorar la salud. Sin embargo, la polifarmacia y el uso inadecuado de 
medicamentos pueden implicar efectos adversos y situaciones de vulnerabilidad que 
condicionen resultados negativos en salud. En el siguiente trabajo se pretende estudiar 
este fenómeno en distintos ámbitos ―a nivel poblacional o comunitario, en pacientes 
institucionalizados y hospitalizados―, analizando su relación con distintos factores que 
pueden ser de interés en el paciente mayor, y especialmente con la fragilidad. 
Finalmente se centra en los ancianos hospitalizados, uno de los sectores más 
vulnerables a la iatrogenia farmacológica, indagando en el impacto de la 
hospitalización sobre la terapia farmacológica, revisando las distintas estrategias que 
se han propuesto para la optimización farmacológica en estos pacientes y explorando 
la utilidad de una intervención específicamente adaptada a estos pacientes en nuestro 
medio. La metodología y resultados más relevantes se resumen a continuación: 
 
Capitulo 1: Prevalencia de polifarmacia y factores asociados en adultos mayores en 
España: datos de la Encuesta Nacional de Salud 2017 
Fundamento y objetivo: Estimar la prevalencia de polifarmacia e hiperpolifarmacia en 
adultos mayores no institucionalizados en España y analizar los factores asociados. 
Material y métodos: Estudio transversal a partir de datos de la Encuesta Nacional de 
Salud de España 2017, con participantes de 65 años o más. Se estimó la prevalencia de 
polifarmacia (≥5 medicamentos) e hiperpolifarmacia (≥10), y la asociación con diversos 
factores mediante regresión logística multivariante. Se realizó un análisis de 
sensibilidad considerando el posible consumo de más de un fármaco para la misma 
indicación (politerapia).  
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Resultados: Se incluyeron 7.023 participantes, con edad media de 76,0 (desviación 
estándar [DE] 7,6) años, 59,4% mujeres y consumo medio de 3,3 (DE 2,2) 
medicamentos por persona. La prevalencia de polifarmacia fue de 27,3% (intervalo de 
confianza del 95%: 26,2-28,3) y la de hiperpolifarmacia de 0,9% (intervalo de confianza 
del 95%: 0,7-1,1). El análisis de sensibilidad estimó que la prevalencia podría ascender 
al menos a un 37,5% y la media a 3,9 (DE 2,5) al considerar la politerapia. Los factores 
que más se asocian a la polifarmacia fueron el número de enfermedades crónicas, el 
grado de dependencia para las actividades básicas de la vida diaria, el estado de salud 
percibido o los contactos con el sistema sanitario; y de forma inversa los déficits 
sensoriales y la incontinencia.  
Conclusiones: La prevalencia de polifarmacia en adultos mayores en atención primaria 
continúa aumentando, y podría estar ampliamente infraestimada. Además de la 
pluripatología, factores como la capacidad funcional o los síndromes geriátricos, 
fundamentales en personas mayores, modulan los hábitos de consumo y prescripción 
de medicamentos en esta población. 
 
Capítulo 2: Relación entre polifarmacia y fragilidad en el anciano: una revisión 
sistemática. 
Objetivos: La fragilidad es un síndrome geriátrico complejo que produce una 
disminución de las reservas fisiológicas. La fragilidad y la polifarmacia son comunes en 
los adultos mayores y han sido objeto de numerosos estudios, aunque no es bien 
conocido el impacto que pueden tener entre sí. Esta es la primera revisión sistemática 
que analiza la evidencia disponible sobre la relación entre la fragilidad y la polifarmacia 
en adultos mayores. 
Métodos: Revisión sistemática de estudios cuantitativos. En septiembre de 2017, se 
realizó una búsqueda bibliográfica exhaustiva de publicaciones en inglés o español en 
MEDLINE, CINAHL, la Cohrane Database y PsycINFO sin aplicar restricciones por fecha 
de publicación. Se consideraron los estudios que analizaron cualquier relación entre la 
fragilidad y la polifarmacia en adultos mayores. 
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Resultados: se incluyeron un total de 25 publicaciones, todas ellas estudios 
observacionales. La evaluación de los criterios de fragilidad de Fried fue el enfoque 
más común, seguido por la escala de fragilidad de Edmonton y la escala FRAIL. 
Dieciséis de los 18 análisis transversales y cinco de los siete análisis longitudinales 
demostraron una asociación significativa entre un mayor número de medicamentos y 
la fragilidad. La relación causal no está clara y parece ser bidireccional. Nuestro análisis 
de los datos publicados sugiere que la polifarmacia podría ser un importante 
contribuyente al desarrollo de la fragilidad. 
Conclusiones: Una reducción de la polifarmacia podría ser una estrategia cautelosa 
para prevenir y manejar la fragilidad. Se necesita más investigación para confirmar los 
posibles beneficios de reducir la polifarmacia en el desarrollo, reversión o retraso de la 
fragilidad. 
 
Capítulo 3: La relación entre la fragilidad, la polifarmacia y la infraprescripción en 
adultos mayores que viven en residencias 
Fundamento y objetivo: La fragilidad, la polifarmacia y la infraprescripción se 
consideran un problema importante en las residencias, pero las posibles relaciones 
entre ellos no son bien conocidas. El objetivo es examinar la posible asociación entre la 
infraprescripción de medicamentos, la polifarmacia y la fragilidad en las personas 
mayores que viven en residencias. 
Métodos: un análisis transversal de un estudio de cohorte en marcha, que incluye 110 
sujetos ≥ 65 años que viven en dos residencias de ancianos. Se aplicaron cuatro escalas 
de fragilidad. La polifarmacia se definió como ≥ 5 medicamentos y la prescripción 
insuficiente se midió con los criterios START (Screening Tool to Alert to Right 
Treatment). Se realizaron modelos de regresión logística para evaluar las asociaciones. 
Resultados: la edad media fue de 86.3 años (DE 7.3) y el 71.8% eran mujeres. El 73.6% 
de los sujetos consumían ≥ 5 medicamentos crónicos y el 60.9% presentaban uno o 
más criterios START. Los participantes no frágiles consumían más medicamentos que 
los sujetos frágiles según los criterios de fragilidad de Fried (8.1 vs 6.7, p = 0.042) y la 
escala FRAIL-NH (7.8 vs 6.8, p = 0.026). Los análisis multivariantes no encontraron 
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asociación entre fragilidad y polifarmacia. Los participantes frágiles según los criterios 
de Fried presentaban un mayor número de criterios START (1.9 frente a 1.0, p = 0.017) 
y una mayor prevalencia de infraprescripción según estos criterios (87.5 frente a 
50.0%), alcanzando el límite de significación estadística en el análisis multivariado. 
Conclusión: la asociación positiva encontrada en estudios previos entre fragilidad y 
polifarmacia no puede extrapolarse a poblaciones institucionalizadas. Hay una 
tendencia hacia tasas más altas de infraprescripción en sujetos frágiles. La 
infraprescripción en adultos mayores frágiles debe redefinirse y se deben desarrollar 
nuevas estrategias para medirla. 
 
Capítulo 4: Impacto de la hospitalización en una Unidad de Agudos de Geriatría sobre 
la polifarmacia y las prescripciones potencialmente inadecuadas: un estudio 
retrospectivo 
Objetivo: La polifarmacia es un síndrome geriátrico altamente prevalente, y los 
ingresos hospitalarios pueden empeorarlo. El objetivo del presente estudio fue 
analizar la influencia de la hospitalización en ancianos en la polifarmacia y distintos 
indicadores de la calidad de la prescripción, y su posible asociación con resultados de 
salud. 
Métodos: se realizó un estudio retrospectivo de 200 pacientes dados de alta de una 
Unidad de Agudos de Geriatría. Se registraron al ingreso y al alta los siguientes 
indicadores de calidad de prescripción: polifarmacia definida como ≥5 medicamentos, 
hiperpolifarmacia (≥10), prescripciones potencialmente inadecuada según criterios de 
Beers y criterios STOPP, prescripciones potencialmente omitidas según criterios START, 
interacciones de medicamentos y carga anticolinérgica del tratamiento  medida con la 
escala ARS. También se registraron la mortalidad, las visitas a urgencias y los ingresos 
hospitalarios durante los 6 meses posteriores al alta, y se analizó mediante regresión 
logística multivariante su posible relación con los indicadores de calidad de la 
prescripción. 
Resultados: El número total de fármacos aumentó al alta (9,1 frente a 10,1; p <0,001), 
sin aumentar los medicamentos crónicos (8,5 frente a 8,3; p=0,699). No se observaron 
variaciones significativas en la prevalencia de la polifarmacia (86,5% 
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vs 82,2%), criterios STOPP (68,5% vs 71,5%), criterios START (58% vs 58%) o las 
interacciones de medicamentos (82,5% vs 83,5%). Los pacientes con fármacos 
anticolinérgicos tendieron a aumentar, no alcanzando significación estadística (39,5% 
vs 44,5%; p = 0,064). La polifarmacia se asoció con las visitas a urgencias (OR 2,62, IC 
95% 1,07–6,40; p = 0,034) y la hiperpolifarmacia con las hospitalizaciones (OR 2,49, IC 
95% 1,25–4,93; p = 0,009). 
Conclusiones: después de la hospitalización en una Unidad de Agudos de Geriatría, la 
prevalencia de la polifarmacia, las prescripciones potencialmente inadecuadas, las 
prescripciones potencialmente omitidas, las interacciones o el uso de fármacos 
anticolinérgicos aún son muy altos. La polifarmacia es un factor de riesgo para la 
hospitalización y las visitas urgencias en ancianos. La medición de los indicadores de 
calidad de la prescripción podría ser útil para diseñar intervenciones para optimizar la 
farmacoterapia y mejorar los resultados de salud en pacientes ancianos en unidades 
de agudos. 
 
Capítulo 5: Intervenciones para optimizar el tratamiento farmacológico en ancianos 
hospitalizados: una revisión sistemática 
Objetivo: Resumir la evidencia sobre las intervenciones orientadas a optimizar el 
tratamiento farmacológico en ancianos hospitalizados.  
Material y métodos: Se realizó una búsqueda en las principales bases de datos 
bibliográficas, seleccionando estudios prospectivos en pacientes mayores de 65 años 
hospitalizados que realizaran intervenciones dirigidas a optimizar el tratamiento 
farmacológico, disminuir la polifarmacia y mejorar la adecuación terapéutica, los 
resultados en salud o el aprovechamiento del sistema sanitario.  
Resultados: Se seleccionaron 18 estudios. Las intervenciones consistieron en revisiones 
de medicación, detección de medicamentos predefinidos como potencialmente 
inadecuados en ancianos, asesoramiento de un equipo especializado en geriatría, uso 
de un sistema informático de apoyo a la prescripción o formación específica al equipo 
de enfermería. Hasta 14 estudios evaluaron la adecuación terapéutica, demostrando 
13 de ellos una mejoría en alguno de los parámetros. Siete estudios midieron el 
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impacto de la intervención sobre la polifarmacia, pero solo uno mejoró los resultados 
respecto al control. Otros siete estudios analizaron la mortalidad, no demostrándose 
una disminución de la misma en ninguno. Solo uno de seis estudios mostró una 
reducción de reingresos hospitalarios y uno de cuatro estudios una disminución de las 
visitas a urgencias. 
Conclusiones: Pese a la heterogeneidad de las intervenciones y de las variables 
analizadas, se obtuvieron mejores resultados en las variables de proceso, 
especialmente en la adecuación terapéutica, que en aquellas que midieron resultados 
en salud, donde hubo una mayor variabilidad.  
 
Capítulo 6: Una estrategia de optimización de tratamientos en una unidad de agudos 
de geriatría: el farmacéutico en el equipo de geriatría 
Objetivo: los pacientes mayores ingresados en unidades geriátricas de agudos (UGA) 
utilizan con frecuencia muchos medicamentos y son particularmente vulnerables a los 
eventos adversos de medicamentos, por lo que se necesitan intervenciones específicas 
en este contexto. En este estudio, describimos una nueva estrategia de optimización 
de medicamentos en una UGA y exploramos su potencial para reducir la polifarmacia y 
mejorar la adecuación de la medicación. 
Métodos: estudio prospectivo con pacientes de ≥ 75 años que ingresaron en una UGA 
en un hospital terciario. Se propuso una intervención basada en una entrevista clínica 
con el farmacéutico, historial farmacoterapéutico y una revisión estructurada de la 
medicación dentro de una valoración geriátrica integral (VGI). Se analizaron las 
diferencias con respecto a la polifarmacia (resultado primario, ≥5 medicamentos 
crónicos), la hiperpolifarmacia (≥10), el número de medicamentos, los problemas 
relacionados con los medicamentos (PRM) y los criterios STOPP (Screening Tool of 
Older Person’s Prescription)/ START (Screening Tool to Alert doctors to Right 
Treatment) entre el ingreso y el alta. 
Resultados: entre octubre de 2016 y abril de 2017, se reclutaron 234 pacientes, con 
una edad media de 87,6 años (DE = 4,6); 143 (61.1%) eran mujeres. La intervención dio 
como resultado una mejoría estadísticamente significativa en la polifarmacia (-10.2%, 
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IC 95%, -15.3, -5.2), hiperpolifarmacia (-16.6%, IC 95%, -22.3, -11.0), número de 
medicamentos (-1.4, IC del 95%, -1.8, -1.0), criterios STOPP (-19.2%, IC del 95%, -24.9, -
13.6), criterios START (-6.8%, IC del 95%, -10.1, -3.5) y PRM (- 2.7, IC del 95%, -2.9, -2.4) 
(p <0.001 para todos ellos). 
Conclusiones: una intervención sistemática dirigida por un farmacéutico en el ingreso 
hospitalario en una UGA en el contexto de una VGI se asoció a una disminución de la 







Thanks to the Complejo Hospitalario de Navarra for the opportunity to take my 
first steps in research with IV Specialized Healthcare Posttraining Program and for 
being always open to this project.  
My deepest gratitude to my supervisor Nicolás Martínez Velilla, for your 
confidence from the first moment, for teaching me everything with generosity and for 
demanding and taking care of me in equal parts. Half of this doctoral thesis is yours. 
Thanks to Mikel Izquierdo for making everything easier and making it possible. 
I would like to thank all my coauthors of the articles of this thesis for everything 
you have contributed: Pablo Aldaz, Javier Alonso, Idoia Beobide, Álvaro Casas, Abel 
Cedeño, Matteo Cesari, Beatriz Contreras, Thamara Domene, Alex Ferro, Arkaitz 
Galbete, Belén González, Marco Inzitari, Mikel Izquierdo, Esther Lacalle, Beatriz 
Larráyoz, Pello Latasa, Vincenzo Malafarina, Itxaso Marín, Nicolás Martínez, and Pilar 
Monforte. 
I also would like to thank Eli Genua for putting the seed of this doctoral thesis, 
and to Idoia, Alex and all the team of Matia for your support and for teaching me so 
much. Eskerrik asko. 
To all the Navarrabiomed team, for your professionalism, availability, and your 
invaluable help always.  
I am also grateful to all the Department of Pharmacy of the Complejo 
Hospitalario de Navarra for their support.  
I would like to give special thanks to Matteo Tosato, Graziano Onder and all the 
team of the Policlinico Gemelli for those months in Rome. Grazie a tutti. 
Escribiendo estos agradecimientos recuerdo a todas las personas que a lo largo 
de los años me han enseñado todo lo necesario para poder llegar hasta aquí (algunas 
ya mencionadas y otras que faltarán): desde mis profesores del colegio o 
universidad(es), hasta aquellos con los que trabajo cada día. Gracias a Fernando 
27 
 
Marcotegui y a todos los adjuntos de Virgen del Camino que me guiaron durante la 
residencia: Marien, Camino, Esther, Mercedes, Javier;  a todas mis compañeras de 
residencia, que fuisteis y sois también maestras, compañeras y amigas, en especial a 
María, Nani, Marta y Pilar; y en general a todas las personas con las que trabajé en ese 
periodo de gran aprendizaje.  
Gracias a todo el Servicio de Geriatría del CHN por acogerme desde el primer día, 
sois los mejores. Gracias especialmente a Javi y María, a todos los geriatras (Belén, 
Álvaro, Itziar, Agurne, Vincenzo, Bea, Abel, Jose Luis), a Itxaso, Fernanda, Ana y Nancy, 
a Carlos y Elena, a enfermeras, auxiliares y a todo el equipo; y a los pacientes y 
familiares  que colaboraron. También a todo el grupo de investigación en Geriatría, de 
los que tengo tanto que aprender. 
Gracias a toda la tropa Goofy por estar siempre ahí, no podría haberlo hecho sin 
vosotros.  
Y finalmente gracias a mi familia, especialmente a mis padres, a Artai y Gala (la 
mayor alegría de estos años de tesis) y a Cris, mi espejo y mi ejemplo para todo.  
 







1. Medication in older adults 
As a result of the increasing life expectancy and decreasing birth rates, an 
accelerated aging of the population has occurred. Currently, almost 19% of the Spanish 
population is aged over 65, which is projected to increase to 35% by 2066 [1]. In 
addition, the proportion of octogenarians, who now represent 6.1% of the entire 
population, is continuing to grow. Spain’s life expectancy at birth is among the highest 
in the world, at 83.1 years (85.7 for women and 80.4 for men) [2], and it is expected to 
become over 85 for both genders by 2040 [3]. 
This demographic shift has huge implications for health care and health 
systems[4].  One of the most important issues to consider is the specific characteristics 
of older adults regarding the use of medications.  
The aging process is characterised by relevant structural and functional 
modifications. The organism presents a decrease in the capacity for adaptation and 
internal response, and an overall reduction in the physiological reserve and defence 
mechanisms. These modifications determine changes in drug pharmacokinetics and 
pharmacodynamics. All phases of pharmacokinetic processes (absorption, distribution, 
metabolism, and excretion) can suffer changes [5, 6]; for example, delayed gastric 
emptying, reduced blood flow, absorption surface, and gastrointestinal motility can 
cause a decrease in absorption. Increased body fat mass and reduced body total water 
volume typically cause an increased volume of distribution and half-life for lipophilic 
drugs and an increased plasma concentrations for water-soluble drugs. First-pass and 
phase I metabolism can also be affected by reduced hepatic blood flow and overall 
liver mass. With respect to excretion, renal elimination of water-soluble drugs can be 
impaired due to reduced renal blood flow and glomerular filtration rate. On the other 
hand, ageing-associated changes in pharmacodynamic processes can be related to 
both differences in baseline performance and differences in sensitivity. The most 
studied changes in pharmacodynamics have been in relation to the central nervous 
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system (CNS) and cardiovascular agents, including exaggerated or paradoxical 
responses to drugs acting on the CNS and modified responses to calcium channel 
blockers (CCB) and β-adrenergic agents [5]. However, as a result of known changes in 
the organ functions and body composition, changes in pharmacodynamics in the 
elderly are less predictable than changes in pharmacokinetics. There exist several 
methodological issues with respect to studies concerning the effects of age on 
pharmacodynamics, and they depend on many different factors; thus no universal 
rules can be stablished [7]. Overall, all ageing-associated changes can affect drug 
effectiveness and toxicity, rendering the use of medications in the elderly a less 
predictable process.  
The lack of evidence regarding the effectiveness and safety of medications in 
older adults is another source of uncertainty. Older people have been systematically 
excluded from clinical trials of drugs, not simply due to age, but as a result of other 
characteristics often present in these patients, such as comorbidity, polypharmacy, 
and cognitive or functional impairment [8, 9]. This limits the generalisability of clinical 
trial findings in the elderly, and forces extrapolation of results from younger 
populations. It would also be necessary to adapt clinical trial outcomes to those 
different from traditional ones in order to consider important variables in older 
populations. Clinical trials do not typically consider short-term objectives such as 
function, walking speed, or quality of life; instead, longer-term objectives, such as 
survival time, are the focus [10]. Moreover, clinical practice guidelines, which usually 
support clinical decisions regarding drug prescription, are based on the scarce 
evidence provided by clinical trials and are focused on individual diseases and not on 
the characteristic multimorbidity of older adults [11].  
On the other hand, clinical practice guidelines are often unable to encompass the 
heterogeneity of elderly patients [11]. Different factors, such as life-expectancy, 
functional and cognitive abilities, social and family environment, quality of life, time to 
benefit from treatment, or patient preferences, priorities, and expectations, will 
modify therapeutic and treatment goals, affecting decision-making regarding the use 
of medications in older adults [12]. Medication prescription needs to be adapted to 
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each patient and situation throughout life, since the concepts of risk and benefit are 
variable, not constant. 
Medication non-adherence is another issue regarding the use of medications in 
older adults that can compromise the effectiveness and safety of therapies. Older 
people may present a higher risk of non-adherence to medications as compared with 
younger populations, with an estimated average adherence rate of less than 45% [13]. 
Non-adherence to treatment is conditioned by polypharmacy and complex regimens of 
medications usually associated with multimorbidity, but also by other factors such as 
functional and cognitive abilities, social situation and family structure, dysphagia, or 
visual and auditory problems. Older people experience practical problems with 
medication use that are not common in younger patients, including problems reading 
or understanding instructions for use, handling packaging, preparing prior to use, or 
drug taking [14].  
The healthcare system itself plays an important role in medication use in older 
adults. Health systems are yet to adapt to the new demographic and epidemiological 
situation, with a predominant profile of elderly patients with chronic diseases, and 
individual diseases still dominate health care delivery [15]. The use of many services 
for the management of individual diseases, including various professionals without 
good communication or coordination and frequent transitions between levels of care, 
can be duplicative and inefficient and may lead to numerous changes in treatment, 
overtreatment, and medication errors. In these cases, the role of the pharmacist can 
be an integrator and coordinator of pharmacological aspects. 
Demographic transition of population aging has been accompanied by an 
epidemiological transition, with a modification of disease patterns towards chronic 
pathologies. Today, most older adults have chronic diseases, and most patients with 
chronic diseases have more than one chronic disorder, which is usually referred to as 
multimorbidity. Is has been estimated that multimorbidity in people above 65 years 
old is 67%, with the prevalence increasing with age and reaching 82% in people over 
85 [15]. With the focus of medical care remaining on the disease, polypharmacy is the 
clearest consequence of multimorbidity on the treatment of elderly patients. 
Polypharmacy, the concurrent use of multiple drugs by an individual, is very common 
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in elderly patients and is considered one of the new geriatric syndromes [16]. There is 
not a clear consensus regarding the definition of polypharmacy, although the use of 
five or more medications is the most common threshold [17]. An increased number of 
medications have been associated with a higher cost, an increase in drug-drug and 
drug-disease interactions, poorer medication adherence, or prescription cascades —
the prescription of a new medicine to treat an adverse drug reaction associated with 
another medicine—[18-20]. Therefore, polypharmacy goes beyond the high number of 
drugs used in quantitative terms, but is related to taking more drugs than clinically 
appropriate in qualitative terms. Although polypharmacy could be appropriate and 
necessary in some cases, it is very unlikely to happen if the treatment is not 
comprehensively reviewed and monitored. For this reason, as an additional concept to 
polypharmacy, the inappropriate prescription in the elderly is defined as: “the use of 
medicines that introduce a significant risk of an adverse drug‐related event where 
there is evidence for an equally or more effective but lower‐risk alternative therapy 
available for treating the same condition. It also includes the use of medicines at a 
higher frequency and for longer than clinically indicated, the use of multiple medicines 
that have recognised drug–drug interactions and drug–disease interactions, and the 
under‐use of beneficial medicines that are clinically indicated but not prescribed for 
ageist or irrational reasons” [21]. Several methods have been developed for the 
quantitation of potentially inappropriate prescription, mainly as criteria or lists of 
medications to avoid; and again, polypharmacy is associated with the presence of 
these prescriptions [22, 23]. In observational studies, both polypharmacy and 
potentially inappropriate prescriptions have shown an association with adverse health 
outcomes such as adverse drug events, falls, delirium, malnutrition, hospital and 
nursing home admissions, and even mortality [24-26]. It is estimated, for example, that 
between 10% and 20% of hospital admissions involving elderly people in Spain are 
related to adverse drugs effects [27, 28], polypharmacy being one of the associated 
factors. In an attempt to preserve or improve the state of health in older adults, 





2. Prevalence of polypharmacy in the older Spanish population 
As a result of the aging population, it has been suggested that the prevalence of 
polypharmacy is increasing, and its complexity and negative consequences for patients 
and healthcare systems and medication use in older people is attracting great interest 
among the medical community and health managers. In Chapter 1, the prevalence of 
polypharmacy in non-institutionalised older adults in Spain according to the last 
published National Health Survey (ENSE) is estimated, and associated factors assessed.  
Other studies have estimated the prevalence based on previous national health 
surveys or European health surveys in Spain [29, 30]; however, the progressive 
demographic and epidemiological changes in our population necessitate an update of 
this information with the latest data. In addition, in the present study, a sensitivity 
analysis was included to reduce possible underestimation due to the methodological 
limitations of the ENSE for pharmacoepidemiological purposes. Analysis variables that 
may be relevant in elderly people, such as dependency for basic activities of daily living 
or geriatric syndromes, were included in the present study, which have not been 
included in previous studies.  
 
3. Frailty and polypharmacy 
Frailty is an age-linked concept that defines a state of vulnerability characterised 
by the inability to adequately respond to stressors, which could have multiple 
implications for medicine use in older people (Figure 1) [31].  
Figure 1: Vulnerability to a sudden change in health status following a minor illness (from Clegg, A, Young, J, 
Iliffe, S, Rikkert, MO, Rockwood, K. Frailty in elderly people. Lancet 2013;381:752-62) 
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The aforementioned demographic and epidemiological transitions announce a 
«third transition» or «clinical transition» that places the focus on functional capacity 
instead of on disease [32, 33]. Disability is the primary manner in which health 
problems manifest in the elderly and what limits patient well-being. Therefore, the 
new challenge for health systems is to prolong disability-free survival and provide 
assistance to a growing number of dependent persons. Within this context, the 
concept of frailty emerged, since it was observed that some people are more 
predisposed to losing functional capacity when presented with a health problem [34]. 
The term began to be used more frequently in the late 1990s, when Campbell and 
Buchner defined it as “a condition or syndrome that results from a multi‐system 
reduction in reserve capacity to the extent that a number of physiological systems are 
close to, or past, the threshold of symptomatic clinical failure, and that is associated 
with an increased risk of disability and death from minor external stresses” [35]. Since 
then, different definitions and measurement tools have been proposed, but two 
approaches or models stand out.   
The frailty phenotype proposed by Fried and colleagues in 2001 [36], resulting 
from a prospective study, the Cardiovascular Health Study (CHS) [37], understands 
frailty as a clinical syndrome that is expressed in five domains: nutritional status, 
energy, physical activity, mobility, and strength.  
There also exist the cumulative deficit model proposed by Rockwood and 
colleagues in 2007 [38], from the Canadian Study of Health and Aging (CSHA) [39]. This 
model understands frailty as the cumulative effect of individual deficits expressed as 
signs, symptoms, abnormal laboratory values, disease states, and disabilities; such 
that, a greater number of deficits corresponds to a greater degree of frailty. According 
to this approach, frailty is a continuous variable that does not end with disability or 
dependence but increases progressively until death. 
Both models have shown predictive value for various adverse health outcomes 
and often overlap in their identification of frailty [40, 41]; however, they cannot be 
considered equivalent, and it has been proposed that they could be useful under 
different circumstances [42].  
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An attempt has been made to reach an operational definition of frailty through 
expert consensus. In 2013, a project led by Rodríguez-Mañas defined frailty as a clinical 
syndrome characterised by decreased reserve and diminished resistance to stresses 
that increases vulnerability [43]. In the same year, Morley et al. defined frailty as “a 
medical syndrome with multiple causes and contributors that is characterised by 
diminished strength, endurance, and reduced physiological function that increase an 
individual’s vulnerability to developing increased dependency and/or death” [44]. 
Despite these attempts, different conceptual views remain, and there are difficulties in 
obtaining a single definition that satisfies all the experts. There appears to be 
consensus, however, that frailty is a state of multidimensional and multifactorial 
vulnerability, which is dynamic and potentially reversible and associated with 
functional capacity, being able to predict adverse health outcomes [45].  
Many tools have been proposed for the detection or measurement of frailty [46]. 
Fried's phenotype translates into five criteria, considering a patient pre-frail when they 
meet one or two of the following conditions, and frail when they meet three or more: 
involuntary weight loss, exhaustion, low energy expenditure, slow gait speed, and 
weak strength. The cumulative deficit model is demonstrated by the frailty index (FI), 
which assesses the total number of deficits as a proportion of the total number of 
items evaluated. The deficit model also uses the Clinical Frailty Scale, which classifies 
individuals into seven groups based on the frailty index [39]. From these two models, 
various modifications have been proposed for the development of numerous frailty 
scales, with some designed in our environment [47], and by pharmacists [48]. Some of 
the most well-known tools, in addition to those already indicated, are the Groningen 
Frailty Indicator [49], Tilburg Frailty Indicator [50], Edmonton Frail Scale [51],  different 
frailty indices, and physical capacity tests such as the Short Physical Performance 
Battery (SPPB) [52]. 
Although primarily associated with the field of geriatrics, frailty has now been 
extended to multiple medical disciplines [53]. Frailty has better predictive value for 
different adverse health outcomes than does chronological age, and the integration of 
this concept avoids ageism bias by allowing objective stratification according to needs 
and risks instead of exclusively by age. Although frailty conditions are not prevalent in 
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community-dwelling elderly people (approximately 11% of people over 65 years old) 
[54], it is gaining importance at a public health level due to the fact that frailty is 
considered a potentially detectable and reversible step prior to disability, and serves as 
a target for preventive interventions that contribute to successful ageing [55].   
Frailty is a syndrome in which multiple interrelated physiological systems are 
involved. The decrease in physiological reserves is accelerated and the homeostatic 
processes begin to fail. The mechanisms involved in its development are complex and 
determined by genetic, environmental, and epigenetic factors that produce cumulative 
damage at both the cellular and molecular level [53]. The nervous, endocrine, and 
immune systems, in addition to skeletal muscle, have been best studied with respect 
to the development of frailty [56, 57]. One example of this implication is sarcopenia, 
which is considered one of the main causes of frailty [58]. Malnutrition is another 
condition that is considered an important risk factor for the development of frailty [59, 
60].  
Recent studies have found that different chronic diseases such as diabetes [61], 
COPD [62], or atrial fibrillation[63] may play a role in the onset of frailty. According to a 
recent review, frailty is also associated with the presence of multiple chronic diseases 
or multimorbidity [64].  
The relationship between frailty and drugs is highly complex due to the 
physiological, cellular, or molecular processes involved in the presentation of frailty 
and drug activity. It seems plausible that the physiological changes that occur in frailty 
have an impact on drug pharmacokinetics and pharmacodynamics. In a systematic 
review, Corsonello et al. found that glomerular filtration rate is associated with degree 
of frailty [65]. Ageing has traditionally been associated with changes in drug 
pharmacokinetics, but this association appears to be stronger with frailty, especially 
for the processes of metabolism and excretion [66-70]. Older people also appear to be 
more sensitive to certain medications; however, evidence for the role of frailty in 
pharmacodynamics or drug efficacy remains underdeveloped [71-73]. Examples of 
altered pharmacodynamics include an increase in sedation produced by some drugs in 
frail patients [74], and a greater susceptibility to fall-risk-increasing drugs [75]. There 
are also plausible mechanisms by which the use of medications can contribute to 
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frailty. A relationship has been found between the number of medications taken and 
weight loss, impaired balance, poor nutritional status, and functional impairment, all 
of which are clinical features of frailty [76]. These data highlight polypharmacy as a 
possible mechanism that contributes to frailty. 
Several observational studies have explored the association between frailty and 
polypharmacy in older people using different methods and objectives [77-79]. In 
Chapter 2, the available research evidence for a relationship between frailty and 
polypharmacy in older adults is summarised in a systematic review.  
 
4. Frailty and underprescription in nursing homes  
Other factors typically associated with polypharmacy may play a role in the 
development of frailty. It has been found that the use of drugs with anticholinergic 
properties is more frequent in frail patients, and that the risk of developing frailty 
increases proportionally with anticholinergic load [80-83]. The use of potentially 
inappropriate medications in elderly patients in relation to frailty has also been 
studied. Cullinan et al. found a positive association between a frailty index and the 
number of STOPP (Screening Tool of Older Persons’ potentially inappropriate 
Prescriptions) criteria [84]. Two studies have demonstrated an increased risk of 
prescribing inappropriate drugs to frail patients according to STOPP criteria [84, 85]. 
Maclagan et al. found a higher prevalence of Beers criteria in frail patients than in 
those who were not [86]. Moreover, Martinot et al. found that the presence of 
potentially inappropriate prescriptions increases the risk of becoming frail according to 
data from a three-year follow-up period [87]. Similarly, frail patients may be more 
exposed to underprescription of beneficial medicines that are clinically indicated, 
which is sometimes included in the potentially inappropriate prescription criteria. 
However, the association between frailty and underprescription has barely been 
studied [88]. In addition,   although the association between polypharmacy and frailty 
has been studied in different settings, the evidence regarding patients in nursing 
homes is scarce [89]. Moreover, the heterogeneity of frailty measurement tools could 
have a role in the results found on this topic. To fill these three knowledge gaps, in 
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Chapter 3, the possible association among polypharmacy, underprescription, and 
frailty in older people living in nursing homes is examined according to different scales. 
 
5. Medicine optimisation in hospitalised older adults 
The data obtained in chapter 1 are very important in understanding the 
characteristics and trends of polypharmacy at the population level. However, in the 
case of polypharmacy, this view can prevent us from adequately estimating the 
magnitude of the problem when it is concentrated in specific population groups. An 
analysis in a more specific care setting can contribute complementary information, 
providing another approach that focusses the problem. Chapter 3 focused on older 
people in nursing homes, a population with high rates of frailty, polypharmacy, and 
inappropriate use of medications [90-92]. In Chapter 4 attention is shifted to another 
population group within the elderly, which is also particularly vulnerable to the harms 
of medications: hospitalised patients. The profile of older inpatients is multimorbidity, 
polypharmacy, and drug-related problems, in addition to complexity as a result of 
functional, cognitive, affective or social reasons. It has been suggested that 
hospitalisation itself may worsen polypharmacy and drug-related problems due to 
concomitant acute and chronic disorders, transitions of care, and the involvement of 
many professionals; however, its effects on the modification of pharmacological 
treatments remain controversial [93-95]. This could lead to worse health outcomes 
during hospitalization or following discharge. In Chapter 4, the influence of 
hospitalisation in an acute geriatric unit on polypharmacy, potentially inappropriate 
prescriptions, and other medication indicators are measured. The possible impact of 
these characteristics on mortality, hospitalisations, and emergency room visits are also 
explored. 
Due to the complexity of medication use in older adults, especially in some 
population sectors such as hospitalised patients, several strategies have been 
proposed to address the problems of polypharmacy and inappropriate use of 
medication, and their negative consequences. There have been a wide range of 
proposed interventions regarding the professionals involved, the tools used, or the 
outcomes measured, which render it difficult to clarify the best strategy for medicine 
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optimisation in older inpatients. For this reason, in Chapter 5, in a systematic review, 
we summarise the evidence regarding interventions aimed at optimising drug 
treatment in hospitalised elderly patients. 
Although hospitalisation has been previously highlighted as a particularly 
appropriate period for the implementation of interventions to improve medication 
appropriateness, medication optimisation strategies in elderly people admitted to 
hospital are not widely extended in Spanish clinical practice. From the beginning of this 
research to the present moment, there have been no experiences in Navarra of 
strategies for medicine optimisation in hospitalised elderly people, beyond medication 
reconciliation in selected patients. Therefore, we intended to implement an 
intervention in our environment that could describe the expected benefits by patients 
and the health administration, and the procedures and tools necessary to make it 
reproducible and applicable to clinical practice.  
The best results with respect to improvements in important health outcomes, 
such as readmissions or emergency room visits, have been shown for multifaceted 
multidisciplinary interventions [96-99]. As medicine experts, pharmacists could be 
valuable in an intervention to optimise treatment in elderly patients. Pharmacist-led 
medication reviews are beginning to be implemented in other countries within 
different health settings with a view to optimising medication in older patients with 
polypharmacy. However, its application is different according to the environment in 
which it is carried out, and it is important that the procedure is adapted to the 
appropriate environment and the patients to whom it is directed. As will be shown in 
chapter 4, the profile of the patient admitted to acute geriatric units is very specific 
regarding complexity and drug-related problems. Acute geriatric units (AGUs) were 
designed to attend to the special needs of older inpatients, and can be defined as 
hospital units with their own physical location and structure, run by a specialised 
multidisciplinary team with direct responsibility for the care of elderly people with 
acute medical disorders. AGUs have shown a functional benefit as compared with 
conventional hospital care and an increased likelihood of living at home following 
discharge [100]. Comprehensive geriatric assessment (CGA),  as the main tool in 
geriatric medicine, is a multidimensional multidisciplinary diagnostic process assessing 
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older people's medical, psychological, and functional capability in order to develop a 
coordinated and integrated plan for treatment and long-term follow-up focused on the 
individual's needs [101]. As we have seen, not only diseases but several other factors 
are important for decision-making regarding the use of medications. Our approach was 
a specific multi-disciplinary intervention focused on drug treatment in the context of a 
CGA in an AGU to improve the use of medications in older inpatients from a holistic 
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Aims and hypothesis  
 
General objective 
Aim: to assess the problem of polypharmacy in the elderly in different settings and its 
relationship with frailty and explore strategies to optimize treatments in most 
vulnerable sectors. 
Hypothesis: polypharmacy is a growing problem in the elderly population that cannot 
be explained by multimorbidity alone, and is especially concentrated in vulnerable 
sectors, where the introduction of multidisciplinary specific strategies from a 
perspective not only focused on the disease can favor a more appropriate use of the 
medications. 
Specific objectives 
Chapter 1: Prevalence of polypharmacy and associated factors in older adults in Spain: 
Data from the National Health Survey 2017 
Aim: to estimate the prevalence of polypharmacy and hyperpolypharmacy in non-
institutionalized older adults in Spain and to assess the associated factors. 
Hypothesis: the prevalence of polypharmacy in non-institutionalized older adults in 
Spain is high and could be associated to other factors than socio-demographic and 
comorbidities.  
 
Chapter 2: The relationship between Frailty and Polypharmacy in older people: a 
Systematic Review 
Aim: to analyse the available research evidence on the relationship between frailty and 
polypharmacy in older adults. 




Chapter 3: The Relationship between frailty, polypharmacy, and underprescription in 
older adults living in nursing homes 
Aim: to examine the possible association between polypharmacy, underprescription, 
and frailty in older people living in nursing homes according to different scales and 
explore the interaction between polypharmacy, multimorbidity, and different 
definitions of frailty. 
Hypothesis: polypharmacy could be associated with frailty and underprescription in 
older adults living in nursing homes, morbidity wouldn´t be the only modulator for this 
association, and could differ depending on the frailty scale used. 
Chapter 4: Impact of hospitalization in an acute geriatric unit on polypharmacy and 
potentially inappropriate prescriptions: A retrospective study 
Aim: to measure the influence of hospitalization in an acute geriatric unit on 
polypharmacy, potentially inappropriate prescriptions, underprescription, drug 
interactions, anticholinergic burden and inappropriate use of drugs in patients with 
impaired renal function. The secondary objective was to measure the possible impact 
of these characteristics on mortality, hospitalizations and emergency room visits in 
these patients. 
Hypothesis: during hospitalization in an acute geriatric unit, polypharmacy, potentially 
inappropriate prescriptions, underprescription, drug interactions, anticholinergic 
burden and inappropriate use of drugs in patients with impaired renal function do not 
decrease, and these measures can be associated with increased mortality, 
hospitalizations and emergency room visits. 
 
Chapter 5: Interventions to optimize pharmacologic treatment in hospitalized older 
adults: a systematic review 
Aim: to summarize the evidence on interventions aimed at optimizing the drug 
treatment of hospitalized elderly patients. 
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Hypothesis: pharmacological treatment of older inpatients can be optimized during 
hospitalization with a wide range of specific interventions.   
 
Chapter 6: A medicine optimization strategy in an acute geriatric unit: the pharmacist 
in the geriatric team 
Aim: to describe a new medicine optimization strategy in an acute geriatric unit and 
explore its effectiveness to reduce polypharmacy and improve medication 
appropriateness. 
Hypothesis: a pharmacist-led medicine optimization strategy in an acute geriatric unit 





Chapter 1:  
Prevalence of polypharmacy and associated factors in older 
adults in Spain: Data from the National Health Survey 2017 
 
1. Introduction 
Over the last few decades, enormous demographic and epidemiological changes 
have occurred in Spain, resulting in an aging population and a greater prevalence of 
chronic diseases [1]. This new situation has been accompanied by an increase in 
chronic drug use to treat these diseases, especially in elderly people [2].  
The use of medications in elderly people is complex, due to age-related changes 
in pharmacokinetics and pharmacodynamics, multimorbidity and other factors that 
condition complexity in the elderly, such as functional and cognitive impairment or 
geriatric syndromes. It is also due to the limited available evidence on the efficacy and 
safety of medicines in this population [3, 4]. Furthermore, the use of multiple drugs 
simultaneously, which has been called polypharmacy, despite being the logical 
response to the coexistence of multiple diseases, can be a problem in and of itself [5]. 
Polypharmacy is associated with an increase in drug-drug and drug-disease 
interactions, a decrease in medication adherence, an increased risk of anticholinergic 
effects and, in general, adverse drug effects, perhaps due to an increase in the number 
of potentially inappropriate prescriptions in a particularly vulnerable population [6, 7]. 
Probably because of all this, polypharmacy has been associated with poorer health 
outcomes in the elderly, increasing the risk of delirium, malnutrition, falls, hospital 
admissions and even mortality, among others [8, 9]. It is estimated, for example, that 
between 10 and 20% of the hospital admissions in older people in our country would 
be related to adverse drug effects, being polypharmacy one of the associated factors 
[10]. In an attempt to preserve or improve health conditions in older adults, excessive 
or not sufficiently careful use of medications can end up being more harmful than 
beneficial. The latest evidence suggests that a high consumption of medications can 
contribute to frailty, regardless of the associated comorbidities, conditioning a worse 
vital prognosis in the elderly [11]. In addition, excessive polypharmacy can have an 
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important economic impact on the public health system, both due to the increase in 
direct expenditure on medications and the indirect costs derived from consultations, 
emergency room visits, or hospital admissions. On the other hand, it must also be 
considered that a high consumption of medications increases the "burden of 
treatment" for the patient, and may affect their perceived health status, their well-
being and their quality of life [12].   
In order to face the causes and consequences of this problem and to improve 
behaviours and strategies towards a more appropriate use of medications at the 
individual and population level, it is essential to know the extent of polypharmacy 
among the elderly in our population. Other studies have been carried out in order to 
know the prevalence of polypharmacy in the non-institutionalized elderly in Spain, 
some at the local or regional level [13-15] and others based on National or European 
Health Surveys previously conducted in Spain [2, 16]. The demographic and 
epidemiological changes that occur progressively in our population make it necessary 
to update this data, which in recent years has shown an upward trend. The data of the 
National Health Survey of Spain 2017 (ENSE 2017), made by the Ministry of Health, 
Consumption and Social Welfare with the collaboration of the National Institute of 
Statistics, was published in June 2018 and it collects health information related to the 
population residing in Spain in 23,860 homes [17]. It is an investigation that allows us 
to explore numerous aspects of the health of the citizens at a national and regional 
level, and to plan and evaluate the actions in health services. Among others, the ENSE 
provides information on the consumption of medications in a representative sample of 
the entire population, although it requires certain adjustments to adequately estimate 
the prevalence of polypharmacy that have not been carried out in previous studies. 
Moreover, it provides essential information on the elderly population, such as 
functional or cognitive capacity, perception of health status or certain geriatric 
syndromes. The incorporation of these factors into the analysis of polypharmacy in 
elderly people is essential to understand the patterns of drug consumption in the 
elderly, so we included them for the first time in this study together with 




The aim of the present study is to estimate the prevalence of polypharmacy and 
hyperpolypharmacy in non-institutionalized older adults in Spain and to assess the 
associated factors. 
 
2. Material and methods  
2.1 Study design and population 
Cross-sectional study with data obtained from the Spanish National Health 
Survey of 2017 (ENSE 2017), selecting participants who are 65 years old or older. The 
ENSE is the result of the Collaboration Agreement signed between the Spanish Ministry 
of Health, Social Services and Equality and the Spanish National Institute of Statistics, 
and the target population of the study are the people living in the main family 
dwellings of the Spanish territory in 2017. The information was collected through 
computer-assisted personal interviews in the homes of the selected participants, and 
carried out by specifically instructed interviewers. The interviews were conducted 
between October 2016 and October 2017. The ENSE, by using stratified three-stage 
probabilistic sampling, is rendered nationally and regionally representative. The first 
stage units are the census sections, the second stage units are the main family 
dwellings, and the third stage units are adults selected from each home to complete 
the Adult Questionnaire. The sample is distributed among regions assigning one 
portion evenly and another proportionally to the size of the region. The Adult 
Questionnaire had to be answered by the selected adult, except for in the cases of 
hospital admission, disability due to illness/disability or problems due to language. In 
these cases it was allowed that another person answers the questionnaire in the 
selected person’s name.  
Variables 
The main outcome measures are the prevalence of polypharmacy and 
hyperpolypharmacy and the number of medications consumed. Sociodemographic 
factors (sex, age, marital status, educational level), use of the healthcare system 
(hospital admissions and emergency room visits in the last year, consultation with 
general practitioner or specialists in the last 4 weeks, health insurance modality), 
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comorbidity, independence for basic activities of daily living (BADL), perceived health 
status, cognitive impairment and body mass index (BMI) are considered as 
independent variables.  
Polypharmacy is defined as the consumption of 5 or more medications during 
the last two weeks prior to the interview, and hyperpolypharmacy as the consumption 
of 10 or more medications. Participants were specifically asked "which of these drugs 
have you consumed in the last 2 weeks?", considering for the present study the 
following categories: "medicines for the cold, flu, throat, bronchi, for pain, to lower 
fever, restorative such as vitamins, minerals and tonics, laxatives, antibiotics, 
tranquilizers, relaxants and sleeping pills, medications for allergy, for diarrhea, for 
rheumatism, for the heart, for blood pressure, for the stomach and/ or digestive 
disorders, antidepressants or stimulants, hormones for menopause, drugs to lose 
weight, to lower cholesterol, for diabetes and for the thyroid". For the purpose of this 
study, this classification has been equated to the ATC therapeutic groups as much as 
possible. For each individual, all affirmative responses were added, thus estimating the 
total number of medications consumed. Although there is no consensus on the 
definition of polypharmacy, the threshold of 5 or more medications was chosen 
because it is the most commonly used [18].  
A previously validated multimorbidity assessment tool was used to measure the 
global burden of chronic diseases or health problems of the participants [19], adapting 
it to the questions of the ENSE regarding whether they had ever suffered the 
conditions considered. This tool collects 918 ICD-10 codes and groups them into 60 
categories of chronic diseases. Each of these categories has been compared to a 
question from the ENSE whenever possible, reflecting the most important pathologies 
(hypertension, hypercholesterolemia, chronic kidney disease, ischemic heart disease, 
other cardiac pathologies, osteoarthritis, auditory or visual impairment, obesity, 
thyroid pathologies, depression, malignant neoplasms, diabetes, stroke, osteoporosis, 
cataracts, asthma, COPD, peptic ulcer, prostatic diseases, other genitourinary 
pathologies, chronic anxiety, migraine, chronic allergy, mental health problems, 
chronic venous disease, cirrhosis, hepatic dysfunction and chronic skin conditions) 
(extended in supplementary material). The proposed methodology allows us to detect 
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a comprehensive set of chronic diseases that either have a long-lasting impact on older 
adults’ autonomy and quality of life or require enduring contacts with healthcare 
services. This tool, therefore, is well suited to describe the burden of chronic 
multimorbidity in our study population. Multimorbidity is expressed as the number of 
chronic health problems considered by this tool. The Katz Index [20] was used to 
evaluate the dependency for the basic activities of daily living, adapting it from the 
questions of the ENSE 2017, considering these 6 categories: difficulty for daily basic 
activities: showering or bathing without help; getting dressed and undressed without 
help; going to the toilet without help; sitting down, getting up from a chair or a bed, 
lying down without help; partial or total incontinence; feeding themselves (description 
in supplementary material). A score of 0 was assigned as very dependent and 6 as 
independent. The participants were considered to have cognitive impairment when 
they answered that they had been limited for at least the last 6 months to perform the 
activities that people usually do, due to a mental problem alone or a physical and 
mental one together. Finally, the participants were classified according to the following 
BMI ranges: <18.5 kg/m2 insufficient weight, ≥18 and <25 kg/m2 normal weight, ≥25 
and <30 kg/m2 overweight and ≥30 kg/m2 obesity. 
2.2 Statistical analysis  
First of all, a descriptive analysis was carried out showing the main characteristics 
of the study population using numbers and proportions in the case of qualitative 
variables and using means and standard deviations (SD) for quantitative variables. The 
prevalence of polypharmacy and hyperpolypharmacy was estimated with their 
corresponding 95% confidence intervals (CI). For the comparison of means, the 
Student test was used and for the comparison of proportions, the Pearson Chi-square 
test. The association between the consumption of the most frequent medications and 
the most common pathologies registered in the ENSE for which they are indicated was 
analyzed using the Chi-square test. 
One of the major limitations of the ENSE to estimate the prevalence of 
polypharmacy is that, as it only allows dichotomous yes/no responses to the 
consumption of different types of drugs, it does not contemplate the use of 
combination therapies for the same pathology (it always considers monotherapy). In 
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order to obtain an estimate closer to reality, a sensitivity analysis was carried out in 
which the fact that a proportion of the participants would be receiving combination 
therapy for two of the most frequent chronic health problems such as hypertension 
and diabetes in which this situation is common was contemplated. The average 
number of drugs consumed and the prevalence of polypharmacy and 
hyperpolypharmacy were calculated assuming that patients taking antihypertensive 
drugs consumed 1.8 antihypertensive drugs per patient (one antihypertensive drug 
alone in 38.3% of cases, two antihypertensive drugs in 43.5% of patients, three 
antihypertensive drugs in 15% of cases and four antihypertensive drugs in 3.2% of 
cases, based on previous literature[21, 22]); and that patients who used drugs for 
diabetes took an average of 1.5 antidiabetic agents (monotherapy in 54.2% of cases 
and two antidiabetic drugs in 45.8% of cases[23]). A homogeneous distribution for all 
participants in all polypharmacy categories was assumed. 
To identify factors associated with polypharmacy and hyperpolypharmacy, a 
multivariate logistic regression analysis was performed with all the variables included 
in Table 1. A limit for statistical significance of alpha <0.05 was established. All 
statistical analyses were performed with the IBM SPSS Statistics version 20 software 
(IBM Corp, Armonk, NY, USA). 
2.3 Ethical considerations 
 This study respects the fundamental principles established in the Declaration of 
Helsinki and its updates, and meets the requirements established in the legislation in 
the field of biomedical research, the protection of personal data and bioethics. 
According to the Methodology of the National Health Survey of Spain (ENSE) “the 
microdata files are anonymized. The microdata files of the ENSE are apt for public 
consumption and non‐identifiable, and therefore do not require agreements for their 
use. The files apt for public consumption are not considered confidential, in accordance 
with Regulation (EU) 2016/679 of the European Parliament and of the Council, of 27 
April 2016, on the protection of natural persons with regard to the processing of 
personal data and the free movement of such data. It is not necessary to apply the 
principles of data protection to anonymous information, that is, information that does 
not relate to an identified or identifiable natural person, nor to data that has been 
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converted into anonymous so that the interested party is not identifiable, or is no 
longer identifiable. Consequently, the Regulation does not affect the treatment of the 
information published by the ENSE. Even for statistical or research purposes, its use 
does not require the approval of an accredited ethics committee.” 
 
3. Results 
3.1 Main Characteristics 
The total sample of the ENSE 2017 comprises 29,195 individuals, of whom 7023 
who were 65 years old or older were selected. The mean age was 76.0 years (Standard 
deviation, SD 7.6), and 59.4% were women. The main characteristics of the 
participants are described in Table 1. 92.5% declared having a chronic or long-term 
health problem at the time of the interview (chronic meaning it has lasted or is 
expected to last at least 6 months). The most frequent chronic health problems were 
hypertension (56.0%), osteoarthritis (51.8%), hypercholesterolemia (43.3%), diabetes 
(22.4%), depression (18.0%), osteoporosis (13.0%), prostatic diseases (12.2%), chronic 
anxiety (11.3%), COPD (10.2%) and thyroid diseases (10.2%). Women had a higher 
mean number of chronic health problems than men (4.7 (SD 2.9) vs 3.8 (SD 2.6)), as 
well as older people compared to the youngest: 5.1 (SD 2.9) in the case of the older 
than 85, 4.8 (SD 2.9) in those 76 to 85 years old and 3.8 (SD 2.7) in those 65 to 75 years 
old. In the same way, people with higher levels of education suffered fewer chronic 
health problems than those with a lower level of education: without studies: 5.6 (SD 
3.2), primary studies: 4.6 (SD 2.8), secondary studies 3.8 (SD 2.6) and university studies 
3.5 (SD 2.5). Men rated their health status in the last 12 months as good or very good 
in 52.6% of cases compared to 40.4% in women, as medium in 34.2% of cases 
compared to 38.7% in women, and as bad or very bad in 13.1% of cases compared to 
20.9% in women (p <0.001). Men rated the pain suffered in the last 4 weeks as none 
(48.4%), very mild (10.7%), mild (15.1%), moderate (17.5%), severe (6.7%), and 





Table 1. Characteristics of study participants   










































Marital status (n=7012) 
 Single  
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 Widower 
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 Secondary education, baccalaureate or 
 professional education 












































































Sensory deficits  
 Auditory deficit 
           No 
           Yes 
 Visual deficit  
           No 












































Perceived health status  


























Health insurance modality 
 Public healthcare  
 State mutualities 












































































BMI, mean (SD) 
 Insufficient weight 
 Normal weight 
 Overweight 
 Obesity 






















SD: standard deviation, BMI: body mass index 





Out of all the participants, 91.9% reported having consumed some medication 
prescribed by a doctor in the last two weeks, and 11.2% some medication not 
prescribed by a doctor. Overall, 91.9% had used some medication in the last two 
weeks; 1914 individuals presented polypharmacy (27.3%, 95% CI 26.2-28.3) and 65 
presented hyperpolypharmacy (0.9%, 95% CI 0.7-1.1). Women presented 
polypharmacy and hyperpolypharmacy more frequently than men (31.3% vs 21.3%, p 
<0.001 and 1.3% vs 0.3%, p <0.001 respectively). Polypharmacy was more frequent in 
individuals between 76 and 85 years old (65-75 years: 21.6%, 76-85: 33.5% and> 85: 
33.0%). The differences between men and women were maintained in the different 
age groups, although they were not statistically significant in those older than 85 
(Figure 1).  
 
Figure 1. Prevalence of polypharmacy (%) by age group and sex 
 
Differences were found in the prevalence of polypharmacy among the different 
regions (Figure 2). Ceuta, Cantabria and La Rioja presented the lowest polypharmacy 
rates, while Andalusia, Galicia and Navarra presented the highest. Regarding the most 
consumed drugs, the most used groups were antihypertensive drugs (56.4%), 
analgesics (47.0%), lipid modifying agents (38.2%), drugs for the alimentary tract 
(32.2%), anxiolytics, hypnotics and sedatives (26.8%), drugs used in diabetes (20.2%) 
















Figure 2. Prevalence of polypharmacy by region 
 
Figure 3 shows the differences in the consumption of different drugs according 
to sex and age group.  
 
Figure 3. Consumption of different drugs by sex and age group 
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Figure 4 shows the association between the consumption of the most frequent 
medications and the most common pathologies recorded for which they are indicated.  
 
Figure 4. Prevalence of common drugs and diseases with common indications 
Participants consumed a mean of 3.3 (SD 2.2) medications, 2.9 (SD 2.0) in men 
and 3.6 (SD 2.3) in women (p <0.001). 
Sensitivity analysis considering the possible combination therapy for 
hypertension and diabetes showed that the mean number of medications consumed 
amounted to 3.9 (SD 2.5) drugs per person, and that the prevalence of polypharmacy 
and hyperpolypharmacy amounted to 37.5% and 2.5% respectively. 
The multivariate analysis showed that polypharmacy was positively associated 
with the number of chronic health problems, the dependence for BADL, a worse 
perceived health status, hospital admissions or emergency room visits in the last year, 
consultations in the last month with a general practitioner and medical specialist, 
obesity and widowhood; but not with sex or with being older. Furthermore, it was 
negatively associated with visual and auditory impairment and with urinary 
incontinence. The adjusted odds ratios (OR) for the presence of polypharmacy are 
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Table 2.Number of medications and factors associated with polypharmacy   
 No. medications Polypharmacy (≥5) 
 Mean (SD) Adjusted OR (CI95%) 
Sex 
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 76-85   









Marital status (n=7012) 
 Single  
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 Without studies 
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 Secondary education, baccalaureate or 
 professional education 
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 4-5  
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Cognitive impairment 








Sensory deficits  
 Auditory deficit 
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 Visual deficit  
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Perceived health status  
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SD: standard deviation, BMI: body mass index. OR: odds ratio 
* Due to the lost values for marital status (n = 11), odds ratios and confidence intervals were calculated for a 





In this study that assess the prevalence of polypharmacy and hyperpolypharmacy 
in the non-institutionalized elderly population of Spain, frequent drug use was found 
(up to 91.9% of respondents), and it was estimated that 27.3% of the elderly 
population presents polypharmacy (95% CI 26.2-28.3) and only 0.9% 
hyperpolypharmacy (95% CI 0.7-1.1). Important differences were found in the 
prevalence of polypharmacy among the different regions, with values ranging between 
4.7% and 32.4%. These variations could be due to differences in socio-demographic 
determinants and in health systems between different regions. There were also 
notable differences between both sexes in the pattern of drug consumption. Globally, 
women consumed more drugs than men, especially when considering analgesics, 
anxiolytics, hypnotics and sedatives, antidepressants, laxatives, and drugs for thyroid 
and antirheumatic pathologies. Men, however, consumed more drugs used in diabetes 
and drugs for the heart. There was also an increase in the consumption of drugs 
related to the increase in age, except for the case of women older than 85, who had a 
lower prevalence of polypharmacy than those who were between 76 and 85 years old. 
Some drug groups showed an increase in use with age (such as analgesics, laxatives, 
anxiolytics, hypnotics and sedatives, drugs for the heart, for the alimentary tract, and 
other medicines), but this trend was not present for other pharmacological groups 
such as lipid modifying agents, thyroid therapy or drugs for the respiratory system. 
Despite the differences found in the prevalence of polypharmacy in different sexes and 
age groups, the multivariate analysis including several factors found no association 
between the presence of polypharmacy and age or sex. There was also no association 
between polypharmacy and other characteristics in which a higher prevalence was 
found, such as a lower level of education or the presence of cognitive impairment.  
However, there was a positive association with the number of chronic health 
problems, dependence for basic activities of daily living, perceived health status or 
contacts with the health system; and a negative association with sensory deficits and 
incontinence. This data indicates that the increase in the prevalence of polypharmacy 
in women, older individuals or those with less educational level is probably due to the 
greater presence of other explanatory factors in these population groups (for example, 
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the greater number of chronic health problems in women and older people, a worse 
perceived health status, or a greater dependence for the basic activities of daily living). 
The differences in the baseline characteristics of the different population sectors could 
also explain the different patterns in the consumption of certain groups of medicines. 
For example, the greater degree of pain and dependence and the worse perceived 
health status in women may be related to the greater consumption of analgesics, 
antidepressants and anxiolytics, hypnotics and sedatives in this population sector. 
Furthermore, the multivariate analysis also suggests that certain characteristics such as 
sensory deficits and incontinence could lead to a lower prescription of drugs regardless 
of the number of diseases, which could be understood either as a sign of 
underprescription in these people or as an adapted prescription to the characteristics 
of the patient (in terms of prognosis, therapeutic objective, etc.). In any case, it is 
shown that drug prescription does not depend only on the number of diseases, it also 
depends on how they affect health status and daily life of the individuals, and on the 
interaction with the health system.   
The prevalence of polypharmacy found in previous studies has a great variability 
depending on the place and the methodology of each study. Some population studies 
performed in other countries in patients over 65 in primary care, estimated that the 
prevalence of polypharmacy reached 44% in Sweden [24], 39% in the United States 
[25], 41.2% in Switzerland [26] and up to 70.3% in France [27]. Other studies carried 
out at the regional level in Spain in elderly people in primary care, which recorded 
each drug individually, show prevalences between 45% and 83.1% [13-15]. A recent 
study carried out across Europe estimates a prevalence of polypharmacy between 26.3 
and 39.9%, reaching 31.6% in Spain [28], according to our same definition and taking 
data from surveys. There are also studies that estimated the prevalence of 
polypharmacy in non-institutionalized Spanish elderly population with previous 
National Health Surveys or European Health Surveys in Spain [2, 16]. Martín-Pérez et 
al. [2] showed a prevalence of polypharmacy of 19.7% and 24.5% in the ENSE of 2006 
and 2012, respectively, using our same definition of polypharmacy, and the mean of 
drugs consumed estimated in these surveys was 2.87 and 2.93 medications per 
individual respectively, compared to the estimate of 3.3 in our study. Likewise, 
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Carmona-Torres et al. [16] estimated that the prevalence of polypharmacy was 21.9% 
and hyperpolypharmacy 0.6%, taking 4 surveys carried out between 2006 and 2014 
into account. It should be noted that in the study carried out by Carmona-Torres et al. 
they included homeopathic and naturist products in the calculation of the number of 
medicines consumed, which we have not included here since they cannot be 
considered medicines, which could have slightly overestimated the figures in their 
study. From all this data we can derive the conclusion that there is a tendency to 
increase the consumption of drugs, polypharmacy and hyperpolypharmacy in the 
elderly population in Spain over recent years. This may be due to several factors, such 
as the increase in multimorbidity, the appearance of new drugs in the market or the 
medicalization of life [29]. Regarding the most consumed type of drugs, we found 
similar results to other studies, predominantly antihypertensive drugs, analgesics, lipid 
modifying agents and drugs for the alimentary tract [16], coinciding with the more 
frequent chronic health problems in this population.  
Regarding the implications of the results of this study, we must highlight the 
consequences that the increase of polypharmacy in the elderly population in our 
country may pose, beyond the direct increase in cost. Polypharmacy entails a greater 
therapeutic complexity when associated with an increase in medication-medication 
and drug-disease interactions, adverse reactions, therapeutic cascades or worse 
therapeutic adherence [9]. But besides being a quantitative issue, it is a qualitative 
change, since polypharmacy is closely linked to the inappropriate use of medications, 
which refers to treatments in which the risk is higher than the expected clinical 
benefit, especially when there are safer or more effective therapeutic alternatives [30]. 
Polypharmacy and the inappropriate use of medications are going to pose a growing 
challenge for the clinician, who will find more patients with polypharmacy and with 
greater complexity, so it is essential to know the most common potentially 
inappropriate medications in our environment (such as the use of benzodiazepines 
with a long half-life) [31], as well as certain tools that help detect and address this 
problem [32].     
The fact that we have used the official data of the Spanish National Health 
Survey has the advantage of knowing it has been obtained through a careful 
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methodology, including sampling, the design of the forms, the preparation of the 
interviewers, the supervision in the execution, or the data cleansing, which guarantees 
that we obtain a representative sample of the population and highly reliable data. In 
addition, by asking specifically about drugs consumed, the problem of overestimation 
that can occur in studies based on prescription or drug dispensing records ─which 
ignore the degree of adherence to treatment ─is avoided; and by asking about the last 
two weeks the risk of memory bias that occurs if you ask for longer periods of time is 
reduced. It also allows us to obtain data from individuals using different types of health 
insurance (up to 11.4% of participants in this study could use systems other than Public 
Health), something that may bias the results in studies based on medication records in 
public administrations or private insurers alone. In addition to the ENSE methodology 
itself, this study has other strengths, such as evaluating different factors associated 
with polypharmacy through a multivariate analysis that includes very relevant 
variables in elderly people such as dependence for basic activities of daily living or 
geriatric syndromes. This type of variables had not been included in previous studies 
conducted with national health surveys in Spain to study the use of medications, and 
show in this study that they are key factors that modulate the consumption of drugs in 
the elderly population.  
On the other hand, the use of Health Surveys for the estimation of 
pharmacoepidemiological data also has certain limitations. When dealing with self-
reported data, it must be taken into account that the degree of knowledge of the 
medication consumed and specifically its indication is not always optimal, especially in 
elderly people [33] with marked polypharmacy, which could lead to an 
underestimation in the prevalence. This could explain the low prevalence found for 
hyperpolypharmacy. Moreover, the ENSE does not include institutionalized people, 
who are precisely those who show higher levels of polypharmacy as reported by other 
studies [34, 35], which may also lead to an underestimation of polypharmacy in the 
elderly, taking into account that more than 4% of the Spanish population aged 65 or 
over is institutionalized [36]. In addition, the survey methodology itself does not allow 
us to know exactly which therapeutic groups are used, or whether polypharmacy is 
associated with specific pathologies and their severity. Finally, given that the survey 
has not been designed for the purpose of this study, it can only identify the use of 
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medications for each indication, always considering said medications to be used in 
monotherapy. For some of the most common health problems such as hypertension, 
pain or diabetes, the use of several drugs for the same indication is common, whereby 
this may be the most important cause of underestimation of polypharmacy, and part 
of the reason why the polypharmacy prevalence rates are notably lower than in other 
countries around us, where they record each medication individually, such as those 
cited above [24-27]. The sensitivity analysis proposed to try to correct this bias, 
although it only makes the correction for hypertension and diabetes, estimates a 
prevalence of polypharmacy up to 10 points higher (from 27.3% to 37.5%), thus 
approaching the figures obtained in studies carried out in other countries. In fact, the 
studies carried out at a regional level in Spain in elderly people in primary care that 
register each drug individually find rather higher prevalences [13-15], which also seems 
to suggest the underestimation that can occur due to the methodology of the ENSE.   
In conclusion, there is a significant consumption of drugs in the elderly 
population not institutionalized in Spain, and the trend observed in recent years to 
increase the prevalence of polypharmacy over time continues. The factors that are 
most associated with polypharmacy are the number of chronic health problems, 
dependence for basic activities of daily life, perceived health status or contacts with 
the health system; sensory deficits and incontinence being negatively associated. 
Knowing the patterns of drug use in our population and the associated factors is 
essential to understand the phenomenon of polypharmacy in the elderly and the 
extent of its consequences for the population, professionals and health systems. 
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6. Supplementary material 
Table S1. Chronic health problems 
Chronic health problems considered by Calderón-
Larrañaga et al.[19] 
Equivalent chronic health problems in National Health 
Survey of Spain (ENSE) 
Hypertension Hypertension 
Dyslipidemia High cholesterol 
Chronic kidney diseases Kidney problems 
Ischemic heart disease Ischemic heart disease (infarction or angina pectoris, coronary heart 
disease) 
Anemia - 
Osteoarthritis and other degenerative joint diseases Arthrosis 
Colitis and related diseases - 
Deafness, hearing impairment Difficulty hearing in a quiet place: Yes much difficulty or I cannot 
do it at all 
Heart failure Other heart diseases 
Obesity BMI of the adult: obesity 
Thyroid diseases Thyroid problems 
Dementia  
Atrial fibrillation - 
Depression and mood diseases Depression 
Solid neoplasms Malignant tumors 
Diabetes Diabetes 
Cerebrovascular disease Stroke 
Osteoporosis Osteoporosis 
Other musculoskeletal and joint diseases - 
Dorsopathies - 
Glaucoma - 
Cataract and other lens diseases Cataract 
Asthma Asthma 
Other eye diseases - 
COPD, emphysema, chronic bronchitis chronic bronchitis, emphysema, COPD 
Autoimmune diseases - 
Blindness, visual impairment Difficulty to see: Yes, a lot of difficulty or I cannot see at all 
Esophagus, stomach, and duodenum diseases Stomach or duodenal ulcer 
Prostate diseases Prostate problems 
Inflammatory arthropathies - 
Other cardiovascular diseases - 
Neurotic, stress-related and somatoform diseases Chronic anxiety 
Other genitourinary diseases Urinary incontinence or problems of urine control 
Cardiac valve diseases - 
Migraine and facial pain syndromes Migraine or frequent headache 
Other psychiatric and behavioral diseases Other mental problems 
Other neurological diseases - 
Sleep disorders - 
Bradycardias and conduction diseases - 
Peripheral vascular disease - 
Other metabolic diseases - 
Peripheral neuropathy - 
Chronic pancreas, biliary tract and gallbladder diseases - 
Allergy Chronic allergy 
Parkinson and parkinsonism - 
Other respiratory diseases - 
Chronic ulcer of the skin - 
Epilepsy - 
Ear, nose, throat diseases - 
Inflammatory bowel diseases - 
Hematological neoplasms - 
Venous and lymphatic diseases Varicose veins 
Schizophrenia and delusional diseases - 
Blood and blood forming organ diseases - 
Other digestive diseases - 
Chronic infectious diseases - 
Chronic liver diseases Cirrhosis, liver dysfunction 
Multiple sclerosis - 
Other skin diseases Chronic skin problems 





Table S2. Basic activities of daily living (Katz Index)2 
Katz Index of Independence in Activities of Daily Living Equivalent question in the  ENSE Equivalent answer in the ENSE 
Independence (1): 
Bathes self completely or 
needs help in bathing only 
a single part of the body 
such as the back, or 
disabled extremity 




Need help with bathing 
more than one part of the 
body, getting in or out of 
the tub or shower. 
Requires total bathing 
Difficulty for basic daily 
activities: Showering or 
bathing without help 
Yes, a lot of difficulty 
I can not do it by myself 
Independence (1): 
Get clothes from closets 
and drawers and puts on 
clothes and outer 
garments complete with 
fasteners. 
May have help tying 
shoes. 




Needs help with dressing 
self or needs to be 
completely dressed. 
Difficulty for daily basic 
activities: Dress and undress 
without help 
Yes, a lot of difficulty 
I can not do it by myself 
Independence (1): 
Goes to toilet, gets on and 
off, arranges clothes, 
Cleans genital area 
without help. 




Needs help transferring to 
the toilet, cleaning self or 
uses bedpan or commode 
Difficulty for daily basic 
activities: Go to the toilet 
without help 
Yes, a lot of difficulty 
I can not do it by myself 
Independence e (1): 
Moves in and out of bed 
or chair unassisted. 
Mechanical transfer aids 
are acceptable 




Needs help in moving 
from bed to chair or 
requires a complete 
transfer. 
Difficulty for daily basic 
activities: Sit, get up from a 
chair or a bed, lie down 
without help 
Yes, a lot of difficulty 
I can not do it by myself 
Independence (1): 
Exercises complete self 





Is partially or totally 
incontinent of bowel or 
bladder 
Have suffered in the past 12 
months: Urinary incontinence 
or problems with urine control 
Yes 
Independence (1): 
Gets food from plate into 
mouth without help. 
Preparation of food may 
be done by another person 




Needs partial or total help 
with feeding or requires 
parenteral feeding. 
Difficulty for basic daily 
activities: Feeding without 
help 
Yes, a lot of difficulty 
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Interventions to optimize pharmacologic treatment in 
hospitalized older adults: a systematic review 
1. Background
Drug therapy is one of the most important tools available for preserving and 
improving health; however, the use of medications is not without risk. The high 
prevalence of adverse events due to medication [1] is a significant public health 
problem, due to the significant morbidity and mortality they cause [2,3], which entail a 
significant consumption of resources and high healthcare costs [4,5]. This problem is 
especially relevant for the elderly, who have numerous factors that contribute to a 
greater risk of drug iatrogenesis. These factors include age-related changes in 
pharmacokinetics and pharmacodynamics [6,7] and the combination of chronic 
diseases that inevitably lead to polypharmacy. 
A number of studies in Spain have shown that the prevalence of polypharmacy 
(defined as the consumption of more than 5 drugs a day) in patients older than 65 
years is approximately 50% [8,9] and that polymedicated patients consume a mean of 
almost 9 medications a day [8]. Polypharmacy is strongly linked to drug-related 
adverse events, interactions and interferences between the drugs and the disease 
itself [10,11], to lack of treatment adherence [12] and, ultimately, to mortality [13]. 
Other patient-related factors, such as frailty, geriatric syndromes, dependence and 
cognitive impairment, frequently overlap, increasing the complexity of medication use, 
which ultimately leads to poorer health outcomes. For example, it is estimated that 
between 10% and 20% of hospital admissions for elderly patients in Spain are 
associated with medication-related adverse events [14,15], which quadruple the risk 
when compared with younger patients [16]. 
All of these problems gain special relevance in elderly hospitalized patients. 
Hospitalization is an especially delicate situation for the elderly and is associated with 
higher morbidity, mortality and cognitive and functional impairment [17,18]. The 
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incorporation of new prescribers and the increase in the number of drugs during 
hospitalization contribute to the risk of iatrogenesis and the complexity of 
administering drugs [19,20]. 
The progressive aging of the population predicts that medication-related 
problems in the elderly will be increasingly common. Fortunately, most medication-
related adverse events are considered preventable [21]. Improving therapeutic 
appropriateness could therefore help minimize the problem. The issue of prescription 
quality in the elderly has generated significant interest in the scientific community, 
which, in an attempt to define it, has coined terms such as ‘‘therapeutic 
appropriateness’’ and has led to the development of numerous tools to quantify it 
(Appendix A).  
Considering the complexity of administering drugs to elderly hospitalized 
patients and the high prevalence of inappropriate prescriptions [19,22], it seems that 
we need to incorporate strategies aimed at optimizing drug treatment. Although it has 
been previously mentioned that hospitalization is an especially appropriate period for 
implementing strategies for improving the quality of the use of medications [23], most 
studies have been implemented in other healthcare settings. 
The aim of this review is to summarize the evidence on interventions aimed at 
optimizing the drug treatment of hospitalized elderly patients. 
 
2. Materials and methods 
2.1 Search strategy 
In August 2015, we conducted a search in the following scientific literature 
databases to locate primary studies, without setting any date restrictions: MEDLINE, 
EMBASE, CINAHL (Cumulative Index to Nursing and Allied Health Literature) and the 
Cochrane Library. The search was designed with MeSH terms (Medical Subject 
Headings) for MEDLINE and was adapted to the other databases according to its 
descriptors or through keywords. We combined the following search terms: ‘‘Aged’’ 
and (‘‘Hospitalization’’, ‘‘Inpatients’’ or ‘‘Hospitals’’); and (‘‘Drug utilization review’’, 
‘‘Polypharmacy’’, ‘‘Inappropriate prescribing’’ or ‘‘Medication therapy management’’). 
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A manual search was also conducted, reviewing the references cited in the selected 
studies and in relevant systematic reviews. 
2.2 Study selection 
We included studies that met the following criteria: (a) prospective studies (not 
necessarily controlled or randomized), (b) inclusion of interventions aimed at 
optimizing the drug treatment in terms of the prescription, (c) inclusion of at least 80% 
of the sample composed of hospitalized patients 65 years of age or older, and (d) 
measurement of quantifiable process variables (change in therapeutic appropriateness 
measured by validated tools or polypharmacy) or endpoints (clinical, use of healthcare 
resources, financial, humanistic, etc.). 
We excluded studies with the following criteria: (a) systematic reviews and meta-
analyses, presentations at congresses or scientific meetings and study protocols; (b) 
published in languages other than English and Spanish; (c) focus on a single disease or 
medical condition or regarding a certain medication or therapeutic group; and (d) 
inclusion of interventions directed exclusively to improving treatment adherence or 
decreasing reconciliation errors. 
2.3 Data collection and analysis 
To select the studies, 2 reviewers examined the titles and abstracts of those 
studies identified in the search and then examined the full text of those studies that 
were not excluded, ultimately evaluating the ones that met the inclusion criteria. The 
relevant data were extracted from the selected articles, including the study design, 
number of participants, demographic characteristics, type of intervention and 
practitioner who performed it, follow-up time, degree of therapeutic appropriateness, 
polypharmacy, mortality, adverse reactions to medications, falls, changes in Barthel 
index, hospital readmissions, emergency department visits, time of admission, 
financial savings per patient and health-related quality of life. The main characteristics 
of the measurement methods for therapeutic appropriateness employed in the studies 






The quality of the prescription can be assessed using process variables (see 
whether the prescription coincides with the accepted standards) or results 
(consequences for the patient, the healthcare system and society) [24]. 
Ultimately, 2 reviewers separately assessed the included studies according to the 
risk of bias criteria developed by the Cochrane Effective Practice and Organization of 
Care group [25] for the main variables. 
 
3. Results 
3.1 Search results 
Table 1 Methods for as.sessing medication appropñateness. 
Cnterion (yea r of Yearsof CountJ)I Study Main cbaracteristics 
publication) updates poputation 
Explidt aiteria 
Beers criteria 1997, 2003, USA >65 years • List of medicinal products to avoid 
(1991 ) 2007, 2012, • list of medicinal productor lllerapeutic groups to 
2015 avoid in certaio diseases (sioce 1997) 
• Ust of medicinal products to use with caution 
(sine e 2012) 
• lnappropriate prescription dueto drug interactions 
and renal fl.llCtion (since 2015) 
STOPP- START 2014 lreland >65 years • STOPP; list of potentially inappropriate 
criteria (2008) medications, organized tJf physiological system 
• START: underprescription criteria (health cond!lion 
- indicated drugJ 
PRJSCUS list Germany >65 years • list of potentialty inappropria:te medicatkns~ 
(2010) Classified by therapeutic - · 
• Proposes therapeutic altematives and precautions 
if used 
tjational qualily 2010 Sweden >75 years • Spedñc medicinal product indicators: setection, 
indicators in the indication, dosage, potypharmacy, drug interactions~ 
useof drug use of medicinal products wfth altered renal hmction 
therapy for t he and t.n the presence of certain symptoms 
elde<1y (2004) • Spedfic indicators of diagnosis: rational. irrational 
and dangerous use 
K-<NE (1999) 2001 , 2007 USA >65 years • Quatity indicators for improving the quality of care 
frail in various chronic conditions. Not focused exclusivety 
on drug ueatment. 35'% of indicators for treatment 
CriterKJS implidtos 
MAi (199'2) USA Ali • Ten questions are assigned to each medicinal 
product regarding the indication, effectiveness, 
dosage, instructioos, regimen, drug--drug 
interactions, drug- disease interactions, duplicaticwl, 
duration and cost 
• Responses based on a 3-point likert scale (A: 
appropriate. C: inappropriate) .. Each inappropriate 
itero seores between 1 and 3 points based on its 
importance. The sum of att items creates a t.Neigflted 
score for each drug between O and 18. By adding ..., 
the seores for the drugs, we can obtain an overall 
inde.x 
• Higher seores mean lower therapeutic suitability 
FORTA (2008) 2014 Germany >65years • Records inappropfiate prescriptions and om.issions 
for indicated medicinal products 
• Orugs are- ctassified into 4 cate,gories: A 
(Indispensable), B (Beneficial), e (Questionabte), O 
(To be avoided). Based on the evidente of safety, 
efficacy and suitability for the age 
AOU (1999) USA Ali • Measures lllderprescription .. Require-s the dinic.al 
discretion of a healthcare practitione r who compares 
the medica! histo,y and the list of medicinal products 
to estabtish treabnent omissions 
Abl,r.,.,;odons: AC<NE, Assessing (are ofVulnerable Etders; AOU, Assessment of Undenmlization of /,\edication tool; FORTA, Fil fo, the 
Aged; WJ, .Medicatíoo Appropóateness lndex; START, Screening Tool to Alert Ooctors to Rigltt Treatment; SlOl'P, Screening Tool of Older 
Persoos' Potentially lnappro!)Óate Prescñptions. 
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A total of 794 references were identified, among which were 41 duplicates. After 
reviewing the titles and abstracts of 753 publications, 677 were excluded for not 
meeting the inclusion criteria or meeting exclusion criteria. The remaining 76 
publications were assessed. Ultimately, 19 publications were selected for this review. 
These publications referred to 18 studies [26-44] that met all the defined criteria (2 
studies referred to the same publication) (Fig. 1) [37,38]. 
 
 
3.2 Study characteristics 
The number of participants in the studies varied from 43 to 3974, with a mean of 
518 patients and a median of 316. Fifteen studies were conducted in Europe and the 
remaining 3 in the United States. Most studies had a control group, except for 2 
[46,47], and 12 were also randomized. The followup time varied between the 
hospitalization period itself [40,42-44] and 12 months [29,32,41]. 
3.3 Participant characteristics 





ldentified publications {n=794) 
Reviewed tit les and abstracts (n=753) 
Publications identified from other sources 
(n=26) 
Duplicate 
publications ( n=41 ) 
Excluded publications (n=677}: 
Of no interest to the issue reviewed (n=468) 
Not hospitalizad (n=55) 
1---------- Age (n=7) 
Complete publications reviewed 
(n=76} 
Selected publications (n=19) 
( 1 s studies) 
Language (n=10) 
Publication type (n=33) 
Specific disease/therapeutic group 
, (n=104) --------------------------------
Exclusions due to 
intervention/variable 
criteria {n=57) 
Figure 1 Database search. 
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The mean age of the participants ranged from 74.5 [35] to 86.6 years [32]; 2 of 
the studies did not provide this datum [27,28]. The proportion of women ranged from 
3% [28] to 71% [26]; 1 study did not provide this information [42]. The age inclusion 
criteria in the studies were an age greater than 65 years in 9 studies 
[27,28,30,31,35,36,40,43,44], greater than 70 in 4 [29,33,37,42], greater than 75 in 2 
[26,41], and greater than 80 in another [32]. Two studies did not have age criteria for 
inclusion [34,39], but more than 80% of the participants were older than 65 years. A 
number of studies also required other inclusion criteria, such as multiple diseases [44], 
frailty [28,41], and the consumption of more than 3 medications [27,41]. 
3. 4 Intervention characteristics 
The intervention was performed by pharmacists in 9 studies, by a 
multidisciplinary team in 3 [28,36,41] by pharmacists and clinical pharmacologists in 1 
[33], by geriatricians in 1 [37], by nurses in 1 [31], and by physicians other than the 
prescriber (without specifying specialty) in 2 [35,43]. One intervention consisted of a 
software application used by the prescribing physician [40]. 
In terms of type of intervention, most of the studies (13, 72%) conducted 
medication reviews with subsequent recommendations by or discussions with the 
prescribing physician. The intervention in 2 studies was based on detecting explicit 
criteria such as the Screening Tool of Older Person’s Potentially Inappropriate 
Prescriptions (STOPP) [35,41] and the Screening Tool to Alert Doctors to Right 
Treatment (START) [35]. In another study, the intervention consisted of advising a 
team of geriatric medicine specialists [28] We also included a study with an 
educational approach, based on training nurses on clinical pharmacology and tools for 
detecting medication-related problems.31 A number of studies performed other types 
of intervention, such as patient information, counseling and education [27,29,32-
34,37] and medication reconciliation [36,37,39], which are beyond the scope of this 
review. 
3.5 Variables analyzed 
3.5.1 Process variables 
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Among the 14 studies that measured therapeutic appropriateness, 13 achieved 
an improvement in at least one of the parameters due to the intervention. The most 
widely used measurement tool was the Medication Appropriateness Index (MAI) 
[45,46], which was employed in 6 studies [28-30,35,36,43]. All 6 studies showed 
significant improvements in this scale after the intervention. The study by Michelek et 
al [42]. used the Fit for the Aged (FORTA) system [47], achieving an increase in the 
prescription of category A drugs (indispensable) compared with the control group, but 
without reaching statistical significance. Two studies [28,35] measured medication 
underutilization through the Assessment of Underutilization of Medication index [48], 
both of which achieved improvements in this criterion compared with the control 
group. 
In terms of the explicit methods (see Appendix A in the supplementary material), 
the Beers criteria were employed in 4 studies [28,29,40,43], in its updated versions of 
1997 [49] and 2003 [50], but only 2 of them [28,40] achieved improvements after the 
intervention. The STOPP and START criteria [51] were employed to quantify 
therapeutic appropriateness after the intervention in 2 studies. A statistically 
significant improvement was observed with the STOPP criteria [41,43] but not in the 
study that applied the START criteria [43] Only one study measured appropriateness 
using the Priscus criteria [43] but could not demonstrate clear improvement 
attributable to the intervention (42.4-40.6%) (p = .421). Two interventions reported in 
Swedish studies attempted to decrease the prevalence of inappropriate medications 
based on quality indicators described in Sweden [52] one successfully [34], the other 
without achieving significant differences compared with the control group [31]. Two 
studies included the Assessing Care Of Vulnerable Elders (ACOVE) criteria [53] to 
measure underprescription. While Spinewine et al. [29] showed a marked 
improvement with the intervention (OR, 6.1; 95% CI 2.2-17), the improvement did not 
achieve statistical significance (p = .739) in the study by O’Sullivan et al. [43]. The 
studies by Delgado-Silveira et al. [44] and Lipton et al. [27] reported a reduction in 
medication-related problems due to the intervention.  
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Among the 8 studies that measured the effect of the intervention on 
polypharmacy [26,31,36-38,40,42,43], only 1 showed better results than those of the 
control group [26].  
3.5.2 Outcome variables 
Seven of the studies analyzed the effect of the interventions on mortality after a 
follow-up period of 3 [31,33], 6 [35,38,39] or 12 months [29,32] without conclusive 
results. The study by Michalek et al. [42] achieved a significant reduction in the 
number of falls in the intervention group (3.4% vs. 21.4%, p < .001) and an improved 
Barthel index, although that did not achieve statistical significance. In the study by 
Gallagher et al. [35], the reduction in the prevalence of falls 6 months after the 
intervention did not reach statistical significance (p = .332). 
Among the 6 studies that analyzed the influence on hospital readmissions at 3 
[31,33,37], 6 [35], or 12 months of admission [29,32], only the study by Legrain et al. 
[37] achieved a statistically significant reduction (20.2% vs. 28.4%, p = .01). Among the 
4 studies that quantified emergency department visits [29,32,33,39], only the study by 
Gillespie et al. [32] achieved a 47% reduction at 1 year compared with the control 
group. None of the interventions achieved a significant reduction in hospital stays 
[33,35,36,40]. 
In terms of the analysis of secondary costs, Gillespie et al. [32] showed a 
reduction of $400 (USD) per patient when compared with the control group. This 
savings was due to the reduction in expenses associated with readmissions and 
emergency department visits ($230 less per patient when taking into account the 
intervention costs). Legrain et al. [37] showed a reduction of € 797; € 519 per patient if 
the intervention cost was discounted. 
Two studies measured the health-related quality of life using the EuroQol-5D 
questionnaire at 3 [33] and 6 months [34]. Although the first study achieved no 
significant differences, the second showed an improvement in overall health, although 
not in the other parameters. 
The main characteristics and results of the studies are listed in Table 2, which 




Table 2 Main characteristics and results of the studies. 
Author Study design Population (1/ C) lntervention FollOH- Staff who Results (P, primary variables; S, secondary High risk of bias 
Year lnclusion criteria up performed the variables) (type: reason) 
Location Sample (n) time intervention 
% Women 
Age 
Owens 199026 Controlled >75 years Medication review 3 months Drug No. of medications at day 3: 5.3 (1) vs. 5. 9 (C) 
USA randomized n=436 (221 / 215) and (p < .05). No differences at 6 weeks and 3 
Women: 71% recommendation months 
Mean age: to responsible lncrease in the number of medications at day 
83.5/ 83 team 3: 18% (l)vs. 40% (C) (p < .005) 
Medications with no apparent indication: 11% 
(1) vs. 19% (C) (p < .025) 
lnappropriate medications (potential adverse 
effects and availability of an alternative): 20% 
(1) vs. 37% (C) (p < .005) 
Owens 199227 Controlled >65 years, 3 or Medication review 3 months Clinical Patients with MRP: 82% (1) vs. 93% (C) (p= .05) 
USA randomized more medications and pharmacist pharmacists Patients with suboptimal or nonindicated 
n=236 (123/ 113) counseling at medication: 51 (1) vs. 68 (C) (p= .01). Other 
Women: 51% discharge and far categories (dosage or regimen problerns, M-M 
3 months interactions, duplication, allergies): ns 
Mean score differences far: prescription 
appropriateness: O. 59 (1) vs. O. 76 (C) (p = .01 ). 
Dosage: 0.09 (1) vs. 0. 13 (C) (p= .02). 
Suboptimal or nonindicated: 0.17 (1 ) vs. 0.24 
(C) (p= .03). Other categories: ns 
Schmader Controlled >65 years and Geriatric 12 Multidisciplinary (P) ADRs (events per 1000 days): 206 (1) vs. 64 
200428 USA randomized frailty criteria assessment and months team: (C). RR = 1.85 (p= .0001 ) 
n=834 intervention geriatrician, Severe ADRs (events per 1000 days): 27 (1) vs. 
Women: 3/ 2% social worker, 15 (C) (p= .93) 
nurse, (S) Difference in change of: 
pharmacist Unnecessary medications: - 0.5 (p < .0001) 
MAi score: -5.4 (p < .0001 ) 
IM (Beers): -0.1 (p= .03 ) 
Medication underutilization (AOU): -0.3 




Table 2 (Continued) 
Author Study design Population (I / C) lntervention Follc:,,v- Staff who Results (P, primary variables; 5, secondary High risk of bias 
Year lnclusion criteria up performed the variables) (type: reason) 
Location Sample (n) time intervention 
% Women 
Age 
Spinewine Controlled >70 years Medication review 12 Clinical (P) Prescription appropriateness (at admission, Blinding of 
200729 randomized n = 203(103/100) and months pharmacist at discharge and at 3 months): evaluators to the 
Belgium Women: recommendation Change in mean MAi score per patient: results: unblinded 
71.9/66.7% to attending decreases more in intervention group: evaluator 
Mean age: physician 24.1 - 7.1 (p < .001), OR=9.1 (95%CI 4.2-21.6) Contamination: 
82.4/ 81. 9 Patient interview IM reduction (Beers): similar I-C, OR=0.6 (95% physicians who 
and infonnation CI 0.3- 1.1) treated patients in 
Mean change ACOVE criteria underutil izat ion the 2 groups 
per patient: 1 decreases more; OR = 6. 1 (95% CI 
2.2-17) 
(5) Prevalence of unnecessary medicat ions 
(MAi): decreases from 87.4% to 37.5% (1) and 
77.8% (C) 
Mortality at 1 year: 22.5% (1) vs. 30.1% (C) 
(p < .30) 
Readmissions at 1 year: 32.6% (1) vs. 33.7% (C) 
(p= 1.0) 
Emergency department visits at 1 year: 7. 9% 
(1) vs. 12% (C) (p= .45) 
Satisfied with informat ion on medications 
received at 1 month: 80% vs. 60.9% (p= .1) 
Bergkvist Controlled >65 years Medication review 2 weeks Drug Change in MAi score Random sequence 
200930 nonrandom- n = 43 (28/ 25) and discussion after dis- (admission-discharge-after 2 weeks): ns generation: 
Sweden ized Women: 61/64% with charge Reduction in the no. of medications with nonrandomized 
Mean age: 82/84 multidisciplinary inappropriate characteristics according to MAi: Hiding of the 
team less in the intervention group (p = .049) assignment: 
historical cont rol 
lnitial imbalance: 
control group was 
older and had 
more 
inappropriate 



















Controlled >65 years 
nonrandom- n=460(250/ 210) 
ized Women: 56/ 53% 
Mean age: 80.3 
Cont rolled >80 years 
randomized n = 400 (199 / 201) 
Women: 58.7% 













and JWA (Janus 
Web Application) 






Results (P, primary variables; S, secondary 
variables) 
(P) Readmissions at 3 months: 38% (1) vs. 36% 
(C) (p= .86) 
(S) Proportion of inappropriate medications at 
discharge: ns 
Medication-related readmissions: ns 
Deaths: 24% (1) vs. 23. 3% (C) (p =. 91) 
Readmissions: 217 (1) vs. 223 (C) 
(Estímate= O. 97) 
Medication-related readmissions: 9 (1) vs. 45 
(C) (estimate= 0.2) 
Reduction in emergency department visits: 
47%; 49 (1) vs. 93 (C) (Estimate=0.53) 
Difference readmissions + emergency 
department visits: 16%; 266 (1) vs. 316 (C) 
(Estimate = 0.84) 
Mortality at 1 year: 57 (1) vs. 61 (C) (p= .82) 
Overall cost reduction: $400/ patient (I- C) 
Cost reduction by emergency department 
visits: $100/ patient (I-C) 
Cost reduction by readmissions: $300/ patient 
(I-C) 
Savings counting the cost of the intervention: 
$230/patient (I-C) 

















Table 2 (Continued) 
Author Study design Population (1/C) 
Year lnclusion criteria 
Location Sample (n) 
% Women 
Age 
Lisby 201033 Controlled >70 years 




Bladh 201134 Controlled >80% 
Sweden randomized participants > 65 
years 
n = 345 
Women: 61% 
Mean age: 82 
Gallagher Controlled >65 years 














(with MiniQ too() 









Follcm- Staff who 
up performed the 
time intervention 
3 months Pharmacist and 
clinical 
pharmacologist 
6 months Clinical 
pharmacist 
6 months Medica( 
researcher 
Results (P, primary variables; S, secondary 
variables) 
(P) Hospital stay: 239.9 (1) vs. 238.6 (C) h 
(p > .05) 
(S) Time to readmission, no. of readmissions, 
emergency department and PC visits, death, 
health-related quality of life (EQ-5D): ns 
Change in health·related quality of life 
(EQ-5D) at 6 months: greater in overall health 
3.14 (1) vs. 2.77 (C); p= .02, but not in other 
parameters 
PIP: decreases in intervention group 0.39 
(admission) vs. 0.26 (discharge) (p = .039) 
(P) Patients with reduction in MAi 
admission-discharge score: 71.1% (1) vs. 35.4% 
(C) (ARR = 35. 7%) 
Rate of unnecessary polypharmacy at 
discharge: 5.4% (1) vs. 19.8% (C) (p < .001} 
Ali MAi criteria differ significantly between I-C 
at discharge and at 6 months 
Mean MAi score decreases from 10 to 3 (1) 
(p-< .001) and remains after 6 months (p < .001) 
Patients with AOU admission-discharge 
reduction: 31.6% (1) vs. 10.4% (C) (ARR= 21.2%) 
(S) Prevalence decreases after 6 months: 5.8% 
(1) vs. 8.4% (C) (p= .332) 
Mortality after 6 months: 5.3% (1) vs. 7 .3% (C) 
(p= .414) 
Hospital stay: 8 (1) vs. 8. 5 days (C) (p = .471 ) 
Readmission rate: 67 (1) vs. 64 (C) (p= .691 ) 
Fewer visits to PC physician (p= .063) 
High risk of bias 
(type: reason) 
Contamination: 1 
and C same ward 
Blinding of 




and C same ward 
Blinding of 































































( different from 
regular medica! 
team) 
Results (P, primary variables; S, secondary 
variables) 
Reduction in medicines with inappropriate 
characteristics (MAi ): 51 % vs. 39% (p = .0446) 
ITT; 60% vs. 44% (p = . 01 ) PP 
Differences in mean MAi score per patient or 
drug at discharge: ns 
Medication-related readmissions or emergency 
department visits: 6 (1) vs. 12 (C) (p= .0469) 
Hospital stay: 16 vs. 13 days (p= .09) 
(P) Readmissions or emergency department 
visits at 3 months: 23% (l)vs. 30.5% (C) (p= .03) 
and 6 months: 35.3% (1) vs. 40.8% (C) (p= .15) 
Event-free survival at 3 months: longer in 
intervention group HR = O. 72 (p= .03); and at 6 
months: HR= 0.81 (p= .10) 
(S) Readmissions at 3 months: 20.2% (1) vs. 
28.4% (C) (p= .01 ); and at 6 months: 32.5 (I) 
vs. 38.2 (C) (p = .12). 
Mortality at 3 months: 12% (1) vs. 13.2% (C) 
(p= .63); and at 6 months: 17.7% (1) vs. 18.7% 
(C)(p=.74) 
Difference in cost at 6 months (I- C): 
€ 797 / patient 
Savings including intervention cost: 
€ 519/ patient 
Medication-related readmissions: 34.7% vs. 
40.4% (p = . 54). 
No. of medications, polypharmacy, mean daily 
dose: ns 
Difference in cost due to medication-related 
readmissions: €392 vs. €953.5 per patient 
(p= .13) 



















Table 2 (Continued) 
Author Study design Population (1/C) lntervention Folloo- Staff who Results (P, primary variables; S, secondary High risk of bias 
Year lnclusion criteria up performed the variables) (type: reason) 
Location Sample (n) time intervention 
% Women 
Age 
Hellstrom Controlled 85% > 65 years Reconciliat ion, 6 months Clinical (P) Duration of emergency department Random sequence 
201239 nonrandom- n=3974 medication review pharmacist visits/ readmission: HR O. 95 (p = .266) generation: 
Sweden ized (1216/2758) and monitoring (5) Event-free survival : HR= O. 96 (p= .305) nonrandomized 
Women: Mean number of emergency department visits Hiding of the 
54.2/ 55.5% at 6 months: 1.02 (1) vs. 1.03 (C) (p= .89) assignment: 
Mean age: Mortality at 6 months: 18.2% (1) vs. 17.3% (C) historical control 
78.3/79.5 (p=.55) lnitial imbalance: 
Mean numberof PC visits: 1.58 (l)vs. 1.71 (C) intervention group 
(p= .057} younger than 
Patients who visited PC: 68.5% (1) vs. 70.3% (C) control group 
(p= .34) 
Ghibelli Controlled >65 years lntercheck«> Admission Computer Reduction in number of patients with PlM Random sequence 
2013-40 ltaly nonrandom- n = 134 (60/74) (computer system (Beers) admission-discharge: 41 . 7- 11.6% generation: 
ized Women: support system far (p< .001) nonrandomized 
58.3/64.8% prescriptions) Mean reduction in PIM by patient Hiding of the 
Mean age: admission- discharge: 0.5-0.1 (p < .001) assignment: 
81.1/81 .3 Reduction in number of patients with historical control 
potentially severe M-M interaction 
admission-discharge: 45-33.3% (p= .703) 
Reduction in new potentially severe M-M 
interactions: 59-33% (p < .001) 
Hospital stay: 10.4 (1) vs. 10.1 (C) days (p= .84) 
Dalleur Controlled >75 years STOPP 12 Multidisciplinary Reduction in PIM by STOPP criteria at 
201441 randomized Frail patients recommendations months team specialized discharge: 39.7% (1) vs. 19.3% (C) (p= .013) 
Belgium according to the to responsible in geriatric 
ISAR scale and physician medicine 
more than 3 
medicines 
n = 146 (74/72) 
Women: 63% 




Table 2 (Continued} 
Author Study design Population (1/C) 
Year lnclusion cri teria 
Location Sample (n) 
%Women 
Age 
Michalek Controlled >70 years 
2014•2 randomized n=114: 58/ 56 




Uncontrolled >65 years 
(n= 361) 
Women: 50.1% 








FORTA instrument Admission Physicians other 




Structured review Admission Drug 




Results (P, primary variables; 5, secondary 
variables) 
Patients with polypharmacy (>5 medications) 
at discharge: 84% (1) vs. 84% (C) (p = .935) 
lncreases in control and intervention 
Category A FORTA medications at discharge: 4 
vs. 3 (p= .051). lncreases in both 
Over and underprescription: less in 
intervention group (p= .03 and p= .025) 
Patients with an increased Barthel index at 
discharge: 76% (1) vs. 71% (C) (p < .226) 
Patients with falls: 3.4% (1) vs. 21.4% (C) 
(p < .001) 
Proportion of falls/ 1000 patients/ year: 1.5 (1) 
vs. 10.6 (C) days (p = .004) 
Reduction in MAi score from admission to 
discharge: 15-12 (p < .001 ). 59.3% patients 
with lc,,ver seores 
Change in underprescription by ACOVE criteria 
admission-discharge: 28.3-26. 9% (p= .739) 
Median no. of medications: 9 at admission 12 





evaluator is the 
same individual 
who performs the 
at discharge intervention 
Patients with 5 or more medications: 84.5% at 
admission and 95.8% at discharge 
10 or more medications: 43.5% at admission 
and 66.8% at discharge 
Change in STOPP criteria admission-discharge: 
62.4-55.5% patients (p < .001 ) 
Change in Beers CD criteria 
admission-discharge: 31 .8-31.6% patients 
(p= .282) 
Change in Priscus criteria admission-discharge: 
42.4-40.6% patients (p= .421) 
Change in START criteria admission-discharge: 
31 -31.5% patients (p= .512) 
Potential M-M interactions: 57. 7% patients at 
admission and 63. 9% at discharge (p= .50) 
lncorrect dosage in RF: 9. 7% patients at 







































Results (P, primary variables; S, secondary 
variables) 
MRP: 96.4% patients 
PI resolved 58. 9% of the MRP (association 
Pl-resolution; p < .001) 
PIP for START/ STOPP: 65% 







resolution of MRP 
is the one who 
performed the 
intervention 
Abbreviations: AOU, assessment of underutilization of medication index; Beers CD, Beers criteria considering diagnosis; e, control group; HR, hazard ratio; 1, intervention group; CI, 
confidence interval; PI, pharmaceutical intervention; M-M interactions, medication-medication interactions; RF, renal failure; ITT, intent-to-treat analysis; MAi, medica! appropriateness 
index; IM, inappropriate medicat ion; PC, primary care; PIM, potentially inappropriate medication; ns, not statistically significant; PP. per protocol analysis; PIP, potentially inappropriate 




This review provides a summary of the evidence on various strategies for 
optimizing treatments for elderly hospitalized patients, aimed at reducing 
polypharmacy and improving therapeutic appropriateness, health results and the use 
of the healthcare system. 
Among the analyzed variables, it is worth noting the good results regarding the 
improvement in therapeutic appropriateness, which appears to be independent of the 
personnel who perform the intervention and the type of intervention (except in the 
Bergqvist et al. Study [31], which used an educational approach). 
Although the majority of studies managed to improve therapeutic 
appropriateness in one or more of the parameters, the results differed depending on 
the measurement method. While all of the studies that used the MAI scale or STOPP 
criteria achieved an improvement, the same was not true for studies using Beers, 
Priscus or ACOVE criteria. These results provide an introduction to the debate on the 
applicability and validity of measurement tools for appropriateness. The difficulty in 
applying these tools in settings other than those from where the tools originate 
(healthcare levels, countries) has been widely commented in the literature [54-56]. An 
example of this challenge is the use of the Beers criteria in the studies by Spinewine et 
al. [29] (Belgium) and O’Sullivan et al. (Ireland) [43], which were not able to detect 
positive results in terms of therapeutic appropriateness. The usefulness of the Beers 
criteria in the European setting is questionable [57]; however, the criteria are still 
widely used for being one of the first tools developed. The validity of the measurement 
methods for appropriateness has also been the subject of controversy, given that the 
process variables should be related to relevant health outcomes (mortality, morbidity, 
medication-related adverse events and quality of life) to be valid [58]. Although there 
are studies that show a significant association between the use of inappropriate 
medications (according to the Beers criteria) and the health outcomes in certain 
healthcare settings (residence and outpatient) [59-61], the use of inappropriate 
medications for hospitalized patients is not associated with a significant increase in the 
risk of adverse events [62], the hospital stay or mortality [63,64]. The degree of 
therapeutic appropriateness measured with the MAI scale has been shown to be 
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related to health outcomes in the primary care setting [65,66]. The use of 
inappropriate medications, according to the STOPP criteria, has been associated with 
the onset of adverse events in elderly hospitalized patients [67]. However, a study [68] 
showed that most medication-related problems in elderly patients who live in the 
community are not detected using STOPP or START criteria. A number of studies that 
compared the Beers and STOPP criteria seem to show a lower sensitivity for the former 
in detecting potentially inappropriate medications [69,70] or for preventing 
hospitalizations due to medication-related adverse events [67].  
In light of the fact that the available evidence on the predictive validity of explicit 
criteria is not definitive or the fact that the results can differ depending on the method 
of analysis employed, it is worth questioning the suitability of the measurement 
systems for therapeutic appropriateness being used and thus their published results. 
Given that the tools are employed both to measure results and to perform 
interventions, we should consider that the health endpoints can also be affected by 
this validity, especially if the intervention is based exclusively on detecting explicit 
criteria, as in the study by Gallagher et al. [35]. 
The use of explicit methods has numerous practical advantages (Appendix A), but 
interventions based on implicit methods (standardized or not) provide a broader vision 
on the patient’s situation, their preferences, life expectancy and the fixed therapeutic 
objectives. A recent study [71] showed that a number of more significant causes for 
prescribers not modifying the treatment (according to the recommendations included 
in the STOPP/START criteria) are patient disability, dependence and risk of adverse 
events, variables that, in the elderly, can be much more important than survival itself. 
Regardless of the method employed, this type of information is important for adapting 
the intervention to each patient’s needs. However, only 6 [26,29,37,40-42] studies 
conducted a comprehensive geriatric assessment, and 8 studies did not record any 
information on the functional, cognitive and nutritional condition or on the presence 
of geriatric syndromes [27,30,31,33,34,36,39,44]. Only the study by Legrain et al. [37] 
recorded the patients’ preferences regarding their health. If the practitioners who 
conduct the intervention do not know these data, the recommendations for modifying 
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the treatment will not correctly fit the patient’s characteristics and will probably not 
be accepted by the prescriber. 
Acceptance of these recommendations is essential to interpreting the endpoints, 
because the interventions need to result in treatment changes in order to affect the 
patient’s health. Consequently, a low degree of acceptance of the recommendations 
can lead to a lack of improvement in the endpoints. The study by Lisby et al. [33], for 
example, had a degree of acceptance of the recommendations of 39% and achieved no 
benefits in any of the study variables (hospital stay, readmissions, emergency 
department visits, mortality and quality of life). In contrast, those studies with a higher 
proportion of accepted recommendations achieved more noticeable improvements. 
The study by Gillespie et al. [32], in which 77% of the recommendations were 
accepted, showed a reduction in emergency department visits. The study by Legrain et 
al. [37], with an acceptance of 70.9%, hospital readmissions decreased significantly. 
Other factors that could have affected the health outcomes are methodological, 
such as the low number of participants in a number of the studies and the studies’ low 
power for detecting significant differences. The studies that had no statistically 
significant results in terms of mortality, readmissions or emergency department visits 
had not defined these variables as primary objectives [29,33,35,39]. Age is another 
factor worth considering. The studies with better health outcomes were those whose 
participants had a higher mean age [32,37], which suggests that patients with greatest 
risk and frailty are the ones most likely to benefit from strategies that optimize the 
drug therapy. 
In terms of the impact of interventions on other significant variables such as 
quality of life and financial savings, it is difficult to make relevant conclusions, given the 
little evidence provided by the analyzed studies. 
The results of this review are similar to those of other published studies. Various 
reviews have been conducted on the drug treatment optimization in elderly patients, 
not focused on the hospital setting. Two of these studies concluded that some 
interventions with different approaches (educational, treatment reviews, geriatric 
services, multidisciplinary teams, computer support systems, etc.) can improve the 
degree of therapeutic appropriateness [72,73]. In the review by Patterson et al. [74], 
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the impact of these interventions on clinical outcomes was uncertain, although 
benefits were demonstrated in terms of reducing inappropriate prescriptions. In the 
study by Holland et al. [75], which examined the impact of treatment reviews 
performed by pharmacists on hospitalizations and mortality, also found no positive 
effect on these parameters. On the other hand, we found reviews on hospitalized 
patients, although not specifically elderly, such as the study by Christensen et al. [76] 
focusing on medical reviews, which show a reduction in emergency department visits, 
with no influence on mortality or hospital readmissions. Similarly, Graabaek et al. [77], 
in a recent systematic review of medication reviews performed by clinical pharmacists, 
indicated a positive effect in the use and cost of medications and a number of 
improvements in the use of healthcare resources, which was not statistically 
significant. 
In terms of the bias of the included studies, the fact that the evaluator of the 
results knew which group each patient belonged to was a high risk of bias. Given the 
presence of several nonrandomized studies, the risks of associated bias were also 
frequent. 
Future research should be aimed at checking the validity of the tools for 
measuring and improving therapeutic appropriateness, which confer a greater 
reliability to the studies and a greater impact of interventions for optimizing 
therapeutic appropriateness on health outcomes. Moreover, quality controlled clinical 
trials need to be developed, with sufficient sample sizes and with the necessary 
methodological quality to detect the expected impact on clinical variables such as 
hospital readmissions, emergency department visits and quality of life. 
 
5. Conclusions  
The analyzed studies show that the therapeutic appropriateness of elderly 
hospitalized patients can be improved by interventions with various approaches 
(systematic treatment reviews, support software for decision making and detection of 
explicit criteria of inappropriate prescription), implemented by various practitioners 
(clinical pharmacists, geriatricians, multidisciplinary teams, etc.). However, there is 
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significant variability in the endpoints. The role of these interventions in health 
outcomes (the consequences for patients, healthcare system and society) is uncertain. 
We need to address the applicability and validity of the tools that assess 
therapeutic appropriateness to obtain more reliable results with greater impact on 
health. Explicit criteria for optimizing treatments should not be considered the gold 
standard, and their implementation should preferably be combined with implicit 
methods so as to address especially important issues for elderly patients, such as the 
sociofamiliar context, functional and cognitive conditions and life expectancy. 
The clinical variables for elderly patients should be properly selected, given that 
the therapeutic objectives are often different, and the functional aspects or those 
related to quality of life can be more important in this population than others, such as 
mortality. The selection of objectives can benefit from consensus in multidisciplinary 
teams that include a comprehensive geriatric assessment.  
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The concept of "medication appropriateness" has been described in different 
ways. Villafaina and Gavilán [1] define it as the process of choosing the therapy of the 
patient in which, by indication, prescription, dispensation, administration and 
monitoring, the professional can achieve appropriate results to the conditions and 
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circumstances of the patient and of the whole community. Perhaps, the simplest 
definition is that which says that a prescription is appropriate when there is clear 
evidence for its use in that indication, it is well tolerated and cost-effective [2]. Shortly, 
it is a term that speaks about the quality of prescription, and questions whether a 
treatment will provide the greatest expected benefit in a patient.  
In contrast, the terms "inappropriate prescription" or "potentially inappropriate 
medication" refer to treatments in which the risk is greater than the expected clinical 
benefit, especially when there are safer or more effective therapeutic alternatives. It 
also includes the use of drugs at higher doses or duration of the indicated, the use of 
drugs with high risk of interactions, duplicity and the omission of a clinically indicated 
drug [3].  
Over the years, different tools have been developed to evaluate whether a 
certain treatment or medication is appropriate or not. These tools can be used both in 
clinical practice during the process of prescription or medication review, and for 
quantifying medication appropriateness (eg in the field of research, measuring results 
after an intervention). Classically, methods for measuring medication appropriateness 
have been divided into implicit systems (based on clinical judgments) and explicit 
systems (based on criteria centered on the drug) [4].  
Explicit methods are focused on drugs and diseases, usually consist of lists of 
medications or therapeutic groups that should be avoided in elderly people, and are 
made by panels of experts through reviews and consensus. On the other hand, implicit 
methods are centered on the patient and are based on open questions, which require 
the knowledge and interpretation by the clinician of patient's characteristics and 
circumstances.  
Both systems have strengths and limitations. Explicit methods have the 
advantage of being quick and easy to apply, have greater reliability, require little 
preparation and resources and can be systematized or incorporated into computerized 
systems easily; but they have less validity, and do not consider the particularity of each 
patient. The implicit methods have a broader perspective on the patient's situation 
and are more sensitive, but they consume more time and resources, they require a 
more complex preparation and are less reproducible.  
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Some of the most commonly used explicit methods are the Beers criteria, 
STOPP/START (Screening Tool of Older Persons´ potentially inappropriate 
Prescriptions/ Screening Tool to Alert doctors to Right Treatment), PRISCUS, NORGEP 
or McLeod. The most common implicit methods include the MAI (Medication 
Appropriateness Index), and the AOU (Assessment Of Underutilization of medication 
tool). Table 1 describes the most important characteristics of the methods used in the 
studies included in this review. 
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The aim of the present doctoral thesis was to assess the problem of 
polypharmacy in the elderly within different settings and its relationship with frailty, 
and to explore strategies to optimise treatments in the most vulnerable sectors. 
In the study based on the National Health Survey 2017 (Chapter 1), we found 
that polypharmacy is a growing situation in our population when comparing the results 
with those shown in previous studies carried out using the same methodology based 
on data from previous national or European surveys in Spain [1, 2]. However, from this 
study, we can also infer that polypharmacy is not distributed equally among the entire 
older population, and that it is particularly concentrated in certain sectors. Higher 
rates of polypharmacy will be found in older people with multimorbidity and functional 
and cognitive impairment, among others. In our different studies conducted in various 
settings, different consumption of drugs and characteristics were found: in non-
institutionalised older people in Spain, the average number of medications consumed 
was 3.3 (3.9 according to sensitivity analysis) according to the ENSE 2017, 7.2 in 
institutionalised elderly people according to our results, and 9.1 in older people 
admitted to our acute geriatric unit (AGU); and the prevalence of polypharmacy was 
27.3% (37.5% with sensitivity analysis), 73.6%, and 86.5% respectively. The non-
institutionalised elderly had 4.3 chronic health problems per person, and both patients 
in nursing homes and those in the AGU had high rates of comorbidities, although they 
were measured using different tools (3.2 geriatric syndromes per patient in nursing 
homes, age-adjusted Charlson comorbidity index: 8.1 in patients admitted to the AGU). 
A total of 80% of the non-institutionalised population was completely independent 
with respect to basic activities of daily living, while in nursing homes this was 13.6%, 
and in the AGU, 20.5%. In addition, among the non-institutionalised population in 
Spain, only 7.4% had cognitive impairment, while this was 64.2% in nursing homes and 
43.5% in hospitalised older patients in the AGU. 
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It seems clear that polypharmacy can be a particularly relevant problem in 
people with certain characteristics, and therefore in specific settings such as nursing 
homes or certain areas of hospitalisation, due to the high prevalence of polypharmacy 
and associated factors in these settings and the complexity and vulnerability of this 
type of patients, in addition to the possible negative consequences that can result 
from excessive polypharmacy. 
The elderly living in nursing homes have many peculiarities in relation to the use 
of medicines. Some studies have suggested that polypharmacy rates in nursing homes 
are the highest in older populations [3], as well as the use of potentially inappropriate 
medications. This is likely due to the profile of older adults admitted to nursing homes: 
very old age, multimorbidity, and high prevalence of cognitive impairment and 
advanced disability [4]. A recent study has shown that although the prevalence of 
polypharmacy is higher in nursing homes than in the community, when adjusting for 
confounders, living in nursing homes is associated with a lower risk of the prevalence 
and incidence of polypharmacy [5]. Due to the particularities in this population, the 
same rules can not be applied as those to the rest of the elderly population. Health 
and polypharmacy determinants in older nursing home residents depart from those 
usually accounted for in the general population [6, 7]. In the study shown in Chapter 3, 
no relationship was found between the prevalence of polypharmacy and frailty status 
according to any of the proposed definitions. In fact, in our sample, frail participants 
generally consumed fewer medications than non-frail participants. This is the opposite 
behaviour to that expected when considering most of the studies investigating the 
association between frailty and polypharmacy, as was shown in Chapter 2. 
This may be related to the short life expectancy in this population [6, 8]. In 
nursing homes, advanced disability, severe cognitive impairment, and frailty may be 
perceived as end of life markers, which may influence decision-making regarding 
medications. In the same study (Chapter 3), we examined the prevalence of 
underprescription as described by the START criteria and found a high prevalence, 
which is in accordance with that reported by other studies [9, 10]. The drugs and 
characteristics described in explicit criteriam such as the STOPP-START, have been 
considered potentially inappropriate in older patients, since frequently or in most 
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cases, the risks to which they are exposed exceed the expected benefits [11]. However, 
these risks and benefits are not constant, but variable (among different people or in 
the same person over time), and must be defined individually for each patient 
considering all their characteristics and complexity. We must remember that it is the 
drug-patient binomial that leads us to consider the use of a drug (or the omission of a 
drug) as inappropriate. Some studies have described the causes that lead to not 
applying this type of criteria in certain patients, especially the START criteria [12]. From 
this perspective, in many nursing home residents, the START criteria would not be 
considered an inappropriate prescription when taking into account the individual 
characteristics. The results of the study (Chapter 3) also show that the prevalence of 
underprescription was higher in frail subjects, which is in accordance with those 
reported by Meid et al., when studying cardiovascular START criteria [13]. Considering 
the association of frailty with an increased risk of adverse drug reactions [14] and its 
prognostic value for different adverse health outcomes [15], it seems reasonable to 
modify the type of drugs used to avoid high risk drugs with little expected benefit. This 
is why we propose that underprescription in frail older adults should be redefined, and 
new measurement strategies should be developed. Presumably, the START criteria are 
not very useful for frail patients, and specific criteria or tools should be developed for 
this population. 
 
From a global perspective, the significant demographic and epidemiological 
changes that we face represent a great challenge for the administrations and health 
systems and institutions, which, for several years, have been projecting different 
strategies to face these challenges based on diverse conceptual models of the 
management of chronic diseases. Numerous international, national, and regional 
initiatives have emerged, which attempt to create new health care models that adapt 
to the new realities of the population. 
One of the axes commonly present in these initiatives is the stratification of the 
population according to their health-related needs. This is based on population models 
for the care of chronic patients, such as the so-called Kaiser Pyramid of the Kaiser 
Permanente model, which identifies different levels of intervention according to the 
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level of complexity of the chronic patient. In regard to medicines and the possible risks 
derived from their inappropriate use, it is also important to identify patients according 
to their risk of medication use, to be able to carry out treatment interventions adapted 
to patient needs. 
Pharmacists, as members of the healthcare system and medicine professionals, 
are also striving to adapt to new healthcare environments and the needs of chronic 
patients in their areas of competence. Accordingly, in 2012, the Spanish Society of 
Hospital Pharmacy (SEFH) published its own "Strategic Plan of the SEFH on 
Pharmaceutical Care for the Chronic Patient". This document highlights the importance 
of promoting the identification and stratification of chronic patients in accordance with 
the systems developed in various regions of Spain, and developing a pharmaceutical 
care model that includes specific actions for each patient type identified. With the 
intention of addressing this strategic axis, in 2013, SEFH published the "Model of 
Selection and Pharmaceutical Care of Chronic Patients of the Spanish Society of 
Hospital Pharmacy". This document establishes a model for the stratification of 
patients according to their risk of medication use, and proposes different interventions 
according to their needs. Classification considers demographic and social factors, 
cognitive and functional status, clinical and health service utilisation variables, and 
medication-related aspects. Four risk groups have been proposed: level 3 basic risk; 
level 2a, drug risk; level 2b, socio-health risk; and level 1, global risk. Level 1 patients 
would receive the greatest benefit from the most comprehensive pharmacist 
interventions. Although these data have not been published, 91% of patients admitted 
to the AGU of the Complejo Hospitalario de Navarra were classified as level 1 (overall 
risk), and greater than 97% as level 1 or 2a (medication risk), the two groups in which a 
systematic medication review would be recommended. Therefore, the AGU is an area 
of already selected patients regarding medication risk; and directing more 
comprehensive interventions towards this population avoids the need for developing 




There are two reasons that come together in the justification of performing a 
medicine optimisation strategy in the setting of an acute care hospital, specifically in 
an acute geriatric unit. 
Firstly, we found a need to optimise the pharmacological treatment of these 
patients. They are complex patients with a high prevalence of drug related problems or 
indicators that could be related, as the study of patients admitted to this unit shows 
(Chapter 4). At the time of admission, these patients are also in a particularly 
vulnerable situation, since chronic and acute treatment can be conflicting, and they 
can present medication reconciliation problems associated with changes in the level of 
care and the multiple prescribers involved (general practitioners, emergency 
physicians, geriatricians, on-call physicians), perhaps also being exposed to high-risk 
medications associated with hospital use. 
On the other hand, interventions focused on pharmacological treatment in this 
setting can be a great opportunity for several reasons. 
The first reason is the aforementioned presentation of highly selected patients 
without the need for a population screening. In addition, the hospital setting provides 
all the necessary tools for a comprehensive and patient-centred intervention regarding 
drug treatment: complete access to patients' clinical information, both in their history 
of primary care and specialised care (background, laboratory tests, constants, 
anthropometric data, etc.), and medication history, including updated electronic 
prescription and dispensing registries from all settings. The continued presence of the 
patient during admission is an advantage for obtaining or providing information on 
medications, health problems, etc., facilitates shared decision-making and provides the 
possibility to monitor changes that are made in order to prevent or detect possible 
negative effects. In this setting, the pharmacist can interview patients and caregivers, 
and extend the intervention not only to the prescription but also to other medication 
processes, including those at the level of the patient. 
Moreover, the AGU allows the clinical pharmacist to work within a specialised 
and interdisciplinary team, contributing to the improvement of the quality of 
pharmaceutical care. This enables integration of the medicine optimisation strategy 
into the comprehensive geriatric assessment (CGA), making it a real multi-disciplinary 
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process. The CGA, which encompasses all aspects of the patient in their current 
situation, from its holistic approach, provides information of special value for tailored 
interventions. The work of the clinical pharmacist is enriched by the CGA, since it can 
be supplemented with the vision provided by the pharmacist using a clinical interview 
and a systematic medication review. The appropriate use of medications in older 
adults should consider all their circumstances and complexity; thus, we must go 
beyond the sum of single conditions and medication indications. This approach 
reframes the pharmacist's role as a professional providing care as part of a team, 
rather than simply as a medication technician. 
For the design of our intervention, we considered the patient characteristics that 
we observed in our previous study (Chapter 4), the operation and characteristics of the 
AGU and the Complejo Hospitalario de Navarra, and the conclusions of our previous 
systematic review regarding medication optimisation strategies in hospitalised older 
adults. Therefore, we proposed pharmacist-led intervention based on the CGA and 
clinical interview, combining medication reconciliation and review, implicit and explicit 
methods with a computerised decision support system to assist the review process. 
This approach was properly implemented in the AGU, and was well accepted by 
patients and geriatricians, in addition to showing good results in terms of the proposed 
objectives. This type of intervention focusing on hospitalised older adults should be 
considered a complementary strategy that is coordinated with other strategies to 
optimise treatment at the population level or in other settings such as primary care or 
nursing homes. All these are necessary and should ideally coexist to respond in the 
most appropriate way to the problem of polypharmacy depending on the situation and 
the needs of each population group. In line with the above, this strategy responds to 
the need to introduce more complex interventions in patients with more complex 
needs, also regarding the use of medications. 
Moreover, ideally, frailty in older people should also be considered when making 
decisions regarding medications and planning strategies to improve treatment. Our 
systematic review on the relationship between polypharmacy and frailty concluded 
that there is an association between these factors, and that polypharmacy can be an 
important contributor to frailty. Further longitudinal cohort studies are needed, but it 
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suggests that a reduction in polypharmacy could be a cautious strategy to prevent and 
manage frailty. Frailty, as a risk predictor and prognostic measure, can help to more 
precisely define the risk-benefit of drugs in each patient, adapting it to individual 
needs. Therefore, frailty screening could also contribute to a more appropriate use of 
medications, or to design therapeutic optimisation strategies in different settings and 
levels of care (at an epidemiological level, in hospitals, nursing homes, etc.). Some 
clinical practice guidelines are beginning to incorporate specific recommendations for 
frail older patients[16], and the European Medicines Agency has recommended 
baseline characterisation of frailty in patients older than 65 years who participate in 
clinical trials or other clinical investigations, in addition to the incorporation of this 
variable into subgroup analysis [17]. Frailty is a complex concept that is gaining 
increasing interest in research and is progressively moving to clinical practice in many 
disciplines, not only in geriatrics. For this reason, and due to the important relationship 
between frailty and medicines at many levels, the pharmacist must know and properly 
handle the basic notions regarding frailty in elderly patients, and gradually integrate 
these in our professional practice. 
 
Practical applications and future perspectives 
The present thesis aimed to advance the knowledge of polypharmacy as a 
growing phenomenon in older people in different areas of our society. From this point, 
it has also sought to promote the implementation of new roles and integrated 
multidisciplinary care models orientated to patient needs and based on reliable 
evidence from clinical research applied to our environment. It proposes strategies to 
improve the organisation and efficiency of health services in one of the most 
vulnerable sectors of our population, such as the elderly. Our proposal opens new 
avenues for the role of the clinical pharmacist as a professional integrated into health 
teams and gives some preliminary information regarding the benefits that can be 
obtained from this collaboration. 
Given the satisfactory results in terms of feasibility and improvement of 
medication appropriateness, the new work methodologies and multidisciplinary 
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collaboration models described here could serve as a model for the future 
implementation of new services in clinical practice. 
The present project was also intended to advance clinical research within the 
Navarra Health Service and create proposals for innovation in clinical practice that can 
respond to the challenges of ageing, chronicity, and sustainability of the health system. 
New approaches are needed for the development of population-based studies 
on polypharmacy using different methodologies. Moreover, further research is 
required to explore the role of a reduction in polypharmacy in the development, 
reversion, or delay of frailty, and the possible benefits of screening frailty in older 
people to lead interventions on excessive polypharmacy. 
We must also advance in the optimisation of medications in elderly people living 




1. Martin-Perez M, Lopez de Andres A, Hernandez-Barrera V, et al. Prevalencia de 
polifarmacia en la población mayor de 65 años en España: análisis de las Encuestas 
Nacionales de Salud 2006 y 2011/12. Rev Esp Geriatr Gerontol 2017; Feb;52:2-8 
2. Carmona-Torres JM, Cobo-Cuenca AI, Recio-Andrade B, Laredo-Aguilera JA, 
Martins MM, Rodríguez-Borrego MA. Prevalence and factors associated with 
polypharmacy in the older people: 2006-2014. J Clin Nurs 2018; 27(15-16):2942-2952 
3. Jokanovic N, Tan EC, Dooley MJ, Kirkpatrick CM, Bell JS. Prevalence and factors 
associated with polypharmacy in long-term care facilities: a systematic review. J Am 
Med Dir Assoc 2015; 16: 535 e1-12. 
4. Rolland Y, Abellan van Kan G, Hermabessiere S, Gerard S, Guyonnet Gillette S, 
Vellas B. Descriptive study of nursing home residents from the REHPA network. J Nutr 
Health Aging 2009; 13: 679-83. 
5. Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW. The epidemiology of 
polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol 
2018; 10: 289-98. 
195 
 
6. Vetrano DL, Collamati A, Magnavita N, et al. Health determinants and survival 
in nursing home residents in Europe: Results from the SHELTER study. Maturitas 2018; 
107: 19-25. 
7. Onder G, Liperoti R, Fialova D, et al. Polypharmacy in nursing home in Europe: 
results from the SHELTER study. J Gerontol A Biol Sci Med Sci 2012; 67: 698-704. 
8. Kelly A, Conell-Price J, Covinsky K, et al. Length of stay for older adults residing 
in nursing homes at the end of life. J Am Geriatr Soc 2010; 58: 1701-6. 
9. Sloane PD, Gruber-Baldini AL, Zimmerman S, Roth M, Watson L, Boustani M, 
Magaziner J, Hebel JR. Medication undertreatment in assisted living settings. Arch 
Intern Med 2004; 164: 2031-7. 
10. Parsons C, Lapane K, Kerse N, Hughes C. Prescribing for older people in nursing 
homes: a review of the key issues. Int J Older People Nurs 2011; 6: 45-54. 
11. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of 
Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right 
Treatment). Consensus validation. Int J Clin Pharmacol Ther 2008; 46: 72-83. 
12. Lozano-Montoya I, Velez-Diaz-Pallares M, Delgado-Silveira E, Montero-
Errasquin B, Jentoft AJC. Potentially inappropriate prescribing detected by STOPP-
START criteria: are they really inappropriate? Age Ageing 2015; 44: 861-66. 
13. Meid AD, Quinzler R, Freigofas J, et al. Medication underuse in aging 
outpatients with cardiovascular disease: Prevalence, determinants, and outcomes in a 
prospective cohort study. PloS One 2015; 10.e0136339. doi: 
10.1371/journal.pone.0136339. eCollection 2015 
14. Poudel A, Peel NM, Nissen LM, Mitchell CA, Gray LC, Hubbard RE. Adverse 
Outcomes in Relation to Polypharmacy in Robust and Frail Older Hospital Patients. J 
Am Med Dir Assoc 2016; 17: 767.e9-67.e13. 
15. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. 
Lancet 2013; 381: 752-62. 
16. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in 
type 2 diabetes, 2015: a patient-centered approach: update to a position statement of 
the American Diabetes Association and the European Association for the Study of 
Diabetes. Diabetes Care 2015; 38: 140-9. 
196 
 
17. Physical frailty: instruments for baseline characterisation of older populations 
in clinical trials. European Medicines Agency. 9 January 2018 







Chapter 8:  
Conclusions 
 
1. There is a significant consumption of drugs in non-institutionalized elderly 
population in Spain, and the trend observed in recent years to increase the 
prevalence of polypharmacy over time continues. Population-based studies 
carried out so far in Spain have probably underestimated the prevalence of 
polypharmacy in non-institutionalized older adults, which may be at least a 
third greater than previously estimated. The factors that are most associated 
with polypharmacy are the number of chronic health problems, dependence 
for basic activities of daily living, perceived health status or contacts with the 
health system; and inversely, sensory deficits and incontinence. It is important 
to contemplate variables such as function or geriatric syndromes, essential in 
elderly people, to consider the consumption habits and prescription of 
medications in this population. Knowing the patterns of drug use in our 
population and the associated factors is essential to understand the 
phenomenon of polypharmacy in the elderly and the extent of its 
consequences for the population, professionals and health systems. 
 
2. Results from the systematic review suggest that polypharmacy is associated 
with frailty in older people, although the causal relationship is unclear and, in 
fact, appears to be bidirectional. The lack of standardized definitions for frailty 
and polypharmacy hinders research in this area and leads to a wide range of 
outcomes. There is still scarce evidence of the mechanisms involved, and it is 
difficult to form conclusions on clinical practice based on the observational 
studies available at the moment. However, polypharmacy may be recognized as 
a major contributor to the development of frailty. It seems clear that frailty is 
an important issue that must be taken into account for decision-making in drug 
prescribing to older patients, and that polypharmacy should be assessed with 
special caution in frail older adults. Therefore, it has been suggested that a 
198 
 
reduction of polypharmacy could be a strategy to prevent and manage frailty. 
Further research is needed to confirm the possible benefits of reducing 
polypharmacy. 
 
3. There is no clear relationship between the prevalence of polypharmacy and 
frailty status based on different proposed definitions of frailty, and frailty status 
is associated with a lower number of medications among people living in 
nursing homes. Accordingly, the positive association found in previous studies 
between frailty and polypharmacy cannot be extrapolated to institutionalized 
populations. There is a trend of a greater prevalence of underprescription 
according to the START criteria in frail subjects compared with robust ones. To 
promote the appropriate use of drugs in frail patients without falling into 
ageism, we should redefine underprescription in frail older adults and develop 
new strategies to measure it. The Fried criteria could be one of the best 
indicators of medication-related clinical outcomes, but has important 
limitations for the application in nursing homes, while the FRAIL-NH could be 
more useful for disabled people.  
 
4. After hospitalization in an acute geriatric unit, the prevalence of polypharmacy, 
Potentially Inappropriate Prescriptions, Potentially Prescription Omissions, 
drug-drug interactions or drugs with anticholinergic effect continues to be very 
high, which can have important consequences on the health of elderly patients. 
Regarding medication use, polypharmacy is the most important risk factor for 
readmission and emergency room visits in complex elderly hospitalized 
patients. Although it has been suggested that a better quality of prescription is 
seen with hospitalizations in geriatric units, there is still a need to implement 
specific strategies to improve pharmacotherapy in hospitalized older adults.  
 
5. The systematic review concluded that the medication appropriateness in 
elderly hospitalized patients can be improved by interventions with various 
approaches (systematic medication reviews, decision-making support 
softwares, and detection of explicit criteria of inappropriate prescription), 
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implemented by various professionals (clinical pharmacists, geriatricians, 
multidisciplinary teams, etc.). However, there is significant variability in the 
endpoints. The role of these interventions in health outcomes (the 
consequences for patients, healthcare system and society) is uncertain. We 
need to address the applicability and validity of the tools that assess 
medication appropriateness to obtain more reliable results with greater impact 
on health. Explicit criteria for optimizing treatments should not be considered 
the gold standard, and their implementation should preferably be combined 
with implicit methods so as to address especially important issues for elderly 
patients, such as the sociofamiliar context, functional and cognitive status and 
life expectancy. The clinical variables for elderly patients should be properly 
selected, and the selection of objectives can benefit from consensus in 
multidisciplinary teams that include a comprehensive geriatric assessment.  
 
6. There is a need to implement medication optimization strategies in very old 
and complex patients; a systematic pharmacist-led intervention within a 
Comprehensive Geriatric Assessment in the context of an Acute Geriatric Unit is 
a great opportunity to reduce polypharmacy and improve medication 
appropriateness. We propose a strategy with a multidisciplinary team that can 







1. Se encuentra un importante consumo de medicamentos en la población mayor 
no institucionalizada en España, y continúa la tendencia observada en los 
últimos años a aumentar la prevalencia de polifarmacia en el tiempo. Los 
estudios a nivel poblacional realizados hasta ahora en España han 
infraestimado probablemente la prevalencia de polifarmacia en mayores no 
institucionalizados, que puede ser al menos un tercio mayor de los que se había 
estimado previamente. Los factores que más se asocian a la polifarmacia son el 
número de problemas de salud crónicos, la dependencia para las actividades 
básicas de la vida diaria, el estado de salud percibido o los contactos con el 
sistema sanitario;  y de forma inversa los déficits sensoriales y la incontinencia. 
Es importante contemplar variables como la función o los síndromes 
geriátricos, fundamentales en personas mayores, para entender los hábitos de 
consumo y prescripción de medicamentos en esta población. Conocer los 
patrones de consumo de medicamentos en nuestra población y los factores 
asociados es fundamental para comprender el fenómeno de la polifarmacia en 
las personas mayores y el alcance de sus consecuencias para la población, los 
profesionales y los sistemas sanitarios.   
 
2. Los resultados de la revisión sistemática sugieren que existe asociación entre la 
polifarmacia y la fragilidad en las personas mayores, aunque la relación causal 
no está clara y, de hecho, parece ser bidireccional. La falta de definiciones 
estandarizadas de fragilidad y polifarmacia dificulta la investigación en esta 
área y conduce a una amplia variabilidad de resultados. Todavía hay poca 
evidencia sobre los mecanismos involucrados, y es difícil llegar a conclusiones 
aplicables en la práctica clínica en base a los estudios observacionales 
disponibles en este momento. Sin embargo, la polifarmacia puede ser 
reconocida como un importante contribuyente al desarrollo de la fragilidad. 
Parece claro que la fragilidad es un tema importante que debe tenerse en 
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cuenta para la toma de decisiones en la prescripción de medicamentos en 
pacientes mayores, y que la polifarmacia debe evaluarse con especial 
precaución en adultos mayores frágiles. Por lo tanto, se ha sugerido que una 
reducción de la polifarmacia podría ser una estrategia para prevenir y manejar 
la fragilidad. Se necesita más investigación para confirmar los posibles 
beneficios de la reducción de la polifarmacia. 
 
3. En personas mayores que viven en residencias, no existe una relación clara 
entre la prevalencia de la polifarmacia y el estado de fragilidad según las 
diferentes definiciones propuestas de fragilidad, y el estado de fragilidad se 
asocia con un número menor de medicamentos. En consecuencia, la asociación 
positiva encontrada en estudios previos entre fragilidad y polifarmacia no 
puede extrapolarse a poblaciones institucionalizadas. Existe una tendencia a 
una mayor prevalencia de infraprescripción según los criterios START en sujetos 
frágiles en comparación con los robustos. Para promover el uso apropiado de 
medicamentos en pacientes frágiles sin caer en la discriminación por edad, 
debemos redefinir la infraprescripción en adultos mayores frágiles y desarrollar 
nuevas estrategias para medirla. Los criterios de Fried podrían ser uno de los 
mejores indicadores de resultados clínicos relacionados con la medicación, 
pero tienen importantes limitaciones para la aplicación en residencias de 
ancianos, mientras que el FRAIL-NH podría ser más útil para las personas con 
discapacidad. 
 
4. Después de la hospitalización en una unidad de agudos de geriatría, la 
prevalencia de polifarmacia, prescripciones potencialmente inadecuadas,  
prescripciones potencialmente omitidas, interacciones farmacológicas o  
fármacos con efecto anticolinérgico sigue siendo muy alta, lo que puede tener 
importantes consecuencias en la salud de los pacientes ancianos. Con respecto 
al uso de medicamentos, la polifarmacia es el factor de riesgo más importante 
para el reingreso y las visitas a urgencias en pacientes ancianos complejos 
hospitalizados. Aunque se ha sugerido que se observa una mejor calidad de la 
prescripción con las hospitalizaciones en unidades geriátricas, todavía existe la 
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necesidad de implementar estrategias específicas para mejorar la 
farmacoterapia en adultos mayores hospitalizados. 
5. Los estudios analizados en la revisión sistemática muestran que se puede
mejorar la adecuación terapéutica de los ancianos hospitalizados mediante
intervenciones con distintos enfoques (revisiones sistemáticas de tratamiento,
programas informáticos de apoyo a la toma de decisiones, o detección de
criterios explícitos de prescripción inadecuada), desarrolladas por distintos
profesionales (farmacéuticos clínicos, geriatras, equipos multidisciplinares,
etc.). Sin embargo, hay mucha variabilidad en las variables de resultado, por lo
que el papel de estas intervenciones sobre los resultados en salud
(consecuencias para el paciente, el sistema sanitario o la sociedad) es incierto.
Es necesario atender a la aplicabilidad y validez de las herramientas que
evalúan la adecuación terapéutica, para obtener resultados más fiables y con
mayor impacto sobre la salud. Los criterios explícitos para optimizar los
tratamientos no deben considerarse el «patrón oro», y su aplicación debería
combinarse preferentemente con métodos implícitos, para abarcar cuestiones
especialmente importantes en el paciente anciano como el contexto
sociofamiliar, la situación funcional o cognitiva o la expectativa de vida del
paciente. La selección de objetivos puede beneficiarse del consenso en equipos
multidisciplinares que incluyan una valoración geriátrica integral.
6. Existe la necesidad de implementar estrategias de optimización de
medicamentos en pacientes complejos muy ancianos. Una intervención
sistemática dirigida por un farmacéutico dentro de una valoración geriátrica
integral en el contexto de una unidad de geriatría de agudos es una gran
oportunidad para reducir la polifarmacia y mejorar la adecuación de la
medicación. Proponemos una estrategia con un equipo multidisciplinar que
puede mejorar la atención de los pacientes ancianos.
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Encuesta Nacional de Salud
Adultos mayores
Atención primaria
r e s u m e n
Fundamento y objetivo: Estimar la prevalencia de polifarmacia e hiperpolifarmacia en adultos mayores
no institucionalizados en España y analizar los factores asociados.
Material y métodos: Estudio transversal a partir de datos de la Encuesta Nacional de Salud de España
2017, con participantes de 65 años o más. Se estimó la prevalencia de polifarmacia (≥ 5 medicamentos) e
hiperpolifarmacia (≥ 10), y la asociación con diversos factores mediante regresión logística multivariante.
Se realizó un análisis de sensibilidad considerando el posible consumo de más de un fármaco para la
misma indicación (politerapia).
Resultados: Se incluyeron 7.023 participantes, con edad media de 76,0 (desviación estándar [DE] 7,6)
años, 59,4% mujeres y consumo medio de 3,3 (DE 2,2) medicamentos por persona. La prevalencia de
polifarmacia fue de 27,3% (intervalo de confianza del 95%: 26,2-28,3) y la de hiperpolifarmacia de 0,9%
(intervalo de confianza del 95%: 0,7-1,1). El análisis de sensibilidad estimó que la prevalencia podría
ascender al menos a un 37,5% y la media a 3,9 (DE 2,5) al considerar la politerapia. Los factores que más se
asocian a la polifarmacia fueron el número de enfermedades crónicas, el grado de dependencia para las
actividades básicas de la vida diaria, el estado de salud percibido o los contactos con el sistema sanitario;
y de forma inversa los déficits sensoriales y la incontinencia.
Conclusiones: La prevalencia de polifarmacia en adultos mayores en atención primaria continúa aumen-
tando, y podría estar ampliamente infraestimada. Además de la pluripatología, factores como la capacidad
funcional o los síndromes geriátricos, fundamentales en personas mayores, modulan los hábitos de
consumo y prescripción de medicamentos en esta población.
© 2019 Elsevier España, S.L.U. Todos los derechos reservados.
Prevalence of polypharmacy and associated factors in older adults in Spain:






a b s t r a c t
Background and objective: to estimate the prevalence of polypharmacy and hyperpolypharmacy in non-
institutionalised older adults in Spain and assess the associated factors.
Material and methods: a cross-sectional study based on data from the National Health Survey of Spain
2017, with participants aged 65 and over. The prevalence of polypharmacy (≥ 5 medications) and hyper-
polypharmacy (≥ 10) were estimated, as well as the association with several factors through multivariate
logistic regression. A sensitivity analysis was carried out considering the possible consumption of more
than one drug for the same indication (polytherapy).
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Results: 7023 participants were included, with a mean age of 76.0 (SD 7.6), 59.4% female and average
consumption of 3.3 (SD 2.2) drugs per person. The prevalence of polypharmacy was 27.3% (95% CI 26.2-
28.3) and of hyperpolypharmacy 0.9% (95% CI 0.7-1.1). The sensitivity analysis showed that the prevalence
could be at least 37.5% and the average 3.9 (SD 2.5) when considering polytherapy. The factors most
associated with polypharmacy were the number of chronic diseases, degree of dependence for the basic
activities of daily living, self-perceived health or contacts with the health system; and negatively, sensory
deficits and incontinence.
Conclusions: the prevalence of polypharmacy in the elderly in primary care continues to increase and could
be widely underestimated. In addition to multimorbidity, factors such as functional capacity or geriatric
syndromes, fundamental in elderly people, modulate the habits of consumption and prescription of drugs
in this population.
© 2019 Elsevier España, S.L.U. All rights reserved.
Introducción
A lo largo de las últimas décadas se han producido en España
enormes cambios demográficos y epidemiológicos, cuyos resulta-
dos son el envejecimiento de la población y la mayor prevalencia de
enfermedades crónicas1. Esta nueva situación se ha acompañado de
un aumento del consumo de medicamentos de forma crónica para
tratar esas enfermedades, especialmente en personas mayores2.
El uso de medicamentos en personas mayores es de por sí
complejo, debido a los cambios en la farmacocinética y la far-
macodinamia asociados al envejecimiento, a la multimorbilidad y
a otros factores que condicionan la complejidad en los mayores,
como el deterioro funcional y cognitivo o los síndromes geriátri-
cos. También a la escasa evidencia disponible sobre la eficacia y
la seguridad de los medicamentos en esta población3,4. Pero ade-
más, el empleo de múltiples medicamentos simultáneamente, lo
que se ha llamado polifarmacia, a pesar de ser la respuesta lógica a
la coexistencia de múltiples enfermedades, puede resultar un pro-
blema por sí mismo5. La polifarmacia se asocia a un aumento de
interacciones entre medicamentos y entre medicamento y enfer-
medad, a una disminución de la adherencia al tratamiento, a un
mayor riesgo de efectos anticolinérgicos y, en general, a efec-
tos adversos a medicamentos, tal vez por aumentar el número
de prescripciones potencialmente inadecuadas en una población
especialmente vulnerable6,7. Probablemente por todo ello la poli-
farmacia se ha asociado a peores resultados en salud en los mayores,
aumentando el riesgo de delirium, malnutrición, caídas, ingresos
hospitalarios e incluso de mortalidad, entre otros8,9. Se estima, por
ejemplo, que entre un 10% y un 20% de los ingresos hospitalarios
de personas mayores en nuestro país tendrían relación con efectos
adversos a medicamentos, siendo la polifarmacia uno de los fac-
tores asociados10. En un intento de preservar o mejorar el estado
de salud en los adultos mayores, un uso excesivo o no suficien-
temente cuidadoso de los medicamentos puede acabar siendo más
perjudicial que beneficioso. Comienza a haber evidencias de que un
elevado consumo de medicamentos puede contribuir a la fragilidad,
independientemente de las comorbilidades asociadas, condicio-
nando un peor pronóstico vital en las personas mayores11. Además,
la polifarmacia excesiva puede tener un importante impacto eco-
nómico para el sistema sanitario público, tanto por el incremento
del gasto directo en medicamentos, como por los gastos indirectos
derivados de las consultas, visitas a urgencias o ingresos hospita-
larios resultantes. Por otra parte, hay que tener en cuenta también
que un elevado consumo de medicamentos aumenta la «carga del
tratamiento» para el paciente, y puede afectar a su percepción del
estado de salud, a su bienestar y a su calidad de vida12.
Para poder afrontar las causas y las consecuencias de este pro-
blema y mejorar las conductas y estrategias hacia un uso más
adecuado de los medicamentos en las esferas individual y pobla-
cional, es fundamental conocer el alcance de la polifarmacia en las
personas mayores en nuestra población. Se han realizado previa-
mente estudios con el fin de conocer la prevalencia de polifarmacia
en mayores no institucionalizados en España, algunos de ámbito
local o regional13–15 y otros basados en encuestas nacionales
o europeas de salud realizadas previamente en España2,16. Los
cambios demográficos y epidemiológicos que se producen progre-
sivamente en nuestra población hacen necesaria la actualización
de estos datos, que en los últimos años han tenido una tenden-
cia ascendente. En junio de 2018 se hicieron públicos los datos de
la Encuesta Nacional de Salud de España 2017 (ENSE 2017), reali-
zada por el Ministerio de Sanidad, Consumo y Bienestar Social con
la colaboración del Instituto Nacional de Estadística, y que recoge
información sanitaria relativa a la población residente en España en
23.860 hogares17. Es una investigación que permite conocer nume-
rosos aspectos de la salud de los ciudadanos en el ámbito nacional y
autonómico, y planificar y evaluar las actuaciones en materia sani-
taria. Entre ellos, la ENSE aporta información sobre el consumo de
medicamentos en una muestra representativa de toda la pobla-
ción, aunque requiere ciertos ajustes para estimar adecuadamente
la prevalencia de polifarmacia que no han sido realizados en estu-
dios previos. Además, proporciona información de vital interés en la
población de edad avanzada, como la capacidad funcional o cogni-
tiva, la percepción del estado de salud o determinados síndromes
geriátricos. La incorporación de estos factores al análisis sobre la
polifarmacia en personas mayores es fundamental para compren-
der los patrones de consumo de medicamentos en ancianos, por lo
que los incluimos por primera vez en este estudio junto con factores
sociodemográficos, ya presentes en estudios previos con encuestas
de salud.
El objetivo del presente estudio es estimar la prevalencia de
polifarmacia e hiperpolifarmacia en adultos mayores no institu-
cionalizados en España y analizar los factores asociados.
Material y métodos
Diseño del estudio y población
Estudio transversal con datos obtenidos de la ENSE 2017, selec-
cionando los participantes con 65 años o más. La ENSE es el
resultado del convenio de colaboración suscrito entre el Ministerio
de Sanidad, Servicios Sociales e Igualdad y el Instituto Nacional de
Estadística españoles, y la población objeto del estudio son las per-
sonas residentes en viviendas familiares principales del territorio
español en 2017. La información se recogió a través de entre-
vistas personales asistidas por ordenador en los hogares de los
participantes seleccionados, y se llevaron a cabo por entrevistado-
res específicamente instruidos. Las entrevistas se realizaron entre
octubre de 2016 y octubre de 2017. La ENSE tiene representativi-
dad nacional y autonómica, utilizando un muestreo probabilístico
trietápico estratificado, siendo las unidades de primera etapa las
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secciones censales, las unidades de segunda etapa las viviendas
familiares principales y las unidades de tercera etapa un adulto
seleccionado de cada vivienda para cumplimentar el cuestionario
de adultos. La muestra se distribuye entre comunidades autónomas
asignando una parte uniformemente y otra de forma proporcional
al tamaño de la comunidad. El cuestionario de adultos debía ser
respondido por el adulto seleccionado, salvo por ingreso hospitala-
rio, incapacidad por enfermedad/discapacidad o impedimento por
el idioma. En estos casos se admitía que respondiera al cuestionario
otra persona en su nombre.
Variables
Las variables de resultado principales son la prevalencia de
polifarmacia e hiperpolifarmacia y el número de medicamen-
tos consumidos. Se consideran como variables independientes
factores sociodemográficos (sexo, edad, estado civil, nivel de
estudios), de utilización del sistema sanitario (ingreso hospi-
talario y visita a urgencias en el último año, consulta con
el médico de familia y especialista en las últimas 4 sema-
nas, modalidad de seguro sanitario), comorbilidad, independencia
para las actividades básicas de la vida diaria (ABVD), estado de
salud percibido, deterioro cognitivo e índice de masa corporal
(IMC).
Se define la polifarmacia como el consumo de 5 o más medica-
mentos durante las últimas 2 semanas previas a la entrevista, y la
hiperpolifarmacia como el consumo de 10 o más medicamentos. Se
preguntaba específicamente «¿cuál o cuáles de estos medicamen-
tos ha consumido en las últimas 2 semanas?», considerando para el
presente estudio las siguientes: «medicinas para el catarro, gripe,
garganta, bronquios, para el dolor, para bajar la fiebre, reconstitu-
yentes como vitaminas, minerales y tónicos, laxantes, antibióticos,
tranquilizantes, relajantes y pastillas para dormir, medicamentos
para la alergia, para la diarrea, para el reuma, para el corazón, para
la tensión arterial, para el estómago y/o las alteraciones digesti-
vas, antidepresivos o estimulantes, hormonas para la menopausia,
medicamentos para adelgazar, para bajar el colesterol, para la dia-
betes y para el tiroides». Para la redacción de este artículo se ha
equiparado en lo posible esta clasificación a los grupos terapéuticos
ATC. Para cada individuo se sumaron todas las respuestas afirmati-
vas, estimando así el número total de medicamentos consumidos.
Pese a no existir un consenso en la definición de polifarmacia, se
escogió el umbral de 5 o más medicamentos al ser la fórmula más
utilizada18.
Se empleó una herramienta previamente validada de evaluación
de multimorbilidad para medir la carga global de enfermedades
crónicas o problemas de salud de los participantes19, adaptándola
a las preguntas de la ENSE respecto a si ha padecido alguna vez
las condiciones consideradas. Esta herramienta recoge 918 códi-
gos CIE-10 y los agrupa en 60 categorías de enfermedades crónicas.
Se ha equiparado cada una de estas categorías a una pregunta de
la ENSE siempre que ha sido posible, reflejando las enfermedades
más importantes (hipertensión, hipercolesterolemia, enfermedad
renal crónica, cardiopatía isquémica, otras afecciones cardiacas,
artrosis, déficit auditivo o visual, obesidad, enfermedades tiroi-
deas, depresión, neoplasias malignas, diabetes, ictus, osteoporosis,
cataratas, asma, enfermedad pulmonar obstructiva crónica [EPOC],
úlcera péptica, procesos patológicos prostáticos, otras enferme-
dades genitourinarias, ansiedad crónica, migraña, alergia crónica,
problemas de salud mental, enfermedad venosa crónica, cirro-
sis, disfunción hepática y afecciones crónicas de la piel) (Anexo
en material suplementario disponible en la Web). La metodología
propuesta permite capturar un conjunto completo de problemas
de salud crónicos que tienen un impacto duradero en la auto-
nomía y calidad de vida de los adultos mayores, o requieren
contactos frecuentes con los servicios de salud. Este instrumento,
por lo tanto, es adecuado para describir la carga de la enfer-
medad crónica en nuestra población de estudio. Se expresa la
multimorbilidad como el número de problemas de salud cróni-
cos contemplados por esta herramienta. Se utilizó el Índice de
Katz20 para evaluar la dependencia para las actividades básicas
de la vida diaria, adaptándolo a partir de las preguntas de la ENSE
2017, considerando estas 6 categorías: dificultad para actividades
básicas diarias —ducharse o bañarse sin ayuda, vestirse y desves-
tirse sin ayuda, ir al servicio sin ayuda, sentarse, levantarse de
una silla o de una cama, acostarse sin ayuda, incontinencia par-
cial o total; alimentarse sin ayuda (descripción en el ANEXO del
material suplementario disponible en la Web)—. Se asignó una pun-
tuación de 0 como muy dependiente y 6 como independiente. Se
consideró que los participantes presentaban deterioro cognitivo
al responder que se habían visto limitados durante al menos los
últimos 6 meses para realizar las actividades que la gente habitual-
mente hace, debido a un problema de tipo mental, o físico y mental
conjuntamente. Finalmente se clasificó a los participantes según
los siguientes rangos de IMC: < 18,5 kg/m2 peso insuficiente, ≥ 18
y < 25 kg/m2 normopeso, ≥ 25 y < 30 kg/m2 sobrepeso y ≥ 30 kg/m2
obesidad.
Análisis estadístico
Se realizó en primer lugar un análisis descriptivo mostrando
las principales características de la población de estudio mediante
número y proporción para variables cualitativas, y mediante
medias y desviación estándar (DE) para variables cuantitativas.
Se estimó la prevalencia de polifarmacia e hiperpolifarmacia
con sus correspondientes intervalos de confianza del 95% (IC).
Para la comparación de medias se empleó el test de Student
y para las proporciones el test de Chi-cuadrado de Pearson.
Se analizó la asociación entre el consumo de los medicamen-
tos más frecuentes y las enfermedades más comunes registradas
en la ENSE para las que están indicados mediante el test
Chi-cuadrado.
Una de las mayores limitaciones de la ENSE para estimar la
prevalencia de polifarmacia es que al permitir solo respuestas
dicotómicas, sí/no, respecto al consumo de los distintos tipos de
medicamentos no contempla el uso de terapias combinadas para
una misma enfermedad (considera siempre la monoterapia). Para
obtener una estimación más cercana a la realidad se realizó un aná-
lisis de sensibilidad en el que se contempló que una proporción de
los participantes estaría recibiendo terapia combinada para 2 de
los problemas de salud crónicos más frecuentes en que esta situa-
ción es común: la hipertensión y la diabetes. Se calculó por tanto
el número medio de medicamentos consumidos y la prevalencia
de polifarmacia e hiperpolifarmacia, asumiendo que los pacientes
que tomaban antihipertensivos consumían 1,8 antihipertensivos
por paciente (un solo antihipertensivo en el 38,3% de los casos, 2
antihipertensivos en el 43,5% de los casos, 3 antihipertensivos en
el 15% de los casos y 4 antihipertensivos en un 3,2% de los casos,
basándonos en la bibliografía previa21,22), y que los pacientes que
consumían medicamentos para la diabetes tomaban una media de
1,5 antidiabéticos (monoterapia en un 54,2% de los casos y 2 antidia-
béticos en un 45,8% de los casos23). Se asumió que esta distribución
era homogénea para todos los participantes en todas las categorías
de polifarmacia.
Para identificar factores asociados a la polifarmacia e hiperpoli-
farmacia se realizaron análisis por regresión logística multivariante
con todas las variables incluidas en la tabla 1.
Se estableció un límite para la significación estadística de
alfa < 0,05. Todos los análisis estadísticos se realizaron con el soft-
ware IBM SPSS Statistics versión 20 (IBM Corp, Armonk, NY, EE.
UU.).
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Tabla 1
Características de los participantes del estudio
Característica Total (n = 7.023)
N (%)
Con polifarmacia
(n = 1.914) N (%)
Sin polifarmacia
(n = 5.109) N (%)
Valor de p*
Sexo
Hombre 2.850 (40,6) 607 (21,3) 2.243 (78,7) < 0,001
Mujer 4.173 (59,4) 1.307 (31,3) 2.866 (68,7)
Edad (años), media (DE) 76,0 (7,6) 77,6 (7,3) 75,4 (7,6) < 0,001
65-75 3.652 (59,1) 786 (21,6) 2.856 (78,4) < 0,001
76-85 2.502 (35,6) 838 (33,5) 1.664 (66,5)
> 85 879 (12,5) 290 (33,0) 589 (67,0)
Estado civil (n = 7.012)
Soltero 752 (8,1) 120 (21,0) 452 (79,0) < 0,001
Casado 3567 (50,8) 865 (24,3) 2.702 (75,7)
Viudo 2.567 (36,6) 867 (33,8) 1.700 (66,2)
Divorciado/separado 306 (4,4) 61 (19,9) 245 (80,1)
Nivel de estudios
Sin estudios 339 (4,8) 148 (43,7) 191 (56,3) < 0,001
Educación primaria 4.411 (62,8) 1.301 (29,5) 3.110 (70,5)
Educación secundaria, bachillerato o enseñanzas profesionales 1.638 (23,3) 348 (21,2) 1.290 (78,8)
Estudios universitarios o equivalentes 635 (9,0) 117 (18,4) 518 (81,6)
Nacionalidad
Española 6.924 (98,6) 1.896 (27,4) 5.028 (72,6) 0,024
Otros 99 (1,4) 18 (18,2) 81 (81,8)
Índice de Katz, media (DE) 5,5 (1,2) 5,1 (1,5) 5,7 (0,9) < 0,001
6 5.519 (78,6) 1.155 (20,9) 4.364 (79,1) < 0,001
4-5 1.057 (15,1) 508 (48,1) 549 (51,9)
2-3 203 (2,9) 122 (60,1) 81 (39,9)
0-1 244 (3,5) 129 (52,9) 115 (47,1)
Número de problemas de salud crónicos, media (DE) 4,3 (2,8) 7,0 (2,7) 3,3 (2,2) < 0,001
Deterioro cognitivo
No 6.501 (92,6) 1.677 (25,8) 48,24 (74,2) < 0,001
Sí 522 (7,4) 237 (45,4) 285 (54,6)
Déficits sensoriales
Déficit auditivo
No 6.708 (95,5) 1.789 (26,7) 4919 (73,3) < 0,001
Sí 315 (4,5) 125 (39,7) 190 (60,3)
Déficit visual
No 6652 (94,7) 1719 (25,8) 4933 (74,2) < 0,001
Sí 371 (5,3) 195 (52,6) 176 (47,4)
Incontinencia urinaria
No 5909 (84,1) 1347 (22,8) 4562 (77,2) < 0,001
Sí 1114 (15,9) 567 (50,9) 547 (49,1)
Estado de salud percibido
Muy bueno 441 (6,3) 18 (4,1) 423 (95,9) < 0,001
Bueno 2.745 (39,1) 288 (10,5) 2.457 (89,5)
Regular 2.593 (36,9) 918 (35,4) 1.675 (64,6)
Malo 997 (13,9) 529 (54,1) 448 (45,9)
Muy malo 267 (3,8) 161 (60,3) 106 (39,7)
Modalidad de seguro sanitario
Sanidad pública 6.222 (88,6) 1.741 (28,0) 4.481 (72,0) < 0,001
Mutualidades del Estado 283 (4,0) 52 (18,4) 231 (81,6)
Seguro privado 518 (7,4) 121 (23,4) 397 (76,6)
Ingreso hospitalario en el último año
No 5.992 (85,3) 1.460 (24,4) 4.532 (75,6) < 0,001
Sí 1.031 (14,7) 454 (44,0) 577 (56,0)
Servicio de urgencias en el último año
No 4.826 (68,7) 996 (20,6) 3830 (79,4) < 0,001
Sí 2.197 (31,3) 918 (41,8) 1.279 (58,2)
Consulta con médico de familia en el último mes
No 3.971 (56,5) 811 (20,4) 3.160 (79,6) < 0,001
Sí 3.052 (43,5) 1.103 (36,1) 1.949 (63,9)
Consulta con especialista en el último mes
No 5.911 (84,2) 1.472 (24,9) 4.439 (75,1) < 0,001
Sí 1.112 (15,8) 442 (39,7) 670 (60,3)
IMC, media (DE)
Peso insuficiente 72 (1,0) 18 (25,0) 54 (75,0) < 0,001
Normopeso 1.978 (28,2) 449 (22,7) 1.529 (77,3)
Sobrepeso 2.841 (40,5) 729 (25,7) 2.112 (74,3)
Obesidad 1.487 (21,2) 532 (35,8) 955 (64,2)
No sabe/no contesta 645 (9,2) 186 (28,8) 459 (71,2)
DE: desviación estándar; IMC: índice de masa corporal.
* Comparación entre grupo con polifarmacia y sin polifarmacia.
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Aspectos éticos
Este estudio respeta los principios fundamentales establecidos
en la Declaración de Helsinki y sus actualizaciones, y cumple los
requisitos establecidos en la legislación en el ámbito de la investi-
gación biomédica, la protección de datos de carácter personal y la
bioética. Según la metodología de la ENSE los ficheros de microda-
tos están anonimizados. Los ficheros de microdatos de la ENSE son de
uso público, no identificables, y por tanto no requieren acuerdos para
su uso. Los ficheros de uso público no se consideran confidenciales, de
acuerdo con el Reglamento (UE) 2016/679 del Parlamento Europeo y
del Consejo, de 27 de abril de 2016, relativo a la protección de las per-
sonas físicas en lo que respecta al tratamiento de datos personales y a
la libre circulación de estos datos. No es necesario aplicar los principios
de protección de datos a la información anónima, es decir, información
que no guarda relación con una persona física identificada o identifica-
ble, ni a los datos convertidos en anónimos de forma que el interesado
no sea identificable, o deje de serlo. En consecuencia, el Reglamento
no afecta al tratamiento de la información que se publica de la ENSE.
Incluso con fines estadísticos o de investigación, su uso no requiere la
aprobación de un comité de ética acreditado.
Resultados
Características principales
La muestra total de la ENSE 2017 comprende 29.195 individuos,
de los que se seleccionaron 7.023 con 65 o más años. La edad media
fue de 76,0 (7,6) años, y un 59,4% eran mujeres. Las característi-
cas principales de los individuos participantes se describen en la
tabla 1. El 92,5% declararon padecer en el momento de la entrevista
un problema de salud crónico o de larga duración (ha durado o se
espera que dure al menos 6 meses). Los problemas de salud cró-
nicos más frecuentes fueron hipertensión arterial (56,0%), artrosis
(51,8%), hipercolesterolemia (43,3%), diabetes (22,4%), depresión
(18,0%), osteoporosis (13,0%), afecciones prostáticas (12,2%), ansie-
dad crónica (11,3%), EPOC (10,2%) y enfermedades tiroideas (10,2%).
La mujeres presentaban de media un mayor número de problemas
de salud crónicos que los hombres (4,7; DE 2,9 vs. 3,8; DE 2,6),
al igual que las personas de más edad frente a las más jóvenes > 85
años: 5,1 (DE 2,9), 76 a 85 años 4,8 (DE 2,9), 65 a 75 años 3,8 (DE 2,7).
Del mismo modo las personas con mayor nivel de estudios padecían
menos problemas de salud crónicos que aquellas con menor nivel
de estudios: sin estudios 5,6 (DE 3,2), estudios primarios 4,6 (DE
2,8), estudios secundarios 3,8 (DE 2,6) y estudios universitarios 3,5
(DE 2,5). Los hombres valoraron su estado de salud en los últimos
12 meses como bueno o muy bueno en el 52,6% de los casos, frente
a un 40,4% en las mujeres, como regular en un 34,2% de los casos
frente a un 38,7% en mujeres y como malo o muy malo en un 13,1%
de los casos frente a un 20,9% en las mujeres (p < 0,001). Los hom-
bres valoraron el dolor padecido en las últimas 4 semanas como
ninguno (48,4%), muy leve (10,7%), leve (15,1%), moderado (17,5%),
severo (6,7%) y extremo (1,5%), siendo en mujeres un 26,6%, 9,8%,
16,4%, 27,7%, 16,3% y 3,2% respectivamente.
Polifarmacia
Del total de los participantes encuestados el 91,9% refirió haber
consumido algún medicamento recetado por un médico en las
últimas 2 semanas, y el 11,2% algún medicamento no recetado
por un médico. Globalmente, el 91,9% había consumido algún
medicamento en las últimas 2 semanas; 1.914 individuos presen-
taron polifarmacia (27,3%, IC 95%: 26,2-28,3) y 65 presentaron
hiperpolifarmacia (0,9%, IC 95%: 0,7-1,1). Las mujeres presenta-
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Figura 1. Prevalencia de polifarmacia (%) por grupos de edad y sexo.
hombres (31,3% vs. 21,3%, p < 0,001 y 1,3% vs. 0,3%, p < 0,001 res-
pectivamente). La polifarmacia fue más frecuente en los individuos
entre 76 y 85 años (65-75 años: 21,6%, 76-85: 33,5% y > 85: 33,0%).
Las diferencias entre hombres y mujeres se mantuvieron en los
distintos grupos de edad, aunque no fueron estadísticamente signi-
ficativas en mayores de 85 años (fig. 1). Se encontraron diferencias
en la prevalencia de polifarmacia entre las distintas comunida-
des autónomas (fig. 2). Ceuta, Cantabria y La Rioja presentaron
las menores tasas de polifarmacia, mientras que Andalucía, Gali-
cia y Navarra presentaron las más altas. Respecto a los fármacos
más consumidos los grupos más utilizados fueron los antihiper-
tensivos (56,4%), los analgésicos (47,0%), los agentes modificadores
de lípidos (38,2%), los fármacos para el tracto alimentario (32,2%),
ansiolíticos, hipnóticos y sedantes (26,8%), los fármacos usados en
diabetes (20,2%) y los fármacos para el corazón (19,4%). La figura 3
muestra las diferencias en el consumo de distintos fármacos en
función del sexo y del grupo de edad. En la figura 4 se muestra la
asociación entre el consumo de los medicamentos más frecuentes
y las enfermedades más comunes registradas para las que están
indicados.
Los participantes consumían una media de 3,3 (DE 2,2) medi-
camentos, 2,9 (DE 2,0) en hombres y 3,6 (DE 2,3) en mujeres
(p < 0,001).
El análisis de sensibilidad considerando la posible politerapia
para la hipertensión y la diabetes mostró que la media de medi-
camentos consumidos ascendía a 3,9 (DE 2,5) medicamentos por
persona, y que la prevalencia de polifarmacia e hiperpolifarmacia
ascendían a 37,5% y 2,5% respectivamente.
El análisis multivariante mostró que la polifarmacia se aso-
ciaba positivamente al número de problemas de salud crónicos,
a la dependencia para las ABVD, a un peor estado de salud perci-
bido, al ingreso hospitalario o visita a urgencias en el último año,
a la consulta en el último mes con un médico de familia y médico
especialista, a la obesidad y a la viudedad, pero no al sexo ni a una
mayor edad. También se apreció que se asociaba negativamente con
el déficit visual y auditivo y con la incontinencia urinaria. Las odds
ratio (OR) ajustadas para la presencia de polifarmacia se muestran
en la tabla 2.
Discusión
En este estudio que analiza la prevalencia de polifarmacia e
hiperpolifarmacia en la población mayor no institucionalizada en
España se encontró un consumo frecuente de medicamentos (hasta
en un 91,9% de los encuestados), y se estimó que el 27,3% de la
población anciana presenta polifarmacia (IC 95%: 26,2-28,3) y solo
un 0,9% hiperpolifarmacia (IC 95%: 0,7-1,1). Se encontraron dife-
rencias importantes en la prevalencia de polifarmacia entre las
distintas comunidades autónomas, con valores que oscilan entre el
I• • 
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Tabla 2
Número de medicamentos consumidos y factores asociados a polifarmacia
N.◦ medicamentos Polifarmacia (≥ 5)
Media (DE) OR ajustado (IC 95%)
Sexo
Hombre 2,9 (2,0) 1
Mujer 3,6 (2,3) 1,04 (0,89-1,21)
Edad (años)
65-75 2,9 (2,1) 1
76-85 3,7 (2,2) 1,12 (0,96-1,31)
> 85 3,8 (2,2) 1,00 (0,79-1,27)
Estado civil (n = 7.012)a
Soltero 2,9 (2,1) 1
Casado 3,1 (2,1) 1,16 (0,88-1,53)
Viudo 3,7 (2,3) 1,46 (1,10-1,93)
Divorciado/separado 2,8 (2,2) 0,92 (0,60-1,43)
Nivel de estudios
Sin estudios 4,3 (2,4) 1
Educación primaria 3,5 (2,2) 0,82 (0,61-1,10)
Educación secundaria, bachillerato o 2,9 (2,1) 0,87 (0,63-1,22)
enseñanzas profesionales
Estudios universitarios o equivalentes 2,6 (2,1) 0,91 (0,61-1,37)
Nacionalidad
Española 3,3 (2,2) 1
Otros 2,6 (2,4) 0,87 (0,45-1,70)
Índice de Katz
6 2,9 (2,0) 1
4-5 4,6 (2,3) 1,39 (1,06-1,83)
2-3 5,3 (2,5) 1,78 (1,19-2,65)
0-1 4,6 (2,5) 1,67 (1,09-2,56)
Número de problemas de salud crónicos - 1,73 (1,67-1,79)
Deterioro cognitivo
No 3,2 (2,2) 1
Sí 4,5 (2,3) 0,85 (0,66-1,09)
Déficits sensoriales
Déficit auditivo
No 3,3 (2,2) 1
Sí 4,2 (2,3) 0,44 (0,32-0,61)
Déficit visual
No 3,3 (2,2) 1
Sí 4,8 (2,4) 0,73 (0,55-0,97)
Incontinencia urinaria
No 3,0 (2,1) 1
Sí 4,8 (2,4) 0,51 (0,39-0,68)
Estado de salud percibido
Muy bueno 1,5 (1,5) 1
Bueno 2,3 (1,7) 1,66 (0,97-2,85)
Regular 3,9 (2,0) 3,28 (1,92-5,59)
Malo 4,9 (2,3) 4,43 (2,55-7,70)
Muy malo 5,4 (2,5) 3,76 (2,01-7,03)
Modalidad de seguro sanitario
Sanidad pública 3,4 (2,3) 1
Mutualidades del Estado 2,8 (2,0) 0,76 (0,51-1,13)
Seguro privado 3,0 (2,1) 1,22 (0,93-1,62)
Ingreso hospitalario en el último año
No 3,1 (2,1) 1
Sí 4,4 (2,3) 1,24 (1,03-1,50)
Servicio de urgencias en el último año
No 2,9 (2,1) 1
Sí 4,2 (2,3) 1,32 (1,14-1,54)
Consulta con médico de familia en el último mes
No 2,8 (2,1) 1
Sí 3,9 (2,2) 1,37 (1,20-1,57)
Consulta con especialista en el último mes
No 3,2 (2,2) 1
Sí 4,1 (2,3) 1,20 (1,01-1,43)
IMC
Normopeso 2,9 (4,6) 1
Peso insuficiente 3,1 (2,1) 0,86 (0,44-1,66)
Sobrepeso 3,2 (2,1) 1,11 (0,94-1,32)
Obesidad 3,9 (2,3) 1,28 (1,06-1,55)
No sabe/no contesta 3,4 (2,3) 1,12 (0,86-1,46)
DE: desviación estándar; IMC: índice de masa corporal; OR: odds ratio
a Debido a los valores perdidos para el estado civil (n = 11), las odds ratio y los intervalos de confianza se calcularon para una muestra de 7.012 individuos (99,8% del total).
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Figura 3. Consumo de distintos fármacos en función del sexo y del grupo de edad.
4,7% y el 32,4%. Estas variaciones podrían ser debidas a las diferen-
cias en determinantes sociodemográficos y en los sistemas sanita-
rios entre distintas comunidades. Se encontraron también notables
diferencias entre sexos en el patrón de consumo de medicamentos.
Globalmente, las mujeres consumían más medicamentos que los
hombres, y especialmente en analgésicos, ansiolíticos, hipnóticos
y sedantes, antidepresivos, laxantes, fármacos para enfermedades
tiroideas y antirreumáticos. Los hombres consumían, sin embargo,
más fármacos para la diabetes y para el corazón. También se apre-
ció un aumento del consumo de medicamentos en grupos de edad
crecientes, salvo para las mujeres mayores de 85 años, que presen-
taban menor prevalencia de polifarmacia que aquellas que tenían
entre 76 y 85 años. Algunos grupos de medicamentos tenían un con-
sumo creciente al aumentar la edad (como analgésicos, laxantes,
ansiolíticos, hipnóticos y sedantes, fármacos para el corazón, para
el tracto alimentario y otros medicamentos), pero esta tendencia
no se repetía para otros grupos farmacológicos como los agentes
modificadores de lípidos, fármacos para trastornos tiroideos o para
el aparato respiratorio. Pese a las diferencias encontradas en la pre-
valencia de polifarmacia en distintos sexos y grupos de edad, el
-
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Figura 4. Prevalencia de fármacos más frecuentes y enfermedades con indicaciones comunes.
análisis multivariante, incluyendo diversos factores, no encontró
asociación entre la presencia de polifarmacia y la edad o el sexo.
Tampoco se halló una asociación entre la polifarmacia y otras carac-
terísticas en cuya presencia se encontró una mayor prevalencia,
como un menor nivel de estudios o la existencia de deterioro cog-
nitivo. Sí que se evidenció, sin embargo, una asociación positiva con
el número de problemas de salud crónicos, la dependencia para las
actividades básicas de la vida diaria, el estado de salud percibido o
los contactos con el sistema sanitario; y una asociación negativa con
los déficits sensoriales y la incontinencia. Estos datos indican que
el aumento de prevalencia de polifarmacia en mujeres, individuos
de más edad o con menos nivel de estudios se debe probablemente
a la mayor presencia de estos otros factores explicativos en estos
grupos poblacionales (por ejemplo, el mayor número de proble-
mas de salud crónicos en mujeres y personas más mayores, un
peor estado de salud percibido, o una mayor dependencia para las
actividades básicas de la vida diaria). Las diferencias en las carac-
terísticas basales de los distintos sectores poblacionales podrían
explicar también los distintos patrones en el consumo de deter-
minados grupos de medicamentos. Por ejemplo, el mayor grado de
dolor y de dependencia y el peor estado de salud percibido por parte
de las mujeres puede tener relación con el mayor consumo de anal-
gésicos, antidepresivos y ansiolíticos, hipnóticos y sedantes en este
sector poblacional. Por otra parte, el análisis multivariante también
sugiere que ciertas características, como los déficits sensoriales y la
incontinencia, podrían conducir a una menor prescripción de medi-
camentos, independientemente del número de enfermedades, lo
que podría entenderse como un signo de infraprescripción en estas
personas o como una prescripción adaptada a las características
del paciente (en cuanto a pronóstico, objetivo terapéutico, etc.). En
cualquier caso, se muestra que la prescripción de medicamentos no
depende solo del número de enfermedades, sino también de cómo
estas afectan al estado de salud y a la vida diaria de los individuos,
y de la interacción con el sistema sanitario.
La prevalencia de polifarmacia encontrada en estudios previos
tiene una gran variabilidad en función del lugar y de la metodología
de cada estudio. Algunos estudios poblacionales realizados en otros
países en mayores de 65 años en atención primaria estimaron que
la prevalencia de polifarmacia alcanzaba un 44% en Suecia24, un
39% en Estados Unidos25, un 41,2% en Suiza26 y hasta un 70,3%
en Francia27. Otros estudios realizados en el ámbito regional
en España en mayores en atención primaria, que registran cada
fármaco individualmente, muestran prevalencias de entre un 45%
y un 83,1%13–15. Un reciente estudio de ámbito europeo estima una
prevalencia de polifarmacia a partir de encuestas y según la misma
definición de entre un 26,3% y un 39,9%, alcanzando en España un
31,6%28. Existen también estudios que estimaron la prevalencia de
polifarmacia en población mayor española no institucionalizada
con encuestas nacionales de salud previas o encuestas europeas de
salud en España2,16. Martín-Pérez et al.2 mostraron una prevalencia
de polifarmacia de 19,7% y 24,5% en las ENSE de 2006 y 2012 res-
pectivamente utilizando la misma definición de polifarmacia, y la
media de medicamentos consumidos estimada en estas encuestas
fue de 2,87 y 2,93 medicamentos por individuo respectivamente,
frente a los 3,3 estimados en nuestro estudio. Asimismo, Carmona-
Torres et al.16 estimaron que la prevalencia de polifarmacia era del
21,9% y la de hiperpolifarmacia de 0,6% analizando conjuntamente
4 encuestas entre 2006 y 2014. Cabe destacar que en el estudio
de Carmona-Torres et al. incluyen para el cómputo del número de
medicamentos consumidos productos homeopáticos y naturistas,
no incluidos aquí al no poder considerarse medicamentos, lo que
pudo haber sobreestimado ligeramente las cifras. De todos estos
datos se puede deducir que existe una tendencia al aumento en el
consumo de medicamentos, la polifarmacia y la hiperpolifarmacia
1: • 
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en la población de edad avanzada en España a lo largo de los
últimos años. Esto puede deberse a diversos factores, como el
aumento de la multimorbilidad, la aparición de nuevos medica-
mentos en el mercado o la medicalización de la vida29. En cuanto
al tipo de medicamentos más consumidos encontramos resultados
similares a otros estudios, predominando antihipertensivos, anal-
gésicos, agentes modificadores de lípidos y fármacos para el tracto
alimentario16, coincidiendo con problemas de salud crónicos más
frecuentes en esta población.
En cuanto a las implicaciones de los resultados de este estu-
dio, hay que destacar las consecuencias que pueden acompañar al
aumento de la polimedicación en la población mayor en nuestro
país, más allá del aumento directo del gasto. La polifarmacia supone
una mayor complejidad terapéutica al asociarse a un aumento
de las interacciones medicamento-medicamento y medicamento-
enfermedad, reacciones adversas, cascadas terapéuticas o peor
adherencia terapéutica9. Pero además de ser una cuestión cuan-
titativa, es un cambio cualitativo, ya que la polifarmacia está
estrechamente ligada al uso inadecuado de medicamentos, que
hace referencia a los tratamientos en los que el riesgo es supe-
rior al beneficio clínico potencial esperado, especialmente cuando
existen alternativas terapéuticas más seguras o eficaces30. La poli-
farmacia y el uso inadecuado de medicamentos van a suponer un
reto cada vez mayor para el clínico, que encontrará cada vez más
pacientes polimedicados y con mayor complejidad, por lo que es
fundamental conocer los medicamentos potencialmente inadecua-
dos en ancianos más frecuentes en nuestro medio (como el empleo
de benzodiacepinas de vida media larga)31, así como ciertas herra-
mientas que ayuden a detectar y atajar este problema32.
El empleo de los datos oficiales de la ENSE tienen la ventaja
de ser obtenidos mediante una cuidada metodología, incluyendo
el muestreo, el diseño de los formularios, la preparación de los
encuestadores, la supervisión en la ejecución, o la depuración de
los datos, que garantizan contar con una muestra representativa de
la población y con datos altamente fiables. Además, al preguntar
específicamente sobre medicamentos consumidos, se evita el pro-
blema de sobreestimación que puede darse en estudios basados en
registros de prescripción o dispensación de fármacos al desconocer
estos el grado de adherencia al tratamiento; y al preguntar sobre las
2 últimas semanas se reduce el riesgo del sesgo de memoria que se
produce si se pregunta por periodos de tiempo más largos. Permite
también obtener conjuntamente datos de individuos que utilizan
distintas modalidades de seguros sanitarios (hasta un 11,4% de los
participantes en este estudio podrían utilizar sistemas distintos a
la sanidad pública), cuestión que puede sesgar los resultados en
estudios basados en registros de medicación en administraciones
públicas o aseguradoras. Además de la propia metodología de la
ENSE, este estudio cuenta con otras fortalezas, como el evaluar los
distintos factores asociados a la polifarmacia mediante un análisis
multivariante que incluye variables muy relevantes en personas
de edad avanzada, como la dependencia para las ABVD o síndro-
mes geriátricos. Este tipo de variables no habían sido incluidas en
estudios previos realizados con encuestas nacionales de salud en
España para estudiar el uso de medicamentos, y muestran en este
estudio que son factores determinantes que modulan el consumo
de fármacos en la población de edad avanzada.
Por otra parte, el empleo de Encuestas de Salud para la esti-
mación de datos farmacoepidemiológicos tiene también ciertas
limitaciones. Al tratarse de datos autorreportados hay que tener en
cuenta que el grado de conocimiento de la medicación consumida
y específicamente de su indicación no siempre es óptimo, especial-
mente en personas de edad avanzada33 y con polifarmacia marcada,
lo que podría llevar a una infraestimación en la prevalencia. Esto
podría explicar la baja prevalencia encontrada de hiperpolifarma-
cia. Por otra parte, la ENSE no incluye personas institucionalizadas,
que son precisamente aquellas que presentan niveles más altos
de polifarmacia según han reportado otros estudios34,35, lo que
puede conducir también a una infraestimación de la polifarmacia en
mayores a nivel poblacional, teniendo en cuenta que más del 4% de
la población española de 65 años o más estaría institucionalizada36.
Además, la propia metodología de la encuesta no permite conocer
exactamente qué grupos terapéuticos son los que se emplean, o si
la polifarmacia se asocia a enfermedades concretas y a su grave-
dad. Por último, dado que la encuesta no se ha diseñado para este
fin, solo puede identificar el uso de medicamentos para una indi-
cación, considerando que para todas las indicaciones se emplearía
un medicamento en monoterapia. Para algunos de los problemas de
salud más frecuentes, como la hipertensión, el dolor o la diabetes, el
empleo de varios fármacos para la misma indicación es común, por
lo que esta puede ser la causa más importante de infraestimación
de polifarmacia, y lo que puede explicar las tasas de prevalencia de
polifarmacia notablemente más bajas que en otros países de nues-
tro entorno cuando registran cada medicamento individualmente,
como los citados anteriormente24–27. El análisis de sensibilidad pro-
puesto para tratar de corregir este sesgo, aunque solo realiza la
corrección para la hipertensión y la diabetes, estima una prevalen-
cia de polifarmacia hasta 10 puntos más alta (de 27,3% a 37,5%),
acercándose así a las cifras obtenidas en estudios realizados en
otros países. De hecho, los estudios de ámbito regional realizados
en España en mayores en atención primaria que registran cada fár-
maco individualmente hallan prevalencias bastante mayores13–15,
lo que también parece indicar la infraestimación que se puede dar
debida a la metodología de la ENSE.
En conclusión, se encuentra un importante consumo de medi-
camentos en la población mayor no institucionalizada en España, y
continúa la tendencia observada en los últimos años a aumentar la
prevalencia de polifarmacia en el tiempo. Los factores que más se
asocian a la polifarmacia son el número de problemas de salud cró-
nicos, la dependencia para las actividades básicas de la vida diaria, el
estado de salud percibido o los contactos con el sistema sanitario; y
de forma inversa los déficits sensoriales y la incontinencia. Conocer
los patrones de consumo de medicamentos en nuestra población
y los factores asociados es fundamental para comprender el fenó-
meno de la polifarmacia en las personas mayores y el alcance de sus
consecuencias para la población, los profesionales y los sistemas
sanitarios.
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Objective: To summarise the evidence on interventions aimed at optimising the drug treatment
of hospitalised elderly patients.
Material and methods: We conducted a search in the main medical literature databases, select-
ing prospective studies of hospitalised patients older than 65 years who underwent interventions
aimed at optimising drug treatment, decreasing polypharmacy and improving the medication
appropriateness, health outcomes and exploitation of the healthcare system.
Results: We selected 18 studies whose interventions consisted of medication reviews, detection
of predefined drugs as potentially inappropriate for the elderly, counselling from a specialised
geriatric team, the use of a computer support system for prescriptions and specific training
for the nursing team. Up to 14 studies assessed the medication appropriateness, 13 of which
showed an improvement in one or more of the parameters. Seven studies measured the impact
of the intervention on polypharmacy, but only one improved the outcomes compared with the
control. Seven other studies analysed mortality, but none of them showed a reduction in that
rate. Only 1 of 6 studies showed a reduction in the number of hospital readmissions, and 1 of
4 studies showed a reduction in the number of emergency department visits.
Conclusions: Despite the heterogeneity of the analysed interventions and variables, we
obtained better results in the process variables (especially in medication appropriateness) than
in those that measured health outcomes, which had greater variability.
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Intervenciones  para  optimizar  el  tratamiento  farmacológico  en  ancianos
hospitalizados:  una  revisión  sistemática
Resumen
Objetivo:  Resumir  la  evidencia  sobre  las  intervenciones  orientadas  a  optimizar  el  tratamiento
farmacológico  en  ancianos  hospitalizados.
Material  y  métodos: Se  realizó  una  búsqueda  en  las  principales  bases  de  datos  bibliográfi-
cas, seleccionando  estudios  prospectivos  en  pacientes  mayores  de  65  años  hospitalizados  que
realizaran  intervenciones  dirigidas  a  optimizar  el  tratamiento  farmacológico,  disminuir  la  poli-
farmacia  y  mejorar  la  adecuación  terapéutica,  los  resultados  en  salud  o  el aprovechamiento
del  sistema  sanitario.
Resultados:  Se seleccionaron  18  estudios.  Las  intervenciones  consistieron  en  revisiones  de
medicación,  detección  de  medicamentos  predefinidos  como  potencialmente  inadecuados  en
ancianos,  asesoramiento  de  un equipo  especializado  en  geriatría,  uso  de  un  sistema  informático
de apoyo  a  la  prescripción  o formación  específica  al  equipo  de  enfermería.  Hasta  14  estudios
evaluaron  la  adecuación  terapéutica,  demostrando  13  de  ellos  una  mejoría  en  alguno  de  los
parámetros.  Siete  estudios  midieron  el impacto  de  la  intervención  sobre  la  polifarmacia,  pero
solo uno  mejoró  los  resultados  respecto  al  control.  Otros  siete  estudios  analizaron  la  morta-
lidad,  no  demostrándose  una  disminución  de  la  misma  en  ninguno.  Solo  uno  de  seis  estudios
mostró  una  reducción  de  reingresos  hospitalarios  y  uno  de  cuatro  estudios  una  disminución  de
las visitas  a  urgencias.
Conclusiones:  Pese  a  la  heterogeneidad  de  las  intervenciones  y  de  las variables  analizadas,  se
obtuvieron  mejores  resultados  en  las  variables  de  proceso,  especialmente  en  la  adecuación
terapéutica,  que  en  aquellas  que  midieron  resultados  en  salud,  donde  hubo  una  mayor  variabi-
lidad.
© 2015  Elsevier  España,  S.L.U.  and  Sociedad  Española  de  Medicina  Interna  (SEMI).  Todos  los
derechos  reservados.
Background
Drug  therapy  is  one  of  the  most  important  tools  available
for  preserving  and  improving  health;  however,  the  use  of
medications  is  not  without  risk.  The  high  prevalence  of
adverse  events  due  to  medication1 is  a significant  public
health  problem,  due  to  the  significant  morbidity  and  mortal-
ity  they  cause,2,3 which  entail  a significant  consumption  of
resources  and  high  healthcare  costs.4,5 This  problem  is  espe-
cially  relevant  for  the  elderly,  who  have  numerous  factors
that  contribute  to  a  greater  risk  of  drug  iatrogenesis.  These
factors  include  age-related  changes  in  pharmacokinetics  and
pharmacodynamics6,7 and  the  combination  of chronic  dis-
eases  that  inevitably  lead  to  polypharmacy.
A  number  of  studies  in  Spain  have  shown  that  the  preva-
lence  of  polypharmacy  (defined  as  the  consumption  of more
than  5  drugs  a  day)  in  patients  older  than  65  years  is
approximately  50%8,9 and  that  polymedicated  patients  con-
sume  a  mean  of  almost  9  medications  a day.8 Polypharmacy
is  strongly  linked  to drug-related  adverse  events,  interac-
tions  and  interferences  between  the  drugs  and  the  disease
itself,10,11 to  lack  of  treatment  adherence12 and,  ulti-
mately,  to  mortality.13 Other  patient-related  factors,  such
as  frailty,  geriatric  syndromes,  dependence  and  cognitive
impairment,  frequently  overlap,  increasing  the  complexity
of  medication  use,  which  ultimately  leads  to  poorer  health
outcomes.  For  example,  it  is  estimated  that  between  10%
and  20%  of  hospital  admissions  for  elderly  patients  in  Spain
are  associated  with  medication-related  adverse  events,14,15
which  quadruple  the  risk  when  compared  with  younger
patients.16
All  of  these  problems  gain  special  relevance  in  elderly
hospitalized  patients.  Hospitalization  is  an  especially  del-
icate  situation  for  the  elderly  and  is  associated  with
higher  morbidity,  mortality  and  cognitive  and  functional
impairment.17,18 The  incorporation  of  new  prescribers  and
the  increase  in  the  number  of  drugs  during  hospitalization
contribute  to  the  risk  of  iatrogenesis  and  the  complexity  of
administering  drugs.19,20
The  progressive  aging  of  the  population  predicts
that  medication-related  problems  in  the  elderly  will  be
increasingly  common.  Fortunately,  most  medication-related
adverse  events  are  considered  preventable.21 Improving
therapeutic  appropriateness  could  therefore  help  minimize
the  problem.  The  issue  of  prescription  quality  in  the  elderly
has  generated  significant  interest  in  the  scientific  commu-
nity,  which,  in  an  attempt  to  define  it,  has  coined  terms
such  as  ‘‘therapeutic  appropriateness’’  and  has  led  to  the
development  of  numerous  tools  to  quantify  it  (Appendix  A).
Considering  the  complexity  of  administering  drugs  to
elderly  hospitalized  patients  and  the  high  prevalence  of
inappropriate  prescriptions,19,22 it  seems  that  we  need
to  incorporate  strategies  aimed  at  optimizing  drug  treat-
ment.  Although  it  has  been  previously  mentioned  that
hospitalization  is  an  especially  appropriate  period  for  imple-
menting  strategies  for  improving  the  quality  of  the  use  of
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medications,23 most studies have been implemented in other
healthcare settings.
The aim of this review is to summarize the evidence on




In August 2015, we conducted a search in the following
scientific literature databases to locate primary studies,
without setting any date restrictions: MEDLINE, EMBASE,
CINAHL (Cumulative Index to Nursing and Allied Health Lit-
erature) and the Cochrane Library. The search was designed
with MeSH terms (Medical Subject Headings) for MED-
LINE and was adapted to the other databases according
to its descriptors or through keywords. We combined the
following search terms: ‘‘Aged’’ and (‘‘Hospitalization’’,
‘‘Inpatients’’ or ‘‘Hospitals’’); and (‘‘Drug utilization
review’’, ‘‘Polypharmacy’’, ‘‘Inappropriate prescribing’’ or
‘‘Medication therapy management’’). A manual search was
also conducted, reviewing the references cited in the
selected studies and in relevant systematic reviews.
Study selection
We included studies that met the following criteria: (a)
prospective studies (not necessarily controlled or random-
ized), (b) inclusion of interventions aimed at optimizing the
drug treatment in terms of the prescription, (c) inclusion
of at least 80% of the sample composed of hospitalized
patients 65 years of age or older, and (d) measurement of
quantifiable process variables (change in therapeutic appro-
priateness measured by validated tools or polypharmacy) or
endpoints (clinical, use of healthcare resources, financial,
humanistic, etc.).
We excluded studies with the following criteria: (a)
systematic reviews and meta-analyses, presentations at
congresses or scientific meetings and study protocols; (b)
published in languages other than English and Spanish; (c)
focus on a single disease or medical condition or regarding
a certain medication or therapeutic group; and (d) inclusion
of interventions directed exclusively to improving treatment
adherence or decreasing reconciliation errors.
Data collection and analysis
To select the studies, 2 reviewers examined the titles and
abstracts of those studies identified in the search and then
examined the full text of those studies that were not
excluded, ultimately evaluating the ones that met the inclu-
sion criteria. The relevant data were extracted from the
selected articles, including the study design, number of
participants, demographic characteristics, type of interven-
tion and practitioner who performed it, follow-up time,
degree of therapeutic appropriateness, polypharmacy, mor-
tality, adverse reactions to medications, falls, changes in
Barthel index, hospital readmissions, emergency depart-
ment visits, time of admission, financial savings per patient
and health-related quality of life. The main characteristics
of the measurement methods for therapeutic appropriate-
ness employed in the studies are shown in Table 1.
The quality of the prescription can be assessed using pro-
cess variables (see whether the prescription coincides with
the accepted standards) or results (consequences for the
patient, the healthcare system and society).24
Ultimately, 2 reviewers separately assessed the included
studies according to the risk of bias criteria developed by
the Cochrane Effective Practice and Organization of Care
group25 for the main variables.
Results
Search results
A total of 794 references were identified, among which were
41 duplicates. After reviewing the titles and abstracts of 753
publications, 677 were excluded for not meeting the inclu-
sion criteria or meeting exclusion criteria. The remaining
76 publications were assessed. Ultimately, 19 publications
were selected for this review. These publications referred
to 18 studies26--44 that met all the defined criteria (2 studies
referred to the same publication) (Fig. 1).37,38
Study characteristics
The number of participants in the studies varied from 43 to
3974, with a mean of 518 patients and a median of 316. Fif-
teen studies were conducted in Europe and the remaining
3 in the United States. Most studies had a control group,
except for 2,46,47 and 12 were also randomized. The follow-
up time varied between the hospitalization period itself
40,42--44 and 12 months.29,32,41
Participant characteristics
The mean age of the participants ranged from 74.535 to 86.6
years32; 2 of the studies did not provide this datum.27,28 The
proportion of women ranged from 3%28 to 71%26; 1 study
did not provide this information.42 The age inclusion crite-
ria in the studies were an age greater than 65 years in
9 studies,27,28,30,31,35,36,40,43,44 greater than 70 in 4,29,33,37,42
greater than 75 in 226,41 and greater than 80 in another.32
Two studies did not have age criteria for inclusion,34,39 but
more than 80% of the participants were older than 65 years.
A number of studies also required other inclusion criteria,
such as multiple diseases,44 frailty28,41 and the consumption
of more than 3 medications.27,41
Intervention characteristics
The intervention was performed by pharmacists in 9 studies,
by a multidisciplinary team in 3,28,36,41 by pharmacists and
clinical pharmacologists in 1,33 by geriatricians in 1,37 by
nurses in 1,31 and by physicians other than the prescriber
(without specifying specialty) in 2.35,43 One intervention
consisted of a software application used by the prescribing
physician.40
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Table  1  Methods  for  assessing  medication  appropriateness.













USA  >65  years  • List  of  medicinal  products  to  avoid
• List  of  medicinal  product  or  therapeutic  groups  to
avoid  in  certain  diseases  (since  1997)
• List  of  medicinal  products  to  use  with  caution
(since  2012)
• Inappropriate  prescription  due  to  drug  interactions
and  renal  function  (since  2015)
STOPP--START
criteria  (2008)
2014  Ireland  >65  years •  STOPP:  list  of  potentially  inappropriate
medications,  organized  by  physiological  system
• START:  underprescription  criteria  (health  condition
-- indicated  drug)
PRISCUS  list
(2010)
Germany  >65  years  • List  of  potentially  inappropriate  medications.
Classified  by  therapeutic  group.
• Proposes  therapeutic  alternatives  and  precautions
if used
National quality
indicators  in  the
use  of  drug
therapy  for  the
elderly  (2004)
2010  Sweden  >75  years  • Specific  medicinal  product  indicators:  selection,
indication,  dosage,  polypharmacy,  drug  interactions,
use  of  medicinal  products  with  altered  renal  function
and  in  the  presence  of  certain  symptoms
• Specific  indicators  of  diagnosis:  rational,  irrational
and  dangerous  use
ACOVE  (1999) 2001,  2007 USA  >65  years
frail
•  Quality  indicators  for  improving  the  quality  of  care
in  various  chronic  conditions.  Not  focused  exclusively
on drug  treatment.  35%  of  indicators  for  treatment
Criterios implícitos
MAI  (1992)  USA  All  • Ten  questions  are  assigned  to  each  medicinal
product  regarding  the  indication,  effectiveness,
dosage,  instructions,  regimen,  drug--drug
interactions,  drug--disease  interactions,  duplication,
duration  and  cost
• Responses  based  on  a  3-point  Likert  scale  (A:
appropriate,  C:  inappropriate).  Each  inappropriate
item  scores  between  1  and  3 points  based  on  its
importance.  The  sum  of  all  items  creates  a  weighted
score  for  each  drug  between  0 and  18.  By  adding  up
the scores  for  the  drugs,  we  can  obtain  an  overall
index
• Higher  scores  mean  lower  therapeutic  suitability
FORTA (2008)  2014  Germany  >65  years  • Records  inappropriate  prescriptions  and  omissions
for indicated  medicinal  products
• Drugs  are  classified  into  4  categories:  A
(Indispensable),  B  (Beneficial),  C  (Questionable),  D
(To be  avoided).  Based  on  the  evidence  of safety,
efficacy  and  suitability  for  the  age
AOU (1999)  USA  All  • Measures  underprescription.  Requires  the  clinical
discretion  of a  healthcare  practitioner  who  compares
the medical  history  and  the  list of  medicinal  products
to  establish  treatment  omissions
Abbreviations: ACOVE, Assessing Care of Vulnerable Elders; AOU, Assessment of  Underutilization of  Medication tool; FORTA, Fit for the
Aged; MAI, Medication Appropriateness Index; START, Screening Tool to Alert Doctors to Right Treatment; STOPP, Screening Tool of Older
Persons’ Potentially Inappropriate Prescriptions.
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Figure 1 Database search.
In terms of type of intervention, most of the studies
(13, 72%) conducted medication reviews with subsequent
recommendations by or discussions with the prescribing
physician. The intervention in 2 studies was based on detec-
ting explicit criteria such as the Screening Tool of Older
Person’s Potentially Inappropriate Prescriptions (STOPP)35,41
and the Screening Tool to Alert Doctors to Right Treatment
(START).35 In another study, the intervention consisted of
advising a team of geriatric medicine specialists.28 We also
included a study with an educational approach, based on
training nurses on clinical pharmacology and tools for detec-
ting medication-related problems.31 A number of studies
performed other types of intervention, such as patient infor-
mation, counseling and education27,29,32--34,37 and medication




Among the 14 studies that measured therapeutic appropri-
ateness, 13 achieved an improvement in at least one of the
parameters due to the intervention.
The most widely used measurement tool was the Medica-
tion Appropriateness Index (MAI),45,46 which was employed
in 6 studies.28--30,35,36,43 All 6 studies showed significant
improvements in this scale after the intervention. The study
by Michelek et al.42 used the Fit for the Aged (FORTA)
system,47 achieving an increase in the prescription of cat-
egory A drugs (indispensable) compared with the control
group, but without reaching statistical significance. Two
studies28,35 measured medication underutilization through
the Assessment of Underutilization of Medication index,48
both of which achieved improvements in this criterion com-
pared with the control group.
In terms of the explicit methods (see Appendix A in the
supplementary material), the Beers criteria were employed
in 4 studies,28,29,40,43 in its updated versions of 199749 and
2003,50 but only 2 of them28,40 achieved improvements after
the intervention. The STOPP and START criteria51 were
employed to quantify therapeutic appropriateness after the
intervention in 2 studies. A statistically significant improve-
ment was observed with the STOPP criteria41,43 but not
in the study that applied the START criteria.43 Only one
study measured appropriateness using the Priscus criteria43
but could not demonstrate clear improvement attributable
to the intervention (42.4--40.6%) (p = .421). Two interven-
tions reported in Swedish studies attempted to decrease
the prevalence of inappropriate medications based on qual-
ity indicators described in Sweden,52 one successfully,34
the other without achieving significant differences com-
pared with the control group.31 Two studies included the
Assessing Care Of Vulnerable Elders (ACOVE) criteria53 to
measure underprescription. While Spinewine et al.29 showed
a marked improvement with the intervention (OR, 6.1; 95%
CI 2.2--17), the improvement did not achieve statistical
significance (p = .739) in the study by O’Sullivan et al.43
The studies by Delgado-Silveira et al.44 and Lipton et al.27
reported a reduction in medication-related problems due to
the intervention.
Document downloaded from http://www.revclinesp.es/ day 15/05/2016. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.
' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' --------1 
210 M. Gutiérrez Valencia et al.
Among the 8 studies that measured the effect of the
intervention on polypharmacy,26,31,36--38,40,42,43 only 1 showed
better results than those of the control group.26
Outcome variables
Seven of the studies analyzed the effect of the interven-
tions on mortality after a follow-up period of 331,33 635,38,39
or 12 months,29,32 without conclusive results. The study by
Michalek et al.42 achieved a significant reduction in the
number of falls in the intervention group (3.4% vs. 21.4%,
p < .001) and an improved Barthel index, although that did
not achieve statistical significance. In the study by Gallagher
et al.,35 the reduction in the prevalence of falls 6 months
after the intervention did not reach statistical significance
(p = .332).
Among the 6 studies that analyzed the influence on
hospital readmissions at 3,31,33,37 635 or 12 months of
admission,29,32 only the study by Legrain et al.37 achieved a
statistically significant reduction (20.2% vs. 28.4%, p = .01).
Among the 4 studies that quantified emergency department
visits,29,32,33,39 only the study by Gillespie et al.32 achieved
a 47% reduction at 1 year compared with the control group.
None of the interventions achieved a significant reduction
in hospital stays.33,35,36,40
In terms of the analysis of secondary costs, Gillespie
et al.32 showed a reduction of $400 (USD) per patient when
compared with the control group. This savings was due to
the reduction in expenses associated with readmissions and
emergency department visits ($230 less per patient when
taking into account the intervention costs). Legrain et al.37
showed a reduction of D 797; D 519 per patient if the inter-
vention cost was discounted.
Two studies measured the health-related quality of life
using the EuroQol-5D questionnaire at 333 and 6 months.34
Although the first study achieved no significant differ-
ences, the second showed an improvement in overall health,
although not in the other parameters.
The main characteristics and results of the studies are
listed in Table 2, which also shows the potential sources of
bias.
Discussion
This review provides a summary of the evidence on various
strategies for optimizing treatments for elderly hospitalized
patients, aimed at reducing polypharmacy and improving
therapeutic appropriateness, health results and the use of
the healthcare system.
Among the analyzed variables, it is worth noting the good
results regarding the improvement in therapeutic appropri-
ateness, which appears to be independent of the personnel
who perform the intervention and the type of intervention
(except in the Bergqvist et al. study,31 which used an edu-
cational approach).
Although the majority of studies managed to improve
therapeutic appropriateness in one or more of the param-
eters, the results differed depending on the measurement
method. While all of the studies that used the MAI scale
or STOPP criteria achieved an improvement, the same was
not true for studies using Beers, Priscus or ACOVE criteria.
These results provide an introduction to the debate on
the applicability and validity of measurement tools for
appropriateness. The difficulty in applying these tools in
settings other than those from where the tools originate
(healthcare levels, countries) has been widely commented
in the literature.54--56 An example of this challenge is the
use of the Beers criteria in the studies by Spinewine et al.29
(Belgium) and O’Sullivan et al. (Ireland),43 which were
not able to detect positive results in terms of therapeutic
appropriateness. The usefulness of the Beers criteria in the
European setting is questionable57; however, the criteria are
still widely used for being one of the first tools developed.
The validity of the measurement methods for appropriate-
ness has also been the subject of controversy, given that
the process variables should be related to relevant health
outcomes (mortality, morbidity, medication-related adverse
events and quality of life) to be valid.58 Although there are
studies that show a significant association between the use
of inappropriate medications (according to the Beers crite-
ria) and the health outcomes in certain healthcare settings
(residence and outpatient),59--61 the use of inappropriate
medications for hospitalized patients is not associated with
a significant increase in the risk of adverse events,62 the
hospital stay or mortality.63,64 The degree of therapeutic
appropriateness measured with the MAI scale has been
shown to be related to health outcomes in the primary care
setting.65,66 The use of inappropriate medications, according
to the STOPP criteria, has been associated with the onset of
adverse events in elderly hospitalized patients.67 However,
a study68 showed that most medication-related problems in
elderly patients who live in the community are not detected
using STOPP or START criteria. A number of studies that com-
pared the Beers and STOPP criteria seem to show a lower
sensitivity for the former in detecting potentially inappro-
priate medications69,70 or for preventing hospitalizations
due to medication-related adverse events.67
In light of the fact that the available evidence on the
predictive validity of explicit criteria is not definitive or the
fact that the results can differ depending on the method of
analysis employed, it is worth questioning the suitability of
the measurement systems for therapeutic appropriateness
being used and thus their published results. Given that the
tools are employed both to measure results and to perform
interventions, we should consider that the health endpoints
can also be affected by this validity, especially if the inter-
vention is based exclusively on detecting explicit criteria,
as in the study by Gallagher et al.35
The use of explicit methods has numerous practi-
cal advantages (Appendix A), but interventions based on
implicit methods (standardized or not) provide a broader
vision on the patient’s situation, their preferences, life
expectancy and the fixed therapeutic objectives. A recent
study71 showed that a number of more significant causes for
prescribers not modifying the treatment (according to the
recommendations included in the STOPP/START criteria) are
patient disability, dependence and risk of adverse events,
variables that, in the elderly, can be much more important
than survival itself. Regardless of the method employed,
this type of information is important for adapting the inter-
vention to each patient’s needs. However, only 626,29,37,40--42
studies conducted a comprehensive geriatric assessment,
and 8 studies did not record any information on the func-
tional, cognitive and nutritional condition or on the presence













































Results (P, primary variables; S, secondary
variables)
















3 months Drug No. of medications at day 3: 5.3 (I) vs. 5.9 (C)
(p < .05). No differences at 6 weeks and 3
months
Increase in the number of medications at day
3: 18% (I) vs. 40% (C) (p < .005)
Medications with no apparent indication: 11%
(I) vs. 19% (C) (p < .025)
Inappropriate medications (potential adverse
effects and availability of an alternative): 20%





>65 years, 3 or
more medications









Patients with MRP: 82% (I) vs. 93% (C) (p = .05)
Patients with suboptimal or nonindicated
medication: 51 (I) vs. 68 (C) (p = .01). Other
categories (dosage or regimen problems, M--M
interactions, duplication, allergies): ns
Mean score differences for: prescription
appropriateness: 0.59 (I) vs. 0.76 (C) (p = .01).
Dosage: 0.09 (I) vs. 0.13 (C) (p = .02).
Suboptimal or nonindicated: 0.17 (I) vs. 0.24




















(P) ADRs (events per 1000 days): 206 (I) vs. 64
(C). RR = 1.85 (p = .0001)
Severe ADRs (events per 1000 days): 27 (I) vs.
15 (C) (p = .93)
(S) Difference in change of:
Unnecessary medications: −0.5 (p < .0001)
MAI score: −5.4 (p < .0001)
IM (Beers): −0.1 (p = .03)
Medication underutilization (AOU): −0.3
(p < .0001)



































Results (P, primary variables; S, secondary
variables)
























(P) Prescription appropriateness (at admission,
at discharge and at 3 months):
Change in mean MAI score per patient:
decreases more in intervention group:
24.1--7.1 (p < .001), OR = 9.1 (95% CI 4.2--21.6)
IM reduction (Beers): similar I--C, OR = 0.6 (95%
CI 0.3--1.1)
Mean change ACOVE criteria underutilization
per patient: I decreases more; OR = 6.1 (95% CI
2.2--17)
(S) Prevalence of unnecessary medications
(MAI): decreases from 87.4% to 37.5% (I) and
77.8% (C)
Mortality at 1 year: 22.5% (I) vs. 30.1% (C)
(p < .30)
Readmissions at 1 year: 32.6% (I) vs. 33.7% (C)
(p = 1.0)
Emergency department visits at 1 year: 7.9%
(I) vs. 12% (C) (p = .45)
Satisfied with information on medications



























Drug Change in MAI score
(admission--discharge-after 2 weeks): ns
Reduction in the no. of medications with
inappropriate characteristics according to MAI:












drugs at the start














































Results  (P,  primary  variables;  S,  secondary
variables)









n  = 460(250/210)
Women:  56/53%
Mean  age:  80.3







and  JWA  (Janus
Web  Application)
3 months Nurses  (P)  Readmissions  at  3  months:  38%  (I)  vs.  36%
(C)  (p  =  .86)
(S)  Proportion  of  inappropriate  medications  at
discharge:  ns
Medication-related  readmissions:  ns

















n  = 400  (199/201)
Women:  58.7%









Drug  Readmissions:  217  (I)  vs.  223  (C)
(Estimate  =  0.97)
Medication-related  readmissions:  9  (I)  vs.  45
(C)  (estimate  =  0.2)
Reduction  in  emergency  department  visits:
47%;  49  (I)  vs.  93  (C)  (Estimate  =  0.53)
Difference  readmissions  + emergency
department  visits:  16%;  266  (I)  vs.  316  (C)
(Estimate  =  0.84)
Mortality  at  1  year:  57  (I)  vs.  61  (C)  (p  = .82)
Overall  cost  reduction:  $400/patient  (I--C)
Cost  reduction  by  emergency  department
visits:  $100/patient  (I--C)
Cost  reduction  by  readmissions:  $300/patient
(I--C)
Savings  counting  the  cost  of  the  intervention:
$230/patient  (I--C)
Contamination:  I
and  C  same  ward



































Results (P, primary variables; S, secondary
variables)


















3 months Pharmacist and
clinical
pharmacologist
(P) Hospital stay: 239.9 (I) vs. 238.6 (C) h
(p > .05)
(S) Time to readmission, no. of readmissions,
emergency department and PC visits, death,
health-related quality of life (EQ-5D): ns
Contamination: I



















Change in health-related quality of life
(EQ-5D) at 6 months: greater in overall health
3.14 (I) vs. 2.77 (C); p = .02, but not in other
parameters
PIP: decreases in intervention group 0.39

























(P) Patients with reduction in MAI
admission--discharge score: 71.1% (I) vs. 35.4%
(C) (ARR = 35.7%)
Rate of unnecessary polypharmacy at
discharge: 5.4% (I) vs. 19.8% (C) (p < .001)
All MAI criteria differ significantly between I--C
at discharge and at 6 months
Mean MAI score decreases from 10 to 3 (I)
(p < .001) and remains after 6 months (p < .001)
Patients with AOU admission--discharge
reduction: 31.6% (I) vs. 10.4% (C) (ARR = 21.2%)
(S) Prevalence decreases after 6 months: 5.8%
(I) vs. 8.4% (C) (p = .332)
Mortality after 6 months: 5.3% (I) vs. 7.3% (C)
(p = .414)
Hospital stay: 8 (I) vs. 8.5 days (C) (p = .471)
Readmission rate: 67 (I) vs. 64 (C) (p = .691)


















































Results (P, primary variables; S, secondary
variables)




















Reduction in medicines with inappropriate
characteristics (MAI): 51% vs. 39% (p = .0446)
ITT; 60% vs. 44% (p = .01) PP
Differences in mean MAI score per patient or
drug at discharge: ns
Medication-related readmissions or emergency
department visits: 6 (I) vs. 12 (C) (p = .0469)




























(P) Readmissions or emergency department
visits at 3 months: 23% (I) vs. 30.5% (C) (p = .03)
and 6 months: 35.3% (I) vs. 40.8% (C) (p = .15)
Event-free survival at 3 months: longer in
intervention group HR = 0.72 (p = .03); and at 6
months: HR = 0.81 (p = .10)
(S) Readmissions at 3 months: 20.2% (I) vs.
28.4% (C) (p = .01); and at 6 months: 32.5 (I)
vs. 38.2 (C) (p = .12).
Mortality at 3 months: 12% (I) vs. 13.2% (C)
(p = .63); and at 6 months: 17.7% (I) vs. 18.7%
(C) (p = .74)
Difference in cost at 6 months (I--C):
D 797/patient









Medication-related readmissions: 34.7% vs.
40.4% (p = .54).
No. of medications, polypharmacy, mean daily
dose: ns
Difference in cost due to medication-related










































Results  (P,  primary  variables;  S,  secondary
variables)








85%  >  65  years









6 months  Clinical
pharmacist
(P)  Duration  of  emergency  department
visits/readmission:  HR  0.95  (p  =  .266)
(S)  Event-free  survival:  HR  = 0.96  (p  = .305)
Mean  number  of  emergency  department  visits
at 6  months:  1.02  (I)  vs.  1.03  (C)  (p  =  .89)
Mortality  at  6  months:  18.2%  (I)  vs.  17.3%  (C)
(p =  .55)
Mean  number  of  PC visits:  1.58  (I)  vs.  1.71  (C)
(p  =  .057)
Patients  who  visited  PC:  68.5%  (I)  vs.  70.3%  (C)




























Reduction  in  number  of  patients  with  PIM
(Beers)  admission--discharge:  41.7--11.6%
(p  <  .001)
Mean  reduction  in  PIM  by  patient
admission--discharge:  0.5--0.1  (p  < .001)
Reduction  in  number  of  patients  with
potentially  severe  M--M  interaction
admission--discharge:  45--33.3%  (p  =  .703)
Reduction  in  new  potentially  severe  M--M
interactions:  59--33%  (p  <  .001)














according  to  the
ISAR  scale  and
more  than  3
medicines
n = 146  (74/72)
Women:  63%











Reduction  in  PIM  by  STOPP  criteria  at
discharge:  39.7%  (I)  vs.  19.3%  (C)  (p  = .013)













































Results (P, primary variables; S, secondary
variables)


















Patients with polypharmacy (>5 medications)
at discharge: 84% (I) vs. 84% (C) (p = .935)
Increases in control and intervention
Category A FORTA medications at discharge: 4
vs. 3 (p = .051). Increases in both
Over and underprescription: less in
intervention group (p = .03 and p = .025)
Patients with an increased Barthel index at
discharge: 76% (I) vs. 71% (C) (p < .226)
Patients with falls: 3.4% (I) vs. 21.4% (C)
(p < .001)
Proportion of falls/1000 patients/year: 1.5 (I)














Admission Drug Reduction in MAI score from admission to
discharge: 15--12 (p < .001). 59.3% patients
with lower scores
Change in underprescription by ACOVE criteria
admission--discharge: 28.3--26.9% (p = .739)
Median no. of medications: 9 at admission 12
at discharge
Patients with 5 or more medications: 84.5% at
admission and 95.8% at discharge
10 or more medications: 43.5% at admission
and 66.8% at discharge
Change in STOPP criteria admission--discharge:
62.4--55.5% patients (p < .001)
Change in Beers CD criteria
admission--discharge: 31.8--31.6% patients
(p = .282)
Change in Priscus criteria admission--discharge:
42.4--40.6% patients (p = .421)
Change in START criteria admission--discharge:
31--31.5% patients (p = .512)
Potential M--M interactions: 57.7% patients at
admission and 63.9% at discharge (p = .50)
Incorrect dosage in RF: 9.7% patients at
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of geriatric syndromes.27,30,31,33,34,36,39,44 Only the study by
Legrain et al.37 recorded the patients’ preferences regarding
their health. If the practitioners who conduct the inter-
vention do not know these data, the recommendations for
modifying the treatment will not correctly fit the patient’s
characteristics and will probably not be accepted by the
prescriber.
Acceptance of these recommendations is essential to
interpreting the endpoints, because the interventions need
to result in treatment changes in order to affect the
patient’s health. Consequently, a low degree of acceptance
of the recommendations can lead to a lack of improvement
in the endpoints. The study by Lisby et al.,33 for exam-
ple, had a degree of acceptance of the recommendations
of 39% and achieved no benefits in any of the study varia-
bles (hospital stay, readmissions, emergency department
visits, mortality and quality of life). In contrast, those stud-
ies with a higher proportion of accepted recommendations
achieved more noticeable improvements. The study by Gille-
spie et al.,32 in which 77% of the recommendations were
accepted, showed a reduction in emergency department
visits. The study by Legrain et al.,37 with an acceptance of
70.9%, hospital readmissions decreased significantly.
Other factors that could have affected the health out-
comes are methodological, such as the low number of
participants in a number of the studies and the studies’
low power for detecting significant differences. The stud-
ies that had no statistically significant results in terms of
mortality, readmissions or emergency department visits had
not defined these variables as primary objectives.29,33,35,39
Age is another factor worth considering. The studies with
better health outcomes were those whose participants had
a higher mean age,32,37 which suggests that patients with
greatest risk and frailty are the ones most likely to benefit
from strategies that optimize the drug therapy.
In terms of the impact of interventions on other signifi-
cant variables such as quality of life and financial savings,
it is difficult to make relevant conclusions, given the little
evidence provided by the analyzed studies.
The results of this review are similar to those of other
published studies. Various reviews have been conducted on
the drug treatment optimization in elderly patients, not
focused on the hospital setting. Two of these studies con-
cluded that some interventions with different approaches
(educational, treatment reviews, geriatric services, mul-
tidisciplinary teams, computer support systems, etc.) can
improve the degree of therapeutic appropriateness.72,73
In the review by Patterson et al.74, the impact of these
interventions on clinical outcomes was uncertain, although
benefits were demonstrated in terms of reducing inappro-
priate prescriptions. In the study by Holland et al.,75 which
examined the impact of treatment reviews performed by
pharmacists on hospitalizations and mortality, also found no
positive effect on these parameters. On the other hand,
we found reviews on hospitalized patients, although not
specifically elderly, such as the study by Christensen et al.76
focusing on medical reviews, which show a reduction in
emergency department visits, with no influence on mortal-
ity or hospital readmissions. Similarly, Graabaek et al.,77 in a
recent systematic review of medication reviews performed
by clinical pharmacists, indicated a positive effect in the use
and cost of medications and a number of improvements in
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the use of healthcare resources, which was not statistically
significant.
In terms of the bias of the included studies, the fact that
the evaluator of the results knew which group each patient
belonged to was a high risk of bias. Given the presence of
several nonrandomized studies, the risks of associated bias
were also frequent.
Future research should be aimed at checking the valid-
ity of the tools for measuring and improving therapeutic
appropriateness, which confer a greater reliability to the
studies and a greater impact of interventions for optimizing
therapeutic appropriateness on health outcomes. Moreover,
quality controlled clinical trials need to be developed, with
sufficient sample sizes and with the necessary method-
ological quality to detect the expected impact on clinical
variables such as hospital readmissions, emergency depart-
ment visits and quality of life.
Conclusions
The analyzed studies show that the therapeutic appropri-
ateness of elderly hospitalized patients can be improved
by interventions with various approaches (systematic treat-
ment reviews, support software for decision making and
detection of explicit criteria of inappropriate prescription),
implemented by various practitioners (clinical pharma-
cists, geriatricians, multidisciplinary teams, etc.). However,
there is significant variability in the endpoints. The role
of these interventions in health outcomes (the conse-
quences for patients, healthcare system and society) is
uncertain.
We need to address the applicability and validity of the
tools that assess therapeutic appropriateness to obtain more
reliable results with greater impact on health. Explicit crite-
ria for optimizing treatments should not be considered the
gold standard, and their implementation should preferably
be combined with implicit methods so as to address espe-
cially important issues for elderly patients, such as the
sociofamiliar context, functional and cognitive conditions
and life expectancy.
The clinical variables for elderly patients should be prop-
erly selected, given that the therapeutic objectives are
often different, and the functional aspects or those related
to quality of life can be more important in this population
than others, such as mortality. The selection of objectives
can benefit from consensus in multidisciplinary teams that
include a comprehensive geriatric assessment.
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